Repair of modified O4-alkyl-pyrimidines by O6-Alkylguanine DNA alkyltransferases by Sacre, Lauralicia
  
Repair of modified O4-alkyl-pyrimidines by  














Presented in Partial Fulfillment of the Requirements 
for the Degree of Master of Science (Chemistry) at 
Concordia University 








© Lauralicia Sacre, 2017  
 CONCORDIA UNIVERSITY 
School of Graduate Studies 
 
This is to certify that the thesis prepared 
By: Lauralicia Sacre  
Entitled: Repair of modified O4-alkyl-pyrimidines by O6-Alkylguanine DNA alkyltransferases  
and submitted in partial fulfillment of the requirements for the degree of 
Master of Science (Chemistry) 
complies with the regulations of the University and meets the accepted standards with respect to originality and 
quality. 
 
Signed by the final examining committee: 
 Dr. Guillaume Lamoureux  Chair 
 Dr. Sebastien Robidoux   Examiner 
 Dr. Joanne Turnbull  Examiner 
 Dr. Christopher Wilds  Supervisor 
 
 
Approved by   




     April 14  2017    
 Dean of Faculty 
 
  iii 
ABSTRACT 
Repair of modified O4-alkyl-pyrimidines by  
O6-Alkylguanine DNA alkyltransferases 
 
Lauralicia Sacre 
O4-Alkyl lesions are a form of DNA damage that occurs due to exposure to some alkylating 
agents, which can be repaired by O6-Alkylguanine DNA alkyltransferases (AGTs). AGTs from 
different species differ in their substrate specificity and proficiency towards repair of these 
lesions. O4-alkyl-pyrimidines with C5-modifications were prepared by using a combination of 
small molecule and solid phase synthesis in order to investigate their repair by different AGT 
homologues such as human AGT (hAGT), E. coli OGT and Ada-C and a hAGT/OGT chimera 
(hOGT). Studies have shown that hAGT is less efficient at removing O4 lesions than the E. coli 
variants. Previous work from our group revealed that replacing the C5-methyl group with 
hydrogen results in an increase in the proficiency of repair of O4-alkyl lesions observed by the 
human homologue. It was observed that the presence of a C5-fluorine atom resulted in a futher 
increase in repair of a O4-methyl lesion, particularly by hAGT and the chimera. Repair of the O4-
methyl lesion increased about 20-fold after 1 min with 5 equivalents of AGT when fluorine 
rather than hydrogen was at the C5-position. Repair of larger lesions at the O4 position such as 
ethyl, benzyl, 4-hydroxybutyl and 7-hydroxyheptyl were also evaluated for analogs with fluorine 
at the C5 position. Interestingly, all substrates were repaired efficiently. Ada-C was able to 
repair larger adducts such as O4-benzyl and O4-4-hydroxybutyl. Human AGT showed a 
preference for the benzyl adduct, as observed previously in the literature. Smaller adducts 
(such as O4-ethyl) were repaired faster than the larger ones by the various AGTs with O4-7-
hydroxyheptyl repair observed to occur more efficiently relative to its 4 carbon analogue 
presumably due to a more flexible chain allowing for a more optimal accommodation for the 
removal of the lesion. Other halogens such as chlorine and bromine at the C5 position were 
  iv 
also analyzed to observed their influence relative to fluorine. Repair of O4-methyl lesions with 
chlorine at the C5-position occurred faster relative to bromine. The larger C5-bromine did 
influence repair with a maximum of 55% removal of the O4-methyl lesion by the AGTs observed. 
The presence of chlorine at the C5-position had a positive influence on removal of the O4-
methyl group by human AGT with slightly faster repair observed compared to the C5-fluorine 
analog. Overall, the presence of the C5-fluorine group was shown to have a positive influence 
on O4-methyl repair by AGT, distinct from the influence of chlorine or bromine at the C5-
position. These studies have expanded our knowledge of the range of subtrates that can be 
repaired by AGTs and may be useful in guiding the design of hAGT inhibitors as therapeutics 
against uncontrolled cellular proliferation seen in cancer. 
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Chapter 1. Introduction 
1.1 DNA Alkylation 
DNA is a complex macromolecule that carries our genetic information. Every day, DNA is 
exposed to endogenous and exogenous agents that can cause damage. Depending on the 
damaging agent, different lesions such as alkylations can be produced. These lesions could be 
detrimental if they do not get repaired as they could eventually lead to mutations or 
modifications in the DNA. DNA alkylation can result from different sources and it could occur at 
the atoms that are more nucleophilic. Most of the resulting adducts are mutagenic or cytotoxic, 
and therefore organisms have developed different mechanisms to repair the vast range of alkyl 
lesions. 
 
1.1.1 Alkylating Agents 
Alkylating agents allow the formation of different covalent adducts between their 
electrophilic moieties and the nucleophilic atoms in DNA. Alkylating agents can be classified as 
monofunctional or bifunctional agents which undergo one or two alkylating events, 
respectively.[1] They can also be divided according to the mechanism of the alkylation reaction, 
which can be either SN1 (unimolecular) or SN2 (bimolecular).
[2] This final classification depends 
on the specific alkylating agent. In these nucleophilic substitutions, the SN2 rate depends on the 
concentration of both the electrophile and the nucleophile (nucleophilic centers in DNA), while 
the SN1 rate only depends on the electrophile (alkylating agent). Therefore SN2 alkylating agents 
are more selective with regards to the positions in DNA with which they react.  Monofunctional 
alkylating agents predominantly act upon the N-atoms of the nucleobases, capable of 
introducing a range of lesions including methyl, ethyl and other adducts. Examples of these are 
N-methyl-N’-nitro-N-nitrosoguanidine (MNNG), N-ethyl-N’-nitro-N-nitrosoguanidine (ENNG), N-
methyl-N’-nitrosourea, which operate via a SN1 mechanism whereas dimethyl sulfate and 
methylmethane sulfonate reaction by a SN2 process.
[3–6]   
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Bifunctional alkylating agents tend to be more damaging and lethal for cells as they can 
potentially generate numerous products including interstrand (involving complementary DNA 
strands) and intrastrand (occurring at the same DNA strand) cross-links (secondary product) in 
addition to mono-adducts (primary product).[1,7] Examples of bifunctional alkylating agents 
include derivatives of chloroethylating agents like chloroethylnitrosourea (CENU) and alkyl 
sulfonates such as busulfan and hepsulfam (SN2 reagents).
[1]  
1.1.2 Sources of Alkylation 
Alkylating agents can be endogenous or exogenous to the cell.  Endogenous sources 
include S-adenosylmethionine, which acts as a methyl donor in many cellular reactions (Figure 
1.1 A).[3] Studies have shown that S-adenosylmethionine could produce O6MedG (about 10-30 
events per day).[8] Exogenous sources involve a long list of nitrosoureas and nitrosamines that 
can be found in alcohol and tobacco.[3,9,10] A high percentage of these exogenous sources can 
also introduce lesions at the oxygen atoms of the nucleobases such as O6 and O4 atoms of 2’-
deoxyguanosine and thymidine, respectively.                                                                                                    
 The alkylation of DNA can be exploited to provide a therapeutic benefit. This is the case 
of some cancer therapeutics, where the DNA alkylation is desired. The introduction of alkyl 
lesions in order to introduce DNA damage can lead to the death of cancer cells. Temozolamide, 
which is a methylating agent that generates DNA mono adducts, is employed in treatment of 
brain tumors (Figure 1.1 C). Bisalkylating agents are also used in treatments against cancer. One 





Figure 1.1: Alkylating agents such as (A) S-Adenosylmethionine, (B) N-methyl-N’-nitrosourea 
and (C) Temozolamide. The electrophilic methyl group is shown in red.  
 
A B C 
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1.1.3 Predominant sites and consequences of DNA alkylation 
 Alkylation with electrophiles occurs on the electron rich atoms (nucleophilic atoms) of 
DNA; therefore it can occur at the DNA backbone or the nucleobases especially at the N- and O-
atoms. Certain atoms and positions are more susceptible than others to alkylation. Alkyl lesions 
can have mutagenic, cytotoxic and even carcinogenic consequences.[13] For instance, lesions at 
the atoms involved in Watson-Crick base pairing tend to be more mutagenic.[14,15]      
 The most vulnerable atom for alkylation is N7 of guanine.[16] For instance when DNA is 
treated with simple methylating agents, around 80% of the methylation occurs at the N7 
position.[1,4] Alkylations at the N7 position predominantly undergo depurination.[4] The second 
most predominant site for alkylation is N3 of adenine. This type of lesion has cytotoxic effects 
as it could cause the blockage of DNA replication.[4,17] The repair of these N-alkylated purines 
occurs normally through base excision repair (BER).[1] 
 Other types of alkyl lesions tend to have a higher mutagenicity effect. This is the case of 
the O-alkylations, particularly O6MedG and O4MeT (Figure 1.2). O6 alkylation tends to occur in 
more significant amounts compared to alkylation at the O4-atom. Analysis of DNA exposed to 
different methylating agents such as N-methyl-N'-nitrosourea (MNU) revealed that among the 





Figure 1.2: Alkylations in (A) dG and (B) T at the O6 and O4 positions, respectively.  
The mutagenicity of the lesions not only depends on how often they occur but in how 
efficiently they get repaired by the organism and their persistence. In the case of O6MedG, if it 
A B 
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is not removed by hAGT (to be introduced later on in this thesis), it has the possibility to cause a 
dG  dA transition where now it can base pair with T (T  dC transition shown in Figure 1.3). 
This O6MedG-T pair can be recognized by the MMR (Mismatch Repair) pathway and two 
possible scenarios could develop; (1) If the lesion occurs on the non-template strand, it can be 
removed and a point mutation will be generated as now the template strand has a thymidine 
rather than a 2’-deoxycytidine or (2) If the lesion is on the template-strand, the MMR 
machinery will keep incorporating T and recognizing it again as a mismatch entering into a futile 
cycle that eventually signals for apoptosis.[5]  
   
Figure 1.3: Watson-Crick base pairing of (A) dA•T, (B) dA• O4-MeT and (C) dG•O4-MeT 
Different studies in mammalian cells have shown that O4MeT lesions persist, positioning 
this lesion in a higher level of toxicity (which could generate T  dC transitions) compared to 
O6MedG.[14] This is due to the fact that mammalian DNA repair mechanisms are not efficient at 
removing this lesion. Studies have revealed that O4MeT is neutral to the presence or absence of 
hAGT and does not get excised by the MMR pathway. On the other hand, the NER (Nucleotide 
Excision Repair) pathway can restore DNA containing this lesion.[20–23]  
 
1.2 DNA Repair mechanisms 
Organisms have evolved different repair pathways in order to fight against modifications to 
DNA. Depending on the type of lesion, different DNA damage repair mechanism would be used. 
The pathways include base excision repair (BER), nucleotide excision repair (NER), mismatch 
repair (MMR), homologous recombination, non-homologous end joining and direct repair.    
A B C 
Alkylation 
at the O4 
T  dC 
transition 
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The importance of research in this field was recognized by the scientific community with the 
2015 Nobel prize in chemistry awarded to Lindahl, Modrich and Sancar for their respective 
work and mechanistic studies in BER, NER and MMR pathways. BER is in charge of removing 
small and non-bulky modifications on the heterocycle. This involves repair of some N-alkylated 
purines (as previously mentioned) and it plays a backup role for repairing O6MedG.[1] NER is 
responsible for the removal of bulky and small adducts including O4-alkyl-T lesions.[24–26] Finally, 
MMR focuses on detecting and correcting the improper incorporation of nucleotides.  As stated 
before, MMR is able to recognize the mismatch which occurs with O6-alkyl-dG.[5]   
 
1.2.1 Direct Repair 
O6-alkyl-dG lesions, and to a lesser extent O4-alkyl-T lesions, can be processed in 
mammalian systems by the direct repair pathway. Direct repair acts upon relatively specific 
forms of damage and does not involve excision of the DNA strand where the lesion is present. 
In humans, there are two direct repair proteins. The first class corresponds to the homologs of 
AlkB protein, ABH2 and ABH3, which perform the direct dealkylation through an oxidative 
process.[4,27,28] These FeII-dependent dioxygenases are specialized in repairing alkyl lesions 
(particularly methylation) at N1 of adenine and N3 of cytosine yielding the repaired base and 
formaldehyde as the other product.[4,27,28]                                                                                                                                             
 The second class are the O6-Alkylguanine DNA Alkyltansferases (AGTs). AGTs are the 
proteins that the different projects in this thesis focus on, specifically human AGT (hAGT), the 
two variants from E. coli (OGT and Ada-C) and a chimera hOGT (discussed later on text). 
 
1.2.2 Direct repair by AGTs 
O6-Alkylguanine DNA Alkyltansferases (AGTs) perform a direct covalent transfer of an 
alkyl group from the damaged base to a nucleophilic cysteine residue present in the active site 
of the protein (Figure 1.6). This direct transfer is irreversible and at the end it generates an 
alkylated protein (which now is deactivated) and the restored DNA. AGTs execute a 
stoichiometric reaction because one AGT protein is required for the removal of one alkyl lesion. 
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They are specialized in repairing the alkylations occurring at the O6-position of 2’-
deoxyguanosine and, to a variable extent, the O4 -position of thymidine.[28–30]  
 
1.3 O6-Alkylguanine DNA Alkyltransferases 
AGTs are relatively small proteins, normally around 19-21kDa.[31] They are present in 
almost all kingdoms of life. Even though AGTs from different species have a similar overall 
structure, their sequence identity is low. Nonetheless, these proteins have conserved important 
features such as a PCHR motif present in the active site. They have a helix-turn-helix DNA 
domain (Figure 1.5) and differ from other DNA binding proteins in the way that they use the 










Figure 1.4: hAGT N-terminal (magenta), Zinc ion (yellow), Helix-3 connecting N- and C-terminal 
(green) and C-terminal (blue) (Model prepared by PyMol using entry PDB 1EH6)[33]  
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1.3.1 hAGT structure and mechanism 
The AGT protein consists of N- and C-terminal domains. The N-terminal domain has a 
structural role and in humans it contains a zinc ion (shown in Figure 1.4), which aids to stabilize 
the interface between the two domains.[33,34] The C-terminal domain is where the active site is 
located as well as the DNA binding region. The DNA binding motif is known as the helix-turn-
helix motif (HTH). In hAGT, the first helix of the domain has residues Tyr114-Ala121 and the 
second helix comprises Ala127-Gly136. This second helix is involved in recognition and interacts 
with the DNA.[34,35]  
The active site and the HTH domain are linked by residue Asn137. The active site pocket, 
containing the conserved PCHR sequence, is situated near the bottom of the solvent accessible 
groove forming the binding channel (Figure 1.5). This grove is approximately 8 Å wide, 9 Å deep 
and 14 Å long, giving it a tunnel-like shape.[33,35] Once in the hAGT active site, the damaged base 








Figure 1.5: hAGT secondary structure showing the HTH domain (magenta), the active site (cyan) 
and the binding to the DNA (orange) at the minor groove (Model prepared by PyMol using 
entry PDB 1T38)[33]  
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The repair reaction performed by AGTs occurs in a SN2 fashion (Figure 1.6). It begins 
with the damaged nucleotide being flipped out of the DNA duplex through the rotation of the 3’ 
phosphate.[29,35] There is a Glu-His-water-Cys hydrogen bond network that increases the 
reactivity of Cys145 (in hAGT) in the active site via a proton transfer, so the second step of 
nucleophilic attack of the thiolate on the alpha-carbon attached to the nucleobase can occur. 
Two products are produced; the irreversibly alkylated protein and the restored DNA.[29,35]  
 
 
Figure 1.6: Repair mechanism of O6-Methyl-dG by hAGT (reproduced from Pegg 2011 Toxicol.) 
Alkylated AGT, which now is inactive, can interfere with the task of other active AGTs, as 
the ability to bind DNA does not get affected even when inactivated. Consequently, they are 
substrates for ubiquitin ligases causing them to get ubiquitinated and later on degraded by the 
proteasome.[29,36–38]  
1.3.2 AGT homologues and their substrate specificity 
E. coli has two AGT variants. The first one to be characterized and with a known crystal 
structure was Ada (39kDa), an adaptive response protein that is highly inducible to alkylation 
damage.[29,39] Only its C-terminal domain (19 kDa) has direct repair activity and is selective 
towards the removal of alkyl lesions.[39] Ada-C has a preference for repairing smaller adducts 
such as methyl groups due to its relatively small active site pocket compared to other AGTs. The 
presence of tryptophan 161 in the active site causes steric exclusion of larger groups.[31] Ada-C 
also contains 2 cysteine residues that can perform direct repair but it is Cys321 that is 
responsible for removal of the alkyl groups from the O6- and O4-atoms of dG and T respectively, 
favoring O6-dG lesions.[13,31,40]  
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OGT is the second variant and in contrast to Ada, it is not inducible and normally present 
in small amounts (about 30 molecules per cell).[39,41–43] Currently, there is no crystal structure 
available of this 19 kDa protein.[39] OGT is able to remove O6MedG and O4MeT lesions 
efficiently, giving preference to the latter. This variant has demonstrated in multiple studies to 
be more tolerant of bulkier substrates than Ada-C and more efficient at repairing both smaller 
adducts and larger alkyl chains (at the O4-position of T) relative to other AGTs. [30,43,44]  
Given the proficient repair of O4-MeT observed by OGT compared to the human 
analogue hAGT, studies to replace certain amino acids by site directed mutagenesis to make 
hAGT more OGT-like have been performed. McManus prepared a chimera of hAGT and OGT 
(termed hOGT) mutating residues 139-159 of hAGT with those present in OGT (residues 133-
153) while maintaining hAGT’s Pro140 residue (aiding in solubility of the protein).[45] This work 
was inspired by a previous study of the Pegg group, who mutated 8 different residues of hAGT 
to the analogous residues from OGT in order to generate hAGT variants capable of repairing O4-
MeT lesions however it presented some solubility issues.[46] Our group’s hOGT chimera 
demonstrated the ability to repair the same adducts as OGT as well as efficiency of repairing 
larger adducts in a manner similar to hAGT.  
Finally, it has been reported that hAGT is capable of repairing small adducts and 
demonstrates a pronounced preference (35-fold higher) for repairing O6-dG over O4-T 
lesions.[43] These studies have been performed on modified bases and substrates incorporated 
in a DNA sequence. In general these AGTs have an inclination for the lesions when they are in 
dsDNA but still they are able to repair when they are in ssDNA.[40]   
 
1.3.3 DNA damage detection and binding to DNA 
How AGTs are able to detect the damaged base has been a question of interest and 
multiple hypotheses have been proposed. AGT binds to DNA and scans through it in a 5’ to 3’ 
direction preferentially searching for places where the native structure might be destabilized 
due to base modifications.[29,34] There are three major contacts made by hAGT; one to a 
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phosphate backbone in the strand containing the flipped base (by the first helix of the HTH), a 
second one to a phosphate backbone in the complementary strand (by some residues such as 
Thr95 and Asn123) and the third along the groove (by the second helix of the HTH).[34]  
AGTs bind to DNA by using a HTH domain at the minor groove of the duplex. The 
recognition sequence has hydrophobic residues with small side chains that allow less specific 
and tight hydrophobic interactions with DNA.[29] The compact size of AGT allows it to occupy an 
area of approximately 7 base pairs when it binds.[37,47,48] Studies of crystal structures have 
shown that there is minimal to no conformational change upon the binding with DNA.[33–35,49] 
Binding of AGTs to the damaged DNA can also have consequences such as interference of the 
NER pathway.[13]  
 
1.3.4 Key AGT residues and examples of their importance 
Various residues are involved in the repair reaction performed by AGT in addition to 
contributing to substrate specificity and positioning. For example, Tyr114 through steric clashes 
and charge repulsion might play a role in promoting nucleotide flipping via the rotation of the 3’ 
phosphodiester into the active site. Crystallographic studies illustrate that its hydroxyl moiety 
interacts via a hydrogen bond with the O2 atom in cytosine and perhaps the same interaction 
might be occurring with thymidine.[34,35]  
The Arg128 residue provides a cationic finger, which intercalates with DNA through the 
minor groove, stabilizing the duplex by hydrogen bonding with the unpaired base.  One of the 
protagonist residues is the active site Cys145 which has a low pKa (about 4.5 in hAGT) and 
demonstrates high reactivity.[50,51] The Cys145 residue performs the nucleophilic attack 
removing the alkyl lesion from the nucleobase.  
Other residues have a less defined function but still play a role in helping to obtain the 
right positioning of the substrate and shape of the active site. Water molecules interact via 
hydrogen bonds with the Cys145, Tyr158, His 146 (normally acting as a general base) and Ile141 
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residues.[33] In addition, proline residues (Pro138 and Pro140) in the human protein allow 
bigger adducts to enter on its active pocket as they help to defined it and to provide a greater 
accessibility.[31]  
Many residues vary between AGTs and in some instances this plays a role in determining 
which substrates are repaired. One of the big differences between hAGT and Ada-C is the 
residues found in the active site. As mentioned previously, the presence of Pro138 and Pro140 
allows hAGT’s active pocket to tolerate the entrance of large adducts, but in the case of Ada-C, 
the absence of these residues (replaced by Lys139 and Ala41) causes a relaxation in the helix 
provoking the pocket to close more and therefore blocking the access to bulky adducts.[33,52] 
One of substrates that hAGT is proficient in reacting with is O6-BndG. One of the reasons why 
this substrate is preferred amongst others is largely due to the hydrophobic stacking 
interactions that occur between the benzyl moiety and the Pro140 ring. Tyr158 side chain  
(which tends to stack against smaller O6-alkyl-dG adducts as well) and the Cβ of Ser159 also 
contribute to these hydrophobic interactions.[33,35] Repair of larger adducts and even crosslinks 
at the O6-atom of dG has been observed by hAGT.[53]  
Due to steric reasons, Ada-C cannot accomodate large adducts such as O6-BndG in its 
active site. The presence of the Trp161 side chain occupies part of the space that larger and 
bulkier adducts such as a benzyl group would require in order to accommodate or even to enter 
the active site. Hence, there is only room available for smaller adducts, preferentially repaired 
by Ada-C.[31] In the case of OGT, it has shown to weakly react with O6-BndG. The absence of 
Trp161 in OGT leaves sufficient space in the active site to accommodate the benzyl group. 
However, the absence of Pro140 removes the favorable hydrophobic interactions between the 
two moieties. The presence of the second proline residue in OGT, may contribute to a wider 
active site entrance relative to Ada-C.[52]  
1.4 C5 modifications: CH3 vs H 
The priority and efficient repair of hAGT towards O6-alkyl lesions and its poor capability 
to deal with O4-alkyl lesions has come into the attention of some researchers. Recent studies 
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have shown that the C5 methyl group in T possibly causes some steric effects in the active site 
of hAGT and other variants, affecting repair. These studies employed the investigation of O4-
alkylated 2’-deoxyuridine series where a hydrogen atom is attached to the C5 position.[54]  
Repair of O4-adducts in 2’-deoxyuridine by the AGTs in this study was dramatically 
increased. Some of the highlights were that removal of the O4-methyl lesion by hAGT occurred 
25-fold faster when H was present at the C5 rather than CH3.  Similar results were obtained 
with the other substrates, for example O4-benzyl dU was repaired efficiently by all AGTs except 
for Ada-C (repair of 4 carbon and 7 carbon alkylene linkers was also inhibited). OGT mediated 
repair was the most efficient and it was able to now repair larger adducts such as 4-
hydroxybutyl and 7-hydroxyheptyl (showing a 30-fold increase compared to its T analogue), 
suggesting that the C5 methyl group might not be allowing the proper introduction or 
accommodation of these substrates.[54]  
The differences observed in repair between the AGT homologues rely on their 
respective active site shapes and sizes. The negative effect of the C5 methyl group was more 
pronounced for hAGT and the chimera hOGT. The modeling studies with hAGT implies that the 
C5 methyl group in T may encounter steric clashes with Arg135 and Ser158 which might not 




Figure 1.7: Structures of (A) O4-alkyl-thymidine and (B) O4-alkyl-2’-deoxyuridine 
 
1.5 Introduction of fluorine in DNA 
1.5.1 Properties of fluorine 
A B 
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Fluorine belongs to the halogen group and is well known for being the most 
electronegative element. Fluorine has a van der Waals radius of 1.47 Å while hydrogen 
corresponds to 1.2 Å and oxygen is 1.52 Å.[55–58] Even though fluorine’s size more closely 
resembles oxygen, its relatively small size has made it an attractive candidate to substitute for 
hydrogen atoms for a number of applications.[59]  
Other characteristics of fluorine is that it has a low polarizability, it can increase the 
acidity of compounds and it has a large electronic effect on residues that are nearby.[60] 
Hydrogen bonds with fluorine (H---F-C bond) are possible but they are much weaker (2.4 
kcal/mol) than those occurring with other heteroatoms such as O and N (~ 5.0 kcal/mol).[56,59] 
Fluorine has been observed to form short contacts with other atoms for example in proteins. 
These short contacts are dependent on the orientation and distance of both atoms.[61]   
1.5.2 Inductive and resonance effects 
The electronic properties of fluorine can be categorized as either inductive or resonance 
effects. According to some Hammett type substituent parameters (σ) determined in various 
studies, it has been determined that fluorine is always electron withdrawing by the inductive 
effect (σi of 0.52) but also acts as electron donating due to the resonance effect (σr of -0.34).
[56]  
The effect of fluorine also depends on its position on the molecule. For example, in 
fluorotoluenes, β-fluorination has show to increase the acidity of C-H bonds through both 
inductive and resonance influence. In the case of α-fluorination, it has shown to decrease C-H 
acidity when the carbanion is almost in a planar geometry due to the π- π interaction between 
both lone-pair of electrons causing a destabilization.[56,62]  
Studies of different pentafluorobenzene compounds have determined the influence of 
fluorine towards certain groups according to whether the fluorines are located ortho, meta or 
para with respect to the substituents. In most of the cases ortho-fluorine with respect to 
substituents like amino, hydroxy and carboxyl groups, contributes the most to the acidity of the 
molecule. The preferential positions towards nucleophilic reactions in the fluorobenzene 
system follow ortho > meta > para and it is mainly governed by the inductive effect (electron-
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accepting) with a slight influence of the resonance effect (π-electron donating). Analysis of 
fluorobenzene also suggests that ortho-fluorine enhances the acidity of the alpha C-H bond as 
well as meta-fluorine, which displays a greater inductive effect than ortho-fluorine in this 
case.[62]  
1.5.3 Fluorine Substitutions  
The use of fluorine in medicinal chemistry and in biological systems has been of great 
interest as it increases the lipophilicity (like aromatic fluorinations) of molecules as well as, in 
certain cases, enhancing their biological activity.[56] Hydrophobic effects normally play a major 
role in protein interactions. It has been demonstrated that the presence of fluorine can cause 
changes in the basicity and acidity of ligand molecules, especially by affecting the pKa of 
neighboring atoms.[55,63]  
A substitution commonly observed in certain amino acids is the change of a methyl for a 
trifluoromethyl group. The presence of CF3 clearly increases the hydrophobic parameter 
(derived from octanol-water partition coefficients) of that specific residue and gives some 
increase in the conformational flexibility.[56,59] When CF3 is compared to CH3 in multiple crystal 
structures it has been observed that fluorination increases the steric size of the alkyl group. In 
this case, the size of CF3 more closely resembles more to an isopropyl group.
[56] For instance 
when CF3 is placed in benzene, it has a π -inductive effect (electron-withdrawing by inductive 
and conjugation effects).[64]  
Fluorinated nucleoside analogues have been under study and some of them have been 
exploited as chemotherapeutics. Fluorine has shown advantageous effects when it is present in 
DNA. Examples of sites where fluorine has been introduced include the nucleobase and the 
sugar. Some of the most efficient radiosensitizers are 5-fluoropyrimidines such as 5-fluorouracil 
(used for treating colorectal and other cancers) and various produgs, with one of their main 
mechanisms of action being the inhibition of the enzyme thymidylate synthase disrupting DNA 
biosynthesis and downstream causing cell death.[65–70] A number of fluorine modified 
oligonucleotides have been developed including the sugar modified 2′-deoxy-2′-fluoro-
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arabinonucleic acids (2’-F-ANA) which has found applications in gene silencing therapies and 
exhibits stability towards nucleases.[71–73]  
1.5.4 Potential interactions of fluorine with proteins 
The interactions that fluorine can have with different atoms in proteins strongly depend 
on their alignments and orientation, which compensate for potential electrostatic repulsions.  
The times fluorine is in short contact with other atoms in proteins have been studied. The 
fluorophilic group that shows the highest contact with fluorine is sulfur. All of the fluorine-
sulfur contacts come from cysteine, whose potentiality for repulsion is perhaps counteracted by 
an extra weak interaction with the sulfhydryl hydrogen.[61]  
The guanidinium group (specifically at the sp2 carbon) of arginine as well as the hydroxyl 
groups (through sp3 oxygen) of tyrosine and serine (normally in a linear arrangement) have also 
been shown to be fluorophilic moieties. Other groups that also show important contacts with 
fluorine are the sp2 N atoms in the aromatic ring of histidine and surprisingly the sp2 hybridized 
O atom of carboxyl groups, which adopt an orthogonal alignment to minimize repulsion, and 
non polar hydrogens.[61,74] Alternatively there are groups that do not interact as much with 
fluorine, probably due to repulsion, such as the N atom of amide linkages. 
 
1.5.5 Other Halogens: Fluorine vs Chlorine vs Bromine                                        
Even though the main focus of the present work is the influence of fluorine, it is of 
interest to analyze other halogens such as chlorine and bromine. Bromine and chlorine (with 
van der Waals radii of 1.85 and 1.75 Å, respectively) are larger than fluorine and at the same 
time they exhibit a increased polarizability, imparting this effect to the molecule to which they 
are part of.[56,75] When the halogen atoms are linked to an aromatic system, they can 
participate in both electron accepting (inductive) and electron donating (through conjugation) 
events. The electronic properties of these halogens suggest that fluorine exhibits a more 
pronounced electron donating resonance effect (conjugation) compared to the other halogens 
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(σr: -0.23 for Cl and σr: -0.19 for Br) probably triggered by the overlapping of the π orbitals as it 
is the smallest of the series.[64] The inductive effect is highest for fluorine (σi: 0.52) but chlorine 
(σi: 0.47) and bromine (σi: 0.44) are not far behind.
[64]   
Studies to investigate the effect of different halogens at the C5 of cytosine have shown 
that the electronic effects can be transmitted through bonds during base pairing. This is the 
case of C5-fluoro in cytosine, which through its O2 disfavors the protonation, which can be 
caused by electrophilic carcinogens, at the N2 of guanine in the CG base pair.[75] In this 
particular experiment, the proton transfer from the N2 atom of G to the O2 atom of C (which 
may occur during carcinogen nucleophilic attacks) was used to measure the strength of the C5 
group effect. If the electronic effects were dominating this interaction, Br would be less 
destabilizing than Cl, which turns out to be less destabilizing than F, and with all of these 
halogens behaving as electron withdrawing substituents.[75]  
Computational studies on 5-halouracils have shown that the C5-X bond length increases 
in going from F (1.34 Å), Cl (1.73 Å) to Br (1.89 Å). On the other hand, the length for the C4-O4 
bond decreases very slightly. Substitution by halogen atoms causes relatively small changes in 
H-bond distances when it base pairs with adenine, but is still within the ranges for optimal 
bonding.[65] The charges on the substituted halogens vary from -0.326 esu for fluorine to 0.099 
esu for bromine, where it is only F that carries a negative charge.[65]  
 Fluorine has been said to increase the lipophilic character of molecules. The lipophilic 
character in halogens also relates to their hydrophobic parameter which increases in the 
following order: F < Cl < Br.[56,63] Taking advantage of all their properties, the use of halogens in 
chemotherapeutic agents has gained significant popularity. For example during radiotherapies, 
halogens are really useful as they are able to localize the influence of radiation due to their 
large cross-sectional area.[65]  
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1.6 Objectives 
 The general objective of this thesis is to study and explore the electronic effects of the 
C5 group in AGT-mediated repair of various O4-alkyl modified pyrimidines. The objective for the 
first project shown in chapter 2 involves studying the repair by different AGTs (hAGT, OGT, Ada-
C and the chimera hOGT) of the methyl adduct at the O4-atom when fluorine is present at the 
C5 position of 2’-deoxyuridine.  Chapter 3 focuses on the effect of C5-fluoro in repair by AGTs of 
different and larger alkyl lesions at the O4-position of 2’-deoxyuridine. Finally, chapter 4 
evaluates and investigates the electronic influence of other halogens such as chloro and bromo 







Figure 1.8: Structure of (A) 5-fluoro-O4-alkyl-2’-deoxyuridine, (B) 5-chloro-O4-methyl-2’-







A B C 
R = Me, Et, Bn, 4COH, or 7COH 
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Chapter 2. Fluorine at the C5 position of 2’-deoxyuridine enhances 
repair of O4-methyl adducts by human O6-alkylguanine DNA 
Alkyltransferase 
2.1 Abstract 
 Alkylations at the O6- and O4-atoms of 2’-deoxyguanosine (dG) and thymidine (T), 
respectively, can be repaired by O6-alkylguanine-DNA alkyltransferases (AGTs). Previous studies 
have shown that human AGT (hAGT) repairs small adducts poorly at the O4-atom of T, in 
comparison to the E. coli variants (OGT and Ada-C) of this protein. The C5 methyl group of the 
thymine nucleobase is suspected to reduce repair efficiencies via possible steric effects.  This 
study examines the “electronic effects” of the substitutent at the C5 position on repair by 
various AGTs using oligonucleotides containing a 5-fluoro-O4-methyl-2’-deoxyuridine (dFU-Me) 
insert. The ability of hAGT, E. coli variants (OGT and Ada-C) and a chimeric hAGT/OGT protein 
(hOGT) to mediate repair of the O4-methyl adduct was investigated. Compared to previous 
studies with O4-methyl-2’-deoxyuridine (dU-Me) and O4-methyl-thymidine (T-Me) substrates, 
the presence of the C5-fluorine atom notably increased repair of the lesion, particularly by 
hAGT and the hOGT chimera. 
2.2 Introduction 
 DNA damage can occur from different environmental factors that can arise from within 
and external to the cell.[76,77] For example alkylating agents such as N-methyl-N’-nitrosourea has 
been shown to introduce alkyl lesions at the O6 and O4 atoms of 2'-deoxyguanosine and 
thymidine respectively.[54,76] Such alkylations have been implicated in severely disrupting proper 
functioning of the cellular machinery, a feature that has been exploited in the treatment of 
cancer by designing drugs, which introduce alkyl lesions. Examples of chemotherapeutic drugs 
include Temozolamide and BCNU (1,3-bis (2-chloroethyl)-1-nitrosourea) which are known to 
target DNA as their main mode of action via the introduction of DNA damage.[78] 
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 The detrimental effects of the naturally produced O6-alkyl dG and O4-alkyl T to hinder 
DNA polymerases and cause transitional events  (G:C to A:T) have been well documented.[78–80] 
Their mutagenic influence arises mainly from the persistence of these lesions in addition to how 
often they occur.[43,81] O6MedG incidences occur more frequently compared to O4MeT in both 
in vitro and in vivo experiments where DNA is subjected to alkylating agents such as N-methyl-
N'-nitrosourea and methyl methanesulfonate.[20,82,83] O4MeT, is however said to have a higher 
level of cytoxicity due to its lower repair efficiency by the cellular repair machinery.[20,84] The 
O4MeT lesion is detrimental as it readily forms a non-wobble base pair with the incorrect dG 
nucleotide, leading to a possible mutagenic outcome if left unrepaired.[80] 
 O6-alkylguanine DNA alkyltransferase proteins (AGTs) are able to identify and remove 
these aforementioned alkylated lesions, via a direct reversal mechanism.[37] The alkylated 
nucleotide is flipped out of the duplex into the active site of the protein, where an activated 
cysteine residue (Cys145 in the human variant) reacts with the alkyl group. In doing so, the alkyl 
group is irreversibly transferred to the protein.[54,78] The protein product is then degraded 
rapidly via the ubiquitin pathway.[36] AGT proteins are found in most kingdoms of life, and 
crystal structures of different AGT variants depict a similar overall structure, despite high or low 
homology.[37] Certain AGT variants, however, display large substrate specificity, as well as 
adduct repair rates. For example, Ada-C and OGT from E. coli have been shown to repair small 
adducts at either the O6-atom of dG or O4-atom of T, with O4-methyl T analogues being repaired 
more efficiently.[84–86] Human AGT (hAGT) has shown a preference for a range of adducts of 
various sizes at the O6-position of dG.[84,85,87–89] 
  Among the substrates hAGT is reported capable of repairing are a wide array of mono-
adducts (like ethyl, benzyl, just for mentioning a few) and O6-alkyl(ene)-dG linked DNA intra- 
and interstrand cross-links. Moreover, O6-benzylguanine (Figure A1.1) as the free base is also a 
very efficient pseudo-substrate for hAGT.[90–92] Studies have also revealed that while Ada-C and 
OGT are efficient at repairing O4MeT DNA adducts, hAGT has a poor activity towards it.[78,84,85] 
Despite hAGT having the ability to recognize and bind to DNA containing O4MeT, it does not 
efficiently remove it. The inability of repair of the mutagenic and cytotoxic O4MeT lesion by 
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MMR and hAGT[13,78]  and the fact that there are no available crystal structures of hAGT- O4MeT 
DNA (Figure 2.1) warrants systematic and in-depth studies of this lesion by researchers in the 
field. 
 In previous work from our lab, the role of the C5 methyl group on O4-alkyl T repair was 
studied.[54] It was believed that a steric clash could be occurring between the C5 methyl group 
(van der Waals radius of 2.0 Å) of the nucleobase and Arg135 of hAGT, preventing successful 
repair. Therefore, DNA containing O4MedU (dU-Me, Figure 2.1) was investigated and repair 
analysis concluded that the steric contributions of the C5 methyl group may be responsible, at 
least in part for hAGT substrate selectivity since the dU substrates were processed more 
efficiently relative to their T counterparts.[54,93] An AGT chimera consisting in the hAGT protein 
with residues 139-159 replaced with those from the OGT active site was also analyzed. The 
chimera exhibited a twenty fold repair enhancement of dU-Me compared to hAGT.[54]  
 Given the effect of the C5 methyl group of O4-alkyl T on AGT-mediated repair, we 
wished to further explore the electronic effects by replacing this group with the electronegative 
fluorine atom at the C5-position. The similar van der Waals radius of fluorine (1.47 Å) and 
hydrogen (1.20 Å) atoms enabled us to evaluate the electronic effects without introducing 
steric additional effects (in comparison to dU-Me).[59,94] 
 Another attractive aspect of studying the replacement of hydrogen with fluorine has 
been its role in drug discovery and presence in therapeutic agents. Fluorine has shown to 
increase the lipophilicity and fat solubility of various compounds.[59,94,95] 5-fluorouracil (Figure 
A1.1) and flunitrazepam are examples of drugs that demonstrate how the presence fluorine 
enhances therapeutic properties relative to the parent compounds.[27-29] 
 Fluorine modified oligonucleotides containing 2’-deoxy-2’-fluororibose (2’F-RNA) and 2’-
deoxy-2’-fluoroarabinose (2’F-ANA) (Figure A1.1) have been shown to influence siRNA 
recognition by RISC, an important feature in strand selectivity and gene silencing traits.[72] In 
this chapter we have investigated the influence of fluorine at the C5 position on an O4-
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methylated pyridimine nucleobase examining the influence on duplex stability and structure in 










Figure 2.1: (A) Structures of the modified O4-methylated pyrimidines, and (B) DNA sequence 
where X corresponds to the modified nucleoside. 
 
2.3 Results and Discussion 
2.3.1 Synthesis of nucleosides and oligonucleotides  
 The structure of dFU-Me and the DNA sequence containing this modification are shown 
in Figure 2.1. Rather than a methyl group attached to the C5-position (T-Me), the dFU-Me 
substrate has a fluorine atom, which allows for exploring the influence of an electron 
withdrawing group at this position. Recently we found that the CH3 group at C5 of O
4MeT 
affects AGT mediated repair.[54] Specifically, an O4MeT containing oligonucleotide was observed 
to be repaired less efficiently relative to O4MedU.[54] A logical extension of this study was to 
X = O4MedFU, dFU-Me 
dFU-Me (O4MedFU) dU-Me (O4MedU) T-Me (O4MeT) 
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examine the electronic effect exerted by substituents at this position i.e replacing a H atom by 
an electronic withdrawing group such as fluorine.  
 The oligomers containing the modified inserts were prepared by a combination of small 
molecules and automated solid-phase synthesis. The synthetic pathway is shown in Scheme 2.1 
and it begins with the commercially available 5-fluoro-2’deoxyuridine (dFU), in which the 5’-
hydroxyl was protected with a 4,4'-dimethoxytrityl group, followed by silylation of the 3’-
hydroxyl functionality using previously published procedures.[97,98] A convertible nucleoside was 
prepared by the addition of a 1,2,4-triazole group at the C4 position of the nucleoside. This 
reaction was optimized for the dFU analog since the procedure commonly used for the T and 
dU series resulted in a number of undesired by-products including detriylated nucleosides.[54,97] 
This may have been due to the presence of the fluorine, which could increase the reactivity at 
the C4 position. The formation of convertible intermediate was accomplished by the slow 
addition of 1,2,4-triazole, triethylamine and phosphoryl chloride in three portions at 30 min 
intervals with stirring at 0oC to a solution containing compound 4.  After four hours, the 
reaction was complete and the convertible nucleoside was then transformed to compound 5 by 
treatment with sodium methoxide in methanol, followed by the removal of the 3’-O-tert-
butyldimethylsilyl group by a fluoride treatment. Finally, compounds 2 and 5 were 
phosphitylated to generate phosphoramidites 3 and 6, respectively, in good yields, using 
previously published procedures.[54] Purification was achieved by using short flash column 
chromatography and the purity of the compounds are demonstrated by their 31P NMR spectra 
(Figure A1.5 and A1.12). The 31P NMR spectra revealed two sharp signals in the 147-149 ppm 
region characteristic of phosphoramidites.[54] 
 Solid-phase synthesis of the oligonucleotide was performed using “fast-deprotecting” 
commercially available 3’-O-phosphoramidites due to the labile nature of the dFU-Me 
adduct.[88] Phenoxyacetic anhydride was employed as the capping reagent to avoid 
transamidation.[99] Total deprotection and cleavage of the oligomers from solid support was 
accomplished with an anhydrous solution of potassium carbonate in methanol (0.05 M) for 4 h 
at 22oC under gentle rocking.[88,97] Excess base was neutralized with an equimolar amount of 
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acetic acid and the solvent removed in a speed-vacuum concentrator. The oligonucleotide 
containing dFU-Me was purified by SAX-HPLC. Characterization by ESI-MS of DNA containing 
the dFU-Me adduct confirms the presence of the modification after the deprotection process 
and it was in agreement with the expected mass (Figure A1.14). Enzymatic digestion of 
modified oligonucleotides using snake venom phosphodiesterase and calf intestinal 
phosphatase enzymes also confirmed nucleoside composition consistent with expected ratios  








Scheme 2.1: Reagents and conditions: (i) DMTr-Cl, pyridine, DMAP, 16 h, 21 oC; (ii) N,N-
diisopropylaminocyanoethylphosphonamidic chloride, DIPEA, THF, 30 min; (iii) DMTr-Cl, 
pyridine, DMAP, 16 h, 21 oC; TBS-Cl, Imidazole, DCM, 16 h, 21 oC; (iv) 1,2,4-Triazole, 
triethylamine, POCl3, MeCN, 16 h, 0 
oC; MeOH, NaOMe, 4 h, 21 oC; TBAF (1M in THF), 30 min; 
(v) N,N-diisopropylaminocyanoethylphosphonamidic chloride, DIPEA, THF, 30 min.  
 
2.3.2 UV thermal denaturation and CD spectroscopy 
 In order to evaluate the effect of the fluorine at the C5 position and the methyl adduct 
at the O4-atom in the stability of the DNA duplex, UV thermal denaturation studies were 
conducted. The results obtained are summarized in Figure 2.2. The introduction of the methyl 































3 (R1 = DMTr, R2 = P(OCEt)(NiPr2))
(ii)
2 (R1 = DMTr, R2 = H)
(R1 = R2 = H)
(i)
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to the unmodified controls. The same relative decrease in Tm upon methylation was observed 
whether the DNA contains the T, dU or the dFU O4-Me lesions. These results suggest that the 
decrease in duplex stability after the incorporation of the methyl group was independent of the 
identity of the nucleobase (T, dU or dFU). The decrease in thermal stability may correspond to 
the disruption of the H-bonding between the O4-methylated dFU and its base-paired 2’-
deoxyadenosine, as well as less optimal base stacking with the adjacent bases. The results were 
in agreement with the data observed previously by our group.[54] Coincidentally, the dU and 
dFU substrates displayed the same Tm value of 58 
oC, as well as their respective modifications 
(dFU-Me and dU-Me), implying that the presence of the fluorine at the C5 position had minimal 








Figure 2.2 : Tm values (
oC) of duplexes containing T, T-Me, dU, dU-Me, dFU, dFU-Me. Colorless 
and grey bars represent the unmodified controls and methylated adducts, respectively. 
Hyperchromicity change (A260) versus temperature (
oC) profiles are shown in Figure A1.17. 
 The CD analysis of the profiles from dFU, dFU-Me, and the control T display 
spectroscopic signatures consistent with the B-form DNA family, exhibiting a maximal positive 
signal at 280 nm, a cross-over near 256 nm, and a maximal negative signal at 245 nm. The CD 
signatures of the duplex containing dFU-Me was similar to the unmodified control DNA duplex 
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DNA duplex structure, as previously reported for the dU series.[54] Basic molecular modeling 
was performed on duplexes containing dFU, dFU-Me and the unmodified control using the 
AMBER force field (Figure A1.20).  The structures of the duplexes generated from molecular 
modeling supported the minor deviations of the signatures observed for the CD experiments, 
displaying minimal global distortions in the DNA duplexes upon introduction of the C5-fluoro or 







Figure 2.3: Circular dichroism spectra of DNA duplexes containing dFU•dA (———), dFU-
Me•dA (—) and unmodified control T•dA DNA (•••). 
 
2.3.3 Repair Assays 
 The repair of dFU-Me substrate was studied with three recombinant AGT proteins 
(hAGT, Ada-C and OGT), and a chimera protein (hOGT). The repair assays were performed as 
described previously by our group, where we monitored production of a product generated 
from BclI cleavage with DNA duplexes designed to contain a cut site.[54] The dFU-Me 
modification is located in a position close to this cut site and if repair of the modified sequence 
to the native (repaired) sequence occurs, Bcll cuts the oligomer into two smaller DNA fragments 
(5 and 9 mers) that are separated by PAGE. The strand containing the modification is 
radiolabeled and a shorter 5mer can be visualized by autoradiography.[54] If the O4-methyl 
group is retained, no repair has occurred and the intact 14mer is observed. 
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 First, a total repair assay was conducted with the dFU-Me substrate using the various 
AGTs, allowing the reactions to proceed overnight at 37 oC. Denaturing PAGE was used to 
resolve the different species after the repair reaction. Repair assay results revealed that dFU-
Me was efficiently repaired by all four AGTs evaluated at five-molar equivalences (reaching 
approximately 80 % repair). These results mirrored trends observed for the total repair assays 








Figure 2.4: Total Repair of (A) dFU (2 pmol) and (B) dFU-Me (2 pmol) by hAGT (10 pmol), OGT 
(10 pmol), Ada-C (10 pmol), and hOGT (10 pmol), for 2.5 h at 37oC. Panel A; Lane 1, dFU DNA; 
lane 2, dFU + Bcll; lane 3, dFU + hAGT; lane 4, dFU + hAGT + Bcll; lane 5, dFU + OGT; lane 6, dFU 
+ OGT+ Bcll; lane 7, dFU + Ada-C; lane 8, dFU + Ada-C + Bcll; lane 9, dFU + hOGT; lane 10, dFU + 
hOGT + BclI. Panel B; Lane 1, dFU-Me DNA; lane 2, dFU-Me + Bcll; Lane 3, dFU-Me; lane 4, dFU-
Me + hAGT; lane 5, dFU-Me + hAGT; lane 6, dFU-Me + hAGT + Bcll; lane 7, dFU-Me + OGT; lane 
8, dFU-Me + OGT+ Bcll; lane 9, dFU-Me + Ada-C; lane 10, dFU-Me + Ada-C + Bcll; lane 11, dFU-
Me + 10 hOGT; lane 12, dFU-Me + hOGT + Bcll. 
 
 The time course assays revealed that dFU-Me was repaired faster compared to the dU-
Me and T-Me analogues. Time course repair studies were performed with the four AGTs 
variants conducted at room temperature (Figure 2.5 and A1.19). Both E. coli variants (OGT and 
Ada-C) required less than 15 s to achieve full repair of dFU-Me. These results were in 
Repair (5mer) 
 %mer)  
Repair (5mer)  
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agreement with the previous studies with dU-Me and T-Me where total repair by OGT and Ada-
Cl occurred in less than 15 s.[54] 
 Remarkably, repair of dFU-Me by hAGT only required approximately 90 s for the 
reaction to reach completion. It was surprising to observe complete repair of dFU-Me by hAGT 
to occur more quickly relative to the dU-Me and T-Me analogues. It was previously shown that 
dU-Me undergoes 25% repair by hAGT in 2.5 min, whereas similar repair levels were obtained 
for T-Me after 30 min. dU-Me hAGT-mediated repair was approximately 12-fold faster 
compared to T-Me in terms of time to achieve 25% substrate repair.[54] dFU-Me total repair by 
hAGT required 20 times less time relative to the dU-Me total repair profile, and more than a 
100 times less time to repair compared to T-Me.  
 Complete repair of dFU-Me by the chimera hOGT occurred in less than 1.5 min, 
displaying a similar repair profile to hAGT. Repair by the hOGT chimera of dFU-Me was similar 
compared to dU-Me. When compared to results from previous studies, dFU-Me appears to 








Figure 2.5: Time course repair assay at room temperature of dFU-Me by OGT (—), Ada-C (—•—
), hAGT (—••—), and hOGT (———) at 5-molar equivalence protein. Graphical illustration 
displays dFU-Me repair [%] over time (min). 
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 Our study shows that the presence of the fluorine at the C5-position not only enhances 
repair by hAGT but also reduces the difference in repair efficiency between hAGT and OGT. It 
appears that the presence of the fluorine at the C5 position weakens the ether O4-C bond 
making it more susceptible to nucleophilic attack by Cys145. Towards this end, computational 
studies using Gaussian 09 and B3LYP/6-31+G(2d,2p) mode were performed with the assistance 
of Dr. Derek O’Flaherty and Philippe Archambault in order to gain a better understanding of the 
effect of fluorine on the electron density of the O4- C bond. The calculations provided the O
4-
C bond length from the geometrically optimized models of the corresponding N1-methylated 
modified pyrimidines (see Figure A1.21). The results revealed that the O4-C bond in dFU may 
be weaker compared to dU and T as it is slightly longer. This may explain why this lesion is 
susceptible to repair by AGTs. Alternatively, the protein’s active site could be participating in 
favourable hydrophobic interactions in the presence of the fluorine atom and computational 
studies are currently underway. The presence of fluorine might also have a substantial effect on 
weak dipolar interactions and basicity of the active site.[59,61] Crystallographic structures of the 
protein complexed with damaged DNA will aid in elucidating the critical interactions, which 
promote hAGT-mediated repair. Moreover, high-resolution structures of duplexes containing 
dFU-Me are currently being investigated via a combination of molecular dynamics and high-
field NMR experiments to gain insights on the impact of this modification on DNA structure.  
 The importance and role of fluorine in biological applications and for drug regimens has 
been well documented.[59,63] The enhanced repair of dFU-Me containing oligomers by hAGT 
reported here may be due to some allosteric interactions occurring with the protein. Moreover, 
the increase in hAGT levels has been correlated to an increase in cellular resistance to certain 
chemotherapeutic agents. Future studies are currently underway with other dFU substrates for 
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2.4 Conclusion 
 Our study describes the synthesis of the dFU-Me phosphoramidite and its incorporation 
into oligonucleotides by solid-phase synthesis in scales and purity sufficient for biochemical and 
biophysical studies. A decrease of 11 oC in the thermal stability was observed for duplexes 
containing the modification relative to the control duplex. The CD data revealed no major 
change on the global structure of DNA containing the methylated dFU insert relative to the 
control duplex.  Repair of dFU-Me by the different AGTs occurred in less than 2 min, with the E. 
coli variants displaying greatest proficienty (with repair occurring in less than 15 sec), which was 
observed previously with substrates containing hydrogen rather than a methyl group at the C5-
position.[54,78] hAGT shows a remarkable increase in its repair efficiency towards dFU-Me 
compared to the dU and T analogues. The presence of fluorine at the C5 position increases 
susceptibility towards hAGT repair.  We suspect that the electronic effect of the fluorine on the 
O4-methyl lesion of the pyrimidine enhances susceptiblity towards thiolate nucleophilic attack 
by AGT. The dFU-Me substrate may find applications for anticancer therapies.[91] Given the fast 
repair of dFU-Me, studies using this substrate as a free nucleoside could help in guiding the 
design of hAGT inhibitors. Further investigation of different dFU substrates to undergo repair by 
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Chapter 3. Influence of fluorine at the C5 position of various O4-
alkylated 2’-deoxyuridines on repair by O6-alkylguanine-DNA 
alkyltranferases  
3.1 Abstract 
 Oligonucleotides containing various alkyl groups at the O4-atom of 5-fluoro-O4-alkyl-
2’deoxyuridine (dFU) were prepared by solid-phase synthesis. UV thermal denaturation studies 
of duplexes containing O4-ethyl-dFU, O4-benzyl-dFU, O4-(4-hydroxybutyl)-dFU, and O4-(7-
hydroxyheptyl)-dFU were found to decrease duplex stability by 10 oC compared to the control 
duplex containing unmodified dFU. Circular dichroism profiles of the modified duplexes all 
resembled a canonical B-form DNA.  Repair of smaller adducts was observed for human and E 
coli. O6-alkylguanine DNA alkyltransferases (Ada-C and OGT). Surprisingly, human AGT and the 
E. coli variant Ada-C displayed proficiency in the repair of larger O4-adducts. Repair of duplexes 
containing an 7-hydroxyheptyl linker at the O4-position of dFU resulted in more efficient repair 
compared to the 4-hydroxybutyl lesion. In contrast to most trends observed, Ada-C was capable 
of repairing the 4-hydroxybutyl adducts but was unable to repair the 7-hydroxyheptyl linker.  
These results reveal the positive influence of the C5-fluorine atom on repair of larger O4-alkyl 
adducts expanding our knowledge of the range of substrates that are able to be repaired by 
AGT.  
3.2 Introduction 
 DNA is continuously exposed to different modifying agents either within the cell or 
coming from the environment. Examples of these agents include various metabolites such as 
nitroso-compounds and the methylating agent S-adenosylmethionine. In addition, certain 
chemotherapeutic regimens employ methylating or chloroethylating agents.[76,77,79,100] O6-
Alkylguanine-DNA-alkyltransferases contribute to the maintenance of genomic integrity by 
repairing alkyl lesions occurring at the O6- and O4- atoms of 2’-deoxyguanosine and thymidine, 
respectively. The alkyl group is transferred from the DNA to the protein via a non-reversible 
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nucleophilic attack by a cysteine thiolate (Cys145 in human AGT (hAGT)) in the active site. 
These alkylations can be detrimental if they are not repaired as they can cause transitions that 
could lead to mutations and carcinogenesis.[43,80,100]  
 Alkylating agents can vary in the size and nature of the lesions introduced in DNA. These 
lesions can range from methyl and ethyl groups, to much larger adducts such as crosslinks 
between residues within DNA (intrastrand or interstrand) or to other biomolecules such as 
proteins.[32,87,88,100,101] The capability of repair by AGTs is related to the accommodation of 
lesions within the protein active site. [52,100] Removal of alkyl lesions occurs via transfer to an 
activated cysteine residue located in the active site of AGT. Crystal structures of human AGT 
and the E. coli AGT variant Ada-C have provided insights about the roles that various active site 
residues play in mediating critical interactions for successful repair. For example, the poor 
repair of O4-alkyl lesions of T by hAGT has been proposed to be linked to less than optimal 
positioning of the target lesion with respect to the activated cysteine responsible for damage 
removal.[33,40,46,102]  
 The identity of residues and the shape of the active site varies between AGT 
homologues. These differences determine in great part the substrate specificity. For instance 
hAGT’s active site has a tunnel-like shape (8 Å wide, 9 Å deep and 14 Å long) that allows for 
accommodation of larger adducts like benzyl and cross-links.[33,35,53,89] The Pro140 residue of 
hAGT stacks with the benzyl group generating favorable hydrophobic interactions. The active 
site of Ada-C is said to be smaller, containing residue Trp161 that impedes larger adducts from 
being accomodated into the active site. The lack of two prolines which are found on hAGT (Lys 
139 and Ala141 instead of Pro138 and Pro140 respectively) may also contribute to the 
narrowing of the active site.[33,35,40,102]  
 Understanding the basis for specificity and discovering new substrates that could be 
repaired more efficiently by AGTs has been investigated by our group and others.[46,54,88,100] 
McManus et al. reported that the C5 methyl group of O4-alkyl-T lesions may contribute to the 
reduced repair observed by hAGT, possibly via steric interactions.[54] Substituting the methyl 
group for hydrogen was shown to drastically improve the efficiency of hAGT in removing alkyl 
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groups at the O4-position. In addition, it has been demonstrated that replacing the C5-methyl 
group of thymidine with fluorine further enhanced susceptibility towards repair of an O4-methyl 
adduct by hAGT. It is believed that the presence of the fluorine atom at this position may 
weaken the O4-Cα bond enhancing susceptibility to undergo transfer to the activated thiolate in 
AGT. In addition, the presence of fluorine may contribute to favourable interactions in the AGT 
active site pocket, with reduced repulsion or steric effects with amino acid side chains. 
 Fluorine substitutions have widely been investigated in studies involving proteins and 
nucleic acids to understand biological properties and mechanisms. Incorporation of fluorine in 
proteins can be used to evaluate the effects of altering the dipole moment of a molecule or 
altering the acidity or basicity of groups that are in close proximity.[59,63] There are numerous 
examples of fluorinated nucleoside analogues, which have demonstrated beneficial properties 
in the treatment of various diseases including cancer. For example, fluoropyrimidine-based 
prodrugs whose mechanism primarily inhibits thymidylate synthase have been used for cancer 
treatment.[67] 5-Fluorouracil, 5-fluoro-2’-deoxyuridine and Capecitabine have also been studied 
as therapeutic agents. [67,69,70] In nucleic acid chemistry, the introduction of fluorine at the sugar 
has produced molecules with interesting properties. One example is 2’-deoxy-2’-fluoro-β-D-
arabinonucleic acid (2’-F-ANA) which exhibits significant resistance towards degradation by 
various nucleases.[71] This modified nucleic acid has been explored as a gene silencing agent for 
RNA interference.[72,73]  
 In the present study, we have investigated the effect of replacing the C5-methyl group 
of thymidine with fluorine on alkyl lesions larger than a methyl group. Fluorine has a dual 
electronic influence due to inductive and resonance effects. In fluorobenzene, fluorine is said to 
have an electron-withdrawing inductive effect and is also electron-donating by resonance on 
the aromatic system.[56,64]  
 The positive influence of fluorine observed on repair by various AGTs towards the O4-
methyl lesion has evoked our interest in investigating bulkier/larger adducts. In the present 
study ethyl, benzyl, 4-hydroxybutyl and 7-hydroxyheptyl adducts at the O4-position of 5-fluoro-
2’-deoxyuridine were synthesized, incorporated into 14-mer oligonucleotides and their 
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influence on duplex stability and structure evaluated by UV thermal denaturation and circular 
dichroism spectroscopy. Susceptibility towards repair of these bulkier adducts by hAGT, in 
comparison to their T (C5-methyl) or dU (C5-hydrogen) counterparts was also investigated.   
3.3 Results and Discussion 
3.3.1 Synthesis of nucleosides and oligonucleotides  
 There have been numerous reports describing how fluorine modifications lead to 
enhancement of the properties of proteins and nucleic acids.[59,63] Previous studies from our 
group have demonstrated the positive influence of replacing the C5 hydrogen atom of 2’-
deoxyuridine with fluorine on the repair of O4-methyl adducts by various AGT homologues. 
Thus, the objective of this study was to examine whether the influence of the C5-fluoro group 
extends to AGT-mediated repair of larger adducts at the O4-atom. The adducts evaluated 
include O4-ethyl-dFU (dFU-Et), O4-benzyl-dFU (dFU-Bn), O4-(4-hydroxybutyl)-dFU (dFU-C4OH), 
and O4-(7-hydroxyheptyl)-dFU (dFU-C7OH). Their chemical structures and the DNA sequences 
highlighting the position of the modification are shown in Figure 3.1.   
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Figure 3.1: (A) Structures of the modified 5-fluoro-2’-deoxyuridine adducts at the O4 position. 
(B) DNA sequence where X corresponds to the modified nucleoside. 
  dFU-Et was chosen as it is slightly larger than a methyl group and is a lesion which can 
occur in genomic DNA as a result of exposure to ethylating agents.[26,90,103] dFU-Bn was inspired 
from the well-characterized inhibitor, O6-benzyl-guanine, which has been said to be one of the 
preferred substrates of hAGT.[35,44,100] Although, preference towards the benzyl adduct is 
altered at the O4-atom of T relative to the O6-atom of dG, recent studies showed that hAGT was 
capable of efficiently repairing O4-benzyl-dU.[54] O4-(4-hydroxybutyl)-dFU and O4-(7-
hydroxyheptyl)-dFU corresponded to the potential hydrolysis adducts of busulfan (sulfonate) 
and hepsulfam (sulfamate) alkylating agents, which can generate a variety of DNA damage 
including mono-adducts and DNA cross-links.[88,89,100] These substrates also allowed for 
comparison with the results of analogues studied previously by our group modified at the O4 
atom of T and dU in the same DNA sequence context. [45,54,88]  
 The synthetic pathway for the target phosphoramidites is shown in Scheme 3.1.  The 
synthesis begins with the protection of the 5’- and 3’-hydroxyl groups of commercially available 
5-fluoro-2’-deoxyuridine (dFU) according to previously published procedures.[97,98] The 
formation of a convertible intermediate was accomplished by the slow addition of 
triethylamine followed by phosphoryl chloride to a solution containing 1,2,4-triazole and 3’-O-
(tert-butyldimethylsilyl)-5’-O-(4,4’-dimethoxytrityl)- 5-fluoro-2’-deoxyuridine stirring at 0oC.[54] 
In order to obtain compounds 2a or 2b, the convertible nucleoside was treated with sodium 
ethoxide in ethanol or benzyl alcohol and DBU, respectively, in MeCN. Fluoride treatment was 
used to remove the 3’-O-tert-butyldimethylsilyl protecting group. Finally compounds 2a and 2b 
were phosphitylated to yield phosphoramidites 3a and 3b using previously published 
procedures from our group.[54,88,89,104] For the adducts containing the terminal hydroxyl 
functionalities, the convertible nucleoside was treated with 1,4-butanediol or 1,7-heptanediol 
in MeCN. Protection of the terminal alcohol on the adducts was performed with phenoxyacetyl 
chloride (also employed as the capping agent during solid phase synthesis).[54,88,99] Removal of 
the 3’-O-tert-butyldimethylsilyl group was achieved by fluoride treatment to yield compounds 
4a and 4b. Finally, phosphitylation of these compounds was performed to furnish compounds 
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5a and 5b, respectively. Purification of all phosphoramidites was achieved by using short flash 
column chromatography and the purity and identity are confirmed by their 31P NMR spectra 
(Figures A2.8, A2.15, A2.22 and A2.29), all of which have two signals in the region of 148-150 
ppm, characteristic of phosphoramidites.  
 Due to the labile nature of the O4-alkyl modifications and our previous observation that 
this is enhaced by the C5-fluoro group, “fast-deprotecting” commercially available 3’-O-
phosphoramidites were employed for solid-phase synthesis.[54,88]  Deprotection after solid 
phase synthesis was achieved by treating the oligomers bound to the solid support with a 
solution of 10% (by volume) DBU in the corresponding alcohol employed during the synthesis of 
each respective modified phosphoramidite (e.g. ethanol for dFU-Et and benzyl alcohol for dFU-
Bn). Using the respective alcohols ensured the retention of the desired O4-modification given 
the labile nature of alkyl lesions at this position.[88,105] 1,7- Heptanediol was particularly difficult 
to remove, which necessitated extractions with DCM in order to eliminate the remnant diol and 
to avoid interference with the desalting process, as observed previously.[54] 
 The oligonucleotides dFU-Et, dFU-Bn, dFU-C4OH, and dFU-C7OH were purified by SAX-
HPLC. Characterization by ESI-MS of DNA containing each of the above mentioned 
modifications confirmed the retention of the desired modifications after the deprotection step 
(Figures A2.30 - A2.33). Moreover, enzymatic digestion of the modified oligonucleotides using 
snake venom phosphodiesterase and calf intestinal phosphatase enzymes was performed and 
the resulting nucleoside mixtures were analyzed by RP-HPLC (amounts, retention times and 
nucleoside ratios are shown in Figures A2.34 - A2.37). The presence of the additional modified 
and four standard nucleosides, in the correct ratio, also serves to confirm the identity of the 















Scheme 3.1: Reagents and conditions: i) 1,2,4-Triazole, triethylamine, POCl3, MeCN, 16 h, 0 
oC; 
EtOH (a-series compounds) or BnOH (b-series compounds), DBU, MeCN, 16 h; TBAF (1M in 
THF), 30 min; ii) N,N-diisopropylaminocyanoethylphosphonamidic chloride, DIPEA, THF, 30 min; 
iii) 1,2,4-Triazole, triethylamine, POCl3, MeCN, 16 h, 0 
oC;  1,4-butanediol (a-series compounds) 
or heptane-1,7-diol (b-series compounds), DBU, MeCN, 16 h; iv) phenoxyacetyl chloride, 
triethylamine, THF, 30 min; TBAF (1M in THF), 30 min; v) N,N-
diisopropylaminocyanoethylphosphonamidic chloride, DIPEA, THF, 30 min.  
 
3.3.2 UV thermal denaturation studies  
 The influence of the various alkyl adducts at the O4 atom of dFU on duplex stability was 
evaluated. As observed previously, the dFU control DNA duplex had a Tm of 58 °C. The presence 
of a methyl group at O4-position of dFU (dFU-Me) was shown to decrease the thermal stability 
of the duplex by approximately 10oC. A similar decrease in thermal stability was observed for 
the other alkyl adducts at the O4-atom including ethyl (dFU-Et), benzyl (dFU-Bn), 4-
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decrease in stability can be attributed to the altered hydrogen bond interactions between the 
bases (Figure 1.3 A and B) and stacking interactions, similar to O4MeT.[80] The results 
demonstrate that the decrease in thermal stability is similar regardless of the adduct size for 
the modifications studied. Moreover, having fluorine versus a methyl or hydrogen atom at the 
C5 position has minimal effect on the thermal stability of the DNA duplexes containing adducts 









Figure 3.2 : Tm values (
oC) of duplexes containing the control dFU (colorless), dFU-Me (grey 
squares), dFU-Et (grey diagonal lines), dFU-Bn (black), dFU-C4OH (grey vertical lines), and dFU-
C7OH (grey horizontal lines).  
 
3.3.3 Circular dichroism  
 Circular dichroism studies were performed in order to evaluate the global structure of 
the DNA duplexes containing the O4-modifications. The CD profiles for duplexes containing dFU-
Et, dFU-Bn, dFU-C4OH and dFU-C7OH (shown in Figure 3.3) exhibit spectroscopic signatures 
characteristic of B-form DNA, with positive and negative signals at around 280 and 245nm, 
respectively. The CD profiles are similar to the control duplex containing dFU, suggesting that 
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the introduction of these modifications at the O4-atom, in spite of their size, has a minimal 








Figure 3.3: Circular dichroism spectra of duplexes containing dFU control (—), dFU-Et (•••), 
dFU-Bn (———), dFU-C4OH (—•—) and dFU-C7OH (—••—). 
 
3.3.4 Repair Assays 
 Repair of these adducts was evaluated with 4 different AGT homologues (in a 5:1 
protein to DNA ratio); human (hAGT), E. coli (Ada-C and OGT), and a chimera protein “hOGT” 
(hAGT where residues 139–159 are replaced with residues 133-153 from OGT but maintaining 
Pro140)[45]. We were interested in evaluating the repair of these adducts at the O4-atom, as 
substrate preference and repair efficiency varies between AGTs.  Of particular interest is the 
influence of the fluoro group at the C5 position, compared to the C5-methyl of T or C5-
hydrogen of dU, on repair efficiency with adducts larger than an O4-methyl group. 
 hAGT is known to have a preference for repair of larger adducts such as the benzyl 
group, especially at the O6-atom of dG.[23,30,106] Of the 4 novel substrates we evaluated, dFU-Bn 
was observed to be repaired the fastest by hAGT, with complete repair achieved in 30 seconds 
(Figure 3.4 A). Surprisingly, hAGT was incapable of repairing the same adduct in thymidine, 
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which differs only in the presence of a methyl group instead of the aforementioned fluoro 
group at the C5-position of the nucleobase.[107] Complete repair of dFU-Et required 
approximately 45 min, slower than dFU-Bn, suggesting that even though the ethyl adduct is 
smaller than Bn the latter adapts better to the active site of hAGT. This may be due to a 
stacking interaction on the benzyl group with Pro140 which may facilitate an optimal 
orientation for binding and thiolate attack.[31,33,35,100] For the alkylene adducts containing 
terminal hydroxyl groups, it was observed (Figure A2.49) that dFU-C7OH (150 min to reach 
about 70% repair) was more efficiently repaired over dFU-C4OH (40% repair after overnight 
incubation). Perhaps the 7 carbon linker may have greater flexability adopting a conformation 
that evades steric clashes in the active site of hAGT. Similar results were found in repair of 
intrastrand and interstrand cross-links, where the 7 carbon linker is repaired preferentially over 
the 4 carbon analog.[7,11,12,89] Studies of crystal structures of hAGT have revealed that its binding 
channel has a tunnel-like shape that allows the entrance and accommodation of larger adducts 
with the reactive Cys145 located at the end of the tunnel (9 Å deep).[33,35,49] Surprisingly, hAGT 
displays no repair of the 4-hydroxybutylene and 7-hydroxyheptylene lesions at the O4-atom of T 
(C5-methyl) or dU (C5-hydrogen),[54] demonstrating that the C5-fluoro modification of dFU 
contributes to increased susceptibility of damage removal at this position. 
 OGT is known to repair a range of alkyl lesions at the O4-position of thymidine.[43,52,54,100] 
The dFU-Et lesion was repaired by OGT in under 15 sec and the dFU-Bn adduct was fully 
repaired in 15 sec (Figure 3.4 B). Previously, it was observed that OGT repair of dU-Bn occurred 
in 15 sec.[54] Larger groups at the O4-position of T such as 4-hydroxybutylene and 7-
hydroxyheptylene are more of a challenge for repair by OGT. Surprisingly after 10 min, dFU-
C7OH was almost fully repaired while less than 50% of dFU-C4OH was repaired (Figure 3.7). For 
the dU series, OGT repair of the 7-hydroxyheptylene and 4-hydroxybutylene adducts occurred 
efficiently within 10 and 2 min respectively, with similar repair profiles observed within the first 
minute of the reaction.[54] The reduced efficiency observed for repair of dFU-C4OH by OGT is 
the first example we have encountered of an O4-alkylated lesion where the C5-fluoro analog (of 
5-fluoro-2’-deoxyuridine) is less efficiently repaired relative to the C5-hydrogen (of 2’-
deoxyuridine) analog. This highlights a balance between the positive influence of the electronic 
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effects of fluorine at the C5-position on AGT repair of O4-alkyl groups with factors such as 
adduct size and flexibility.  
 The other E. coli variant, Ada-C, has a limited range of substrates it can repair. For 
instance it is proficient at repairing smaller adducts such as methyl and ethyl groups at the O6- 
and O4-atoms of dG and T, respectively.[84,108–110] A preference in repair is observed when the 
adduct is a methyl rather than an ethyl group at the O6 position of dG.[108] Ada-C was able to 
reach full repair of dFU-Et in less than 15 sec (Figure 3.4 C) with repair of the O4-ethyl group 
observed to be efficient as the O4-methyl group with a fluorine atom at the C5 position.  
 It has been proposed that larger adducts, such as a benzyl group, might not be repaired 
by Ada-C due to steric obstruction in the protein’s active site.[107,108] Unexpectedly, Ada-C 
demonstrated activity towards dFU-Bn with about 40% repair observed in the first 15 sec and 
60% repair after 150 min. Remarkably, Ada-C also repaired 40% of dFU-C4OH after 150 min 
(Figure A2.49), whereas the 2’-deoxyuridine analogs dU-Bn and dU-4COH were resistant to 
repair.[54] No repair was observed on dFU-C7OH by Ada-C, which may be due to the active site 
not being capable of accommodating the longer linker. Recently, our group showed moderate 
repair of an O4-thymidine-heptylene-O6-2’-deoxyguanosine intrastrand cross-link adduct lacking 
the intradimer phosphodiester group by Ada-C. The repair occurred solely at the O6-position of 
the 2’-deoxyguanosine moiety and marked one of the first examples where Ada-C 
demonstrated proficiency in the repair of larger alkyl adducts. Interestingly, the analogous 
butylene cross-link was inert towards Ada-C repair. An inverted trend is observed for the 
pyrimidyl series described herein for Ada-C. 
 Finally, the chimera hOGT behaved similar to OGT, being more effective at fully 
repairing the smaller dFU-Et adduct within 30 sec (Figure 3.4 D). Full repair of dFU-Bn was 
achieved in about 1 min, which is similar to the results obtained for OGT and hAGT. The 
combination of the optimal accommodation in the active site in addition to the favourable 
effect of fluorine at the C5 position likely contributes to dFU-C4OH and dFU-C7OH repair to be 
higher with hOGT, relative to OGT and hAGT, achieving approximately 70% repair after 45 min 
and 1 min, respectively (Figure 3.7). Again, the 5-fluoro-2’-deoxyuridine series exhibited 
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enhanced susceptibility towards repair of the adducts at the O4-position relative to the 2’-














Figure 3.4:  Time course of repair of dFU-Et (•••), dFU-Bn (———), dFU-C4OH (—•—) and dFU-
C7OH (—••—) at room temperature: A) by hAGT, B) by OGT, C) by AdaC and D) by the chimera 
hOGT.  
 One of the hypotheses as to why the C5-fluorine group has a positive influence on AGT 
repair is that it may exert an effect on the O4-Cα bond of alkyl group attached to the nucleobase 
rendering it more labile for facile transfer to the thiolate anion in the active site. There could be 
an electronic effect occurring within the nucleobase bonds causing the O4-Cα weakening. This 
A B 
C D 
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has been observed in C5-fluoro cytosine, in where the C5-fluoro group through the O2 and N3 
atoms disrupts the CG basepair.[75,111,112] The presence of fluorine in a biomolecule can impart 
interesting properties and allow for probing of the role various residues play in maintaining 
structure and catalyzing reactions.[59,63] There has been much debate on the capability of 
fluorine to participate in hydrogen bonding.[59,74,113,114] Interaction with fluorine depends on the 
distance and position relative to the atoms involved.[61,115] The literature contains numerous 
examples where fluorine influences the basicity or acidity of certain chemical groups.[63] It can 
also generate specific polar and hydrophobic interactions with some protein residues (Figure 
3.5). In the case of a more desolvated cavity, the conditions may be suitable for hydrogen 






   
Figure 3.5: Favourable orientation of C5-F (green atom) for hydrophobic and π-sytem 
interaction with Pro140 (left) and Tyr158 (right) respectively. (Modified from PDB 1T38 using 
UCSF-Chimera) 
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 The existence of short contacts between a fluorine atom and different amino acids have 
been reported.[61,116] Short contacts between the thiol from cysteine and fluorine have been 
described. [61] Histidine has been reported to be able to interact with fluorine via its imidazole 
ring.[74] 
 The high reactivity of Cys145 in AGT has been studied by several groups. Reports have 
suggested that Cys145 has a low pKa that allows it to be in the thiolate form at neutral pH.[50] It 
is possible that the fluorine atom at the C5 position of the O4-alkylated nucleobase, interacts 
with key residues such as Cys145 (C-F bond and thiolate short contacts or even H-bonding) and 
His146 (C-F bond and π-system interaction) in the AGT active site, enhancing the reactivity of 









     Figure 3.6:  hAGT active site with 5-fluoro-O4-methyl-2’-deoxyuridine displaying distance from 
C145 sulphur (yellow atom) to the O4 (red atom) and C5-F (green atom) respectively. (Modified 
from PDB 1T38 using UCSF-Chimera)  
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 To test this hypothesis, it may be worthwhile to prepare AGT mutants to probe these 
possible interactions. In other studies, mutations at key residues have shown to reduce AGT 
repair activity. For example, Y114F or Y114A mutations highlight the importance of Y114 in 
flipping of the nucleoside and positioning of the alkyl lesion.[53,93] Likewise, the P140K mutation 
revealed the importance of hydrophobic interactions between this residue with benzyl moieties 
at the nucleobase.[35] Although the shape and properties of some amino acids in the active site 
are different between AGTs, it may be interesting to explore electrostatic interactions between 
the C5-fluoro group of the nucleobase and key conserved residues. Hydroxyl and guanidinium 
groups have shown to be fluorophilic and amino acids such as tyrosine (Tyr114 and Tyr158) and 
arginine (Arg135) found in the AGT active site contain these groups (Figure 3.6).[61,116] 
 In this study it was observed that the different AGTs deviated from the patterns 
observed regarding repair proficiency of various O4-alkylated T and dU lesions. It is clear that 
the presence of fluorine at the C5-position of the nucleobase generally aids in achieving 
efficient repair (graphic examples shown in Figure 3.7). We hypothesize that eventually a limit is 
reached where there is insufficient space available in the active site cavity to accommodate 
bulky lesions. It is proposed that the C5-fluorine of the alkylated nucleobase could be acting like 
an allosteric effector with possible interactions with AGT active site residues that may 
contribute to enhance activity towards the -carbon. We are currently synthesizing intra- and 
inter-strand crosslinks with C5-fluoro pyrimidines in order to determine whether enhanced 
repair is also observed for these lesions. 















Figure 3.7: Repair of A) dFU-Et, B) dFU-Bn, C) dFU-4COH and D) dFU-7COH at time points by 
hAGT (white bars), Ada-C (granite bars), OGT (black bars), and hOGT (light grey bars).  
 
3.4 Conclusion 
 The synthesis of O4-ethyl-dFU, O4-benzyl-dFU, O4-(4-hydroxybutyl)-dFU, and O4-(7-
hydroxyheptyl)-dFU phosphoramidites as well as their incorporation into oligonucleotides by 
solid-phase synthesis is described. The UV thermal denaturation studies revealed a decrease of 
approximately 10 oC upon the introduction of the alkyl groups at the O4-atom for the various 
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adducts investigated. CD spectra of the DNA duplexes containing these O4-modifications 
suggest minimal differences from a standard B-form structure.  
 Generally, the repair studies showed an enhancement in AGT-mediated repair due to 
the C5-fluoro group. Surprisingly, hAGT demonstrated the ability to repair 4-hydroxybutyl and 
7-hydroxyheptyl lesions at the O4-position of 5-fluoro-2’-deoxyuridine, whereas this protein is 
incapable of repairing these adducts for thymidine and 2’-deoxyuridine. To the extent of our 
knowledge, we have shown the first examples of Ada-C repairing larger O4-adducts like benzyl 
and 4-hydroxybutyl for 5-fluoro-2’-deoxyuridine. Repair by OGT occurred towards all O4-lesions 
evaluated, except for 4-hydroxybutyl which occurred slower for 5-fluoro-2’-deoxyuridine 
compared to 2’-deoxyuridine. The chimera hOGT achieved fast repair for all O4-adducts similar 
to OGT. It was noted that repair of 7-hydroxyheptyl and 4-hydroxybutyl groups at the O4-
position by hOGT occurred about 2x and 40x faster respectively for 5-fluoro-2’-deoxyuridine 
relative to 2’-deoxyuridine. Overall, it was observed that repair of the 7-hydroxyheptyl adduct 
was preferred over 4-hydroxybutyl, with exception of Ada-C (where no repair of 7-
hydroxyheptyl was observed). The longer adduct is inherently more flexibile, which may allow 
for proper orientation of the O4-Cα bond in order for alkyl transfer to the activated thiolate 
group. The active site of Ada-C may be too small to accommodate the 7-hydroxyheptyl adduct. 
 In general, the C5-fluoro group enhanced AGT repair of O4-alkyl pyrimidinyl lesions. This 
modification enabled lesions at the O4-position that were otherwise inert, such as the 4-
hydroxybutyl and 7-hydroxyheptyl, to be acted on by certain AGTs (hAGT for instance). This 
may be attributed in part to favourable interactions of fluorine and the AGT active site enabling 
repair of a wider scope of substrates. Further investigation of the basis of the interactions 
occurring with the dFU substrates will enhance our understanding of AGT-mediated repair.  
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Chapter 4. Influence of halogens at the C5-position of O4-alkyl 
pyrimidines towards repair by O6-alkylguanine-DNA alkyltransferases. 
4.1 Abstract 
 Oligonucleotides containing 5-chloro-O4-methyl-2’-deoxyuridine (dClU-Me) or 5-bromo-
O4-methyl-2’-deoxyuridine (dBrU-Me) were prepared by solid-phase synthesis. Biophysical 
studies of the DNA duplexes containing these modifications revealed an 11 oC decrease in 
thermal stability compared to the duplexes containing 5-chloro-2’-deoxyuridine (dClU) or 5-
bromo-2’-deoxyuridine (dBrU). Circular dichroism profiles demonstrated that the modified 
duplexes maintained an overall B-form DNA structure. Despite the larger size of these atoms 
compared to fluorine or hydrogen, their presence at the C5-position did not impair the ability of 
various AGTs to remove O4-methyl group from these modified 2’-deoxyuridines. Surprisingly, 
dClU-Me was repaired efficiently by human AGT (hAGT) while other AGT proteins (AdaC and 
OGT from E. coli and a chimera hAGT/OGT protein “hOGT”) only displayed moderate repair 
towards this lesion. For dBrU-Me, all AGTs repair similarly with hAGT demonstrating the least 
proficiency towards this adduct. These results suggest a combination of factors contributing to 
the repair proficiency observed between (1) the influence of inductive and resonance effects of 
C5-chloro and C5-bromo groups on the heterocycle and (2) the possible favourable interactions 
(halogen-bonding, short contacts, etc.) of the C5-halogens with AGT’s active site residues.  
 
4.2 Introduction 
 DNA damage in the form of halogenated nucleobases can result from different sources 
including some inflammatory processes or the presence of hypobromous and hypochlorous 
acids.[111,117–119] One of the sites most susceptible to modification is the C5 position of the 
pyrimidine nucleobases. The presence of 5-halogenated pyrimidines can have biological 
consequences which affect DNA-protein interactions and processes such as C5-
methylation.[111,120]  
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 The steric and electronic effects resulting from halogenation are dependent on the 
identity of the halogen. It is well documented that fluorine is commonly used as a substitute for 
hydrogen atoms, although the former is slightly larger whereas chlorine and bromine are closer 
to the size of a methyl group.[111] Recently, the presence of halogens in many biological systems 
has been found to exert interesting properties. Halogen bonding, which is the non covalent 
interaction between an electrophilic region (σ-hole) in the halogen atom with the nucleophilic 
part of another molecule, and short contacts are examples of interaction of halogen atoms with 
proteins and nucleic acids.[121]  
 The influence of replacing the methyl group of 5-methylcytidine with various halogens 
on endonuclease activity has been evaluated. It was shown that MspI cleavage activity was 
unaffected by the presence of halogens at the C5 position whereas HpaII activity was reduced 
in the presence of a fluoro group and completely absent in the presence of either a chloro or 
bromo group.[111] Some halogens have a minimal effect on DNA structure whereas larger ones 
may introduce a structural deformation. It was concluded that steric effects mainly impacted 
the protein-DNA interactions and that the presence of chloro or bromo groups could simulate 
the effect of methylation.[111] In other studies it was noticed that only 5-fluorocytosine could act 
as a methyltransferase trap, whereas the chlorinated and brominated analogues were not able 
to function in the same way probably due to steric reasons.[111]  
 Halogen substituents in pyrimidines have been studied for decades and found 
applications as therapeutics. They have been employed in chemotherapy as radiosensitizers 
due to their large cross-sectional area that enables the absorption of radiation and their Auger 
effect that can induce single and double strand breaks in DNA.[65,122,123]  
 O6-alkylguanine-DNA alkyltransferases (AGTs) are known for being capable of repairing 
alkylation at the O4-position of thymidine, with some variants displaying greater proficiency 
relative to others. It has been proposed that C5-methyl group of thymidine may contribute to 
the reduced repair activity of human AGT towards O4-alkyl lesions.[54] The electron-donating 
nature of the methyl group has made our group interested in analyzing the effect of electron 
withdrawing groups at the C5-position. It was observed in studies performed by our group that 
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the presence of fluorine dramatically increased AGTs efficiency to repair O4-methyl adducts. 
Hence, the purpose this study is to analyze the effect of other halogens including chloro and 
bromo groups at the C5 position, taking into account electronic and steric effects, on repair of 
O4-methylated pyrimidines by AGTs. 
 The presence of halogens on the nucleobases have been shown to influence DNA duplex 
stability. Halogens can alter the pKa of different groups and can influence stabilization of the 
DNA duplex. Studies performed with 5-halogenated cytosine revealed that the pKa of the N3 
atom decreases.[111,124] This change in pKa reduces the strength or even removes one of the 
three hydrogen bonds in CG base pairing.[111,112] Nevertheless, C5-halogenations increase the 
pyrimidine’s polarizability, which leads to an increase of base-stacking interactions, possibly 
contributing to a more stable DNA duplex (higher thermal stability).[111,125]  
 Halogen bonding and short contacts (short distances between a pair of atoms) have 
been observed in nucleic acids-protein structures.[116] The versatility of these halogens allows 
them to have short contacts with O and N atoms such as the backbone carbonyl groups in 
proteins.[115,116] Even though halogen bonds are weaker than hydrogen bonds, they are involved 
in hydrophobic interactions and even form halogen-water bridges, contributing to 
stability.[115,116] The strength of halogen bonding has been observed to increase from chlorine to 
bromine due to the higher polarizability of the latter.[116,126,127] The moderate strength of the 
bromine bond could be one of the reasons why nucleic acids have a tendency to more readily 
be brominated rather than chlorinated.[116]  
 The distance required for hydrogen-bond formation to halides varies depending on the 
donor. Normally this distance increases going through the series from fluoride to iodide.[128] 
Substitutions of hydrogens and hydroxyl groups for halogens in proteins have shown to 
increase their thermal and structural stability. For this and other reasons halogens have been 
also employed for molecular imaging and structural studies.[115]   
 
 






Figure 4.1: (A) Structures of 5-chloro-O4-methyl-2’-deoxyuridine (dClU-Me) and 5-bromo-O4-
methyl-2’-deoxyuridine (dBrU-Me). (B) DNA sequence where X corresponds to the modified 
nucleoside. 
 
4.3 Results and Discussion 
4.3.1 Synthesis of nucleosides and oligonucleotides  
 The structure of dClU-Me, dBrU-Me and the DNA sequence where they are introduced 
are shown in Figure 4.1.  These nucleobase modified oligonucleotides were use to study the 
size and electronic influence of the C5-group relative to their T (C5-methyl), dU (C5-hydrogen) 
and dFU (C5-fluorine) counterparts.[54] Previous studies in our group demonstrated the positive 
influence of fluorine at the C5-position on repair by AGTs possibly due to favorable interactions 
occurring at the protein’s active site as well as the influence that the fluorine atom may have on 
the heterocycle making the O4-Cα bond more susceptible for the thiolate attack. (Chapters 2 
and 3) The investigation of the halide series, in hand with our studies involving the fluorine 
modification, will give us a better understanding on the contributions of size and/or the 
electronic effects of groups at the C5-position on AGT repair.   
 The modified oligomers were obtained after small molecule and solid-phase synthesis. 
The synthetic pathway shown in Scheme 4.1 begins with the protection of the 5’- and 3’-end of 
the commercially available 5-chloro-2’-deoxyuridine (dClU) and 5-bromo-2’-deoxyuridine 
















X = dClU-Me 
       dBrU-Me 
 
       
 
B A 
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intermediate was accomplished by the slow addition of 1,2,4-triazole, triethylamine and 
phosphoryl chloride while stirring at 0oC to a solution containing 3’-O-(tert-butyldimethylsilyl)-
5’-O-(4,4’-dimethoxytrityl)-5-chloro (or bromo)-2’-deoxyuridine.[54] The convertible nucleosides 
were then converted to compounds 5a and 5b by treatment with sodium methoxide in 
methanol, followed by the removal of the 3’-O-tert-butyldimethylsilyl group by a fluoride 
treatment. Finally compounds 2a, 2b, 5a and 5b were phosphitylated to yield phosphoramidites 
3a, 3b, 6a and 6b according to previously published procedures.[54] Purification of all the 
phosphoramidites was achieved by using short flash column chromatography and the 
compounds were characterized by 31P NMR spectroscopy (Figures A3.3, A3.10, A3.13 and 
A3.20). The 31P NMR spectra of each phosphoramidite revealed two signals near 147-149 ppm 
region, which is diagnostic for a phosphoramidite.[54] 
 Due to the labile nature of dFU-Me and other O4-adducts, mild deprotection conditions 
were employed for oligonucleotides containing these halogen analogues.[88] “Fast-
deprotecting” commercially available 3’-O-phosphoramidites were used for solid-phase 
synthesis and phenoxyacetic anhydride was used as the capping reagent.[99] Total deprotection 
and cleavage of the oligomers from the solid support was accomplished with an anhydrous 
solution of potassium carbonate in methanol (0.05 M) for four hours at 21oC under gentle 
rocking, followed by neutralization of the excess base with an equimolar amount of acetic acid. 
[88,97] Oligonucleotides containing the different modifications (dClU, dClU-Me, dBrU and dBrU-
Me) were purified by SAX-HPLC and characterized by ESI-MS. The ESI-MS results showed the 
presence of the modifications and the observed masses are in agreement with the expected 
masses (Figures A3.21, A3.22, A3.23 and A3.24). Enzymatic digestion of modified 
oligonucleotides using snake venom phosphodiesterase and calf intestinal phosphatase 
enzymes, followed by analysis using reversed phase HPLC, confirmed the nucleoside 
composition of the oligomers to be consistent with expected ratios  (Figures A3.25 and A3.26).   
 
 











Scheme 4.1: Reagents and conditions: (i) DMTr-Cl, pyridine, DMAP, 16 h, 21 oC; (ii) N,N-
diisopropylaminocyanoethylphosphonamidic chloride, DIPEA, THF, 30 min; (iii) DMTr-Cl, 
pyridine, DMAP, 16 h, 21 oC.; TBS-Cl, Imidazole, DCM, 16 h, 21 oC; (iv) 1,2,4-Triazole, 
triethylamine, POCl3, MeCN, 16 h, 0 
oC; MeOH, NaOMe, 4 h, 21 oC.; TBAF (1M in THF), 30 min; 
(v) N,N-diisopropylaminocyanoethylphosphonamidic chloride, DIPEA, THF, 30 min.  
 
4.3.2 UV thermal denaturation and CD spectroscopy 
 UV thermal denaturation studies were conducted in order to assess the influence of 
chlorine or bromine at the C5-position of the O4-methylated adducts on stability of the DNA 
duplexes. The results are summarized in Figure 4.2 and suggest that upon the methylation at 
the O4-position, there is a decrease in thermal stability of 11 oC relative to the unmodified 
controls. A similar decrease was observed for dFU-Me and the T and dU analogues.[54] The 
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bonding between the dClU-Me:dA and dBrU-Me:dA base pairs and their influence on 
diminished stacking with the flanking base pairs. It was observed that the dClU and dBrU 
controls had a moderately higher Tm value than the dFU (and dU) control (Figures 4.2 and 
A3.31). The difference may be attributed to the higher polarizability of chlorine and bromine, 
relative to fluorine, on the pyrimidine ring that can improve base-stacking.[111,125] The dClU and 
dBrU containing duplexes have a thermal stability slightly lower relative to the T control (62 oC). 
The close resemblance to the T control suggests that C5-chlorine and C5-bromine behave more 
like a methyl than fluorine in terms of their contribution to duplex stability.[111] Overall, the 
presence of chlorine and bromine at the C5 position of 2’-deoxyuridine exhibits a minimal 










Figure 4.2 : Tm values (
oC) of duplexes containing dFU, dFU-Me, dClU, dClU-Me, dBrU, dBrU-
Me. Colorless and grey bars represent the unmodified controls and methylated adducts, 
respectively.  
 The CD profiles shown in Figure 4.3 display spectroscopic signatures consistent with a B-
form DNA family (a maximum at around 280 nm and minimum at approximately 245 nm). The 
CD signatures of dClU-Me and dBrU-Me were similar to their unmodified counterparts (dClU 
and dBrU) and the DNA duplex containing T at the same position. The results suggest that the 
  54 
presence of the O4-methyl group did not cause any major alteration in the overall structure of 
the DNA, as previously observed for dFU, dU and T series.[54] The small variations observed in 
the CD data and the difference in molar absorptivity of the signatures are related to the change 
in the ellipticities due to the 5-halogen substitutions. From the different 5-halogen substitutions 
studied by our group, the duplex containing the C5-fluorine group has the highest ellipticity 
while the lowest ellipticity is observed for the C5-bromine modification which has a higher 
polarizability.[129] The electronic effect of each halogen has an influence on the ellipticities 
observed. Overall, the introduction of the C5-chlorine or C5-bromine group did not induce a 
significant distortion to the global B-form DNA structure.[112]  
 







Figure 4.3: Circular dichroism spectra of duplexes containing dClU (—), dClU-Me (•••), dBrU  
(———), dBrU-Me (—•—) and T (—••—) .  
 
4.3.3 Repair Assays 
 Repair of the C5-halogenated O4-methyl adducts by different AGTs including human AGT 
(hAGT), E. coli OGT and Ada-C in addition to a hAGT / OGT chimera (hOGT) was evaluated. 
These proteins exhibit a wide variety in substrate preference and active site residues between 
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them. Exploring their proficiency at removing O4-methyl lesions allows us to examine if the C5-





Figure 4.4: Time course repair assay of (A) dClU-Me and (B) dBrU-Me by hAGT (•••), OGT (——
—), Ada-C (—•—) and hOGT (—••—) at 5-molar equivalence of protein.  
 
 All four AGTs in this study were found to repair dClU-Me (Figure 4.1 A and Figure 
A3.38). hAGT was the most efficient, demonstrating full repair of dClU-Me in less than 2 min. 
Surprisingly, repair of dClU-Me by hAGT appears to be more efficient than the dFU-Me 
analogue. This was not expected as it was assumed that the bulkier chlorine atom could 
encounter steric clashes in hAGT’s active site. Clearly the C5-chlorine group is readily 
accommodated and may be participating in favorable interactions with active site residues. The 
chimera hOGT protein, where the hAGT protein has twenty active site residues replaced by 
these found in OGT (except for the active site Pro140 residue), displayed reduced proficiency 
towards the dClU-Me substrate achieving almost 50% repair after reaction overnight.  
 The E. coli variants (OGT and Ada-C) were found to have similar proficiency towards 
dClU-Me. These variants reached about 65% repair, which remains at a constant level after 45 
min (Figure A3.38). Although OGT and Ada-C are known to efficiently repair small lesions such 
as methyl groups, the presence of the C5-chlorine group limits a high level of repair efficiency. 
A B 
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Ada-C has been described to have a small and crowded active site, which may not be able to 
accommodate the C5-chlorine group of the O4-methylated nucleobase. Some experiments have 
shown the favorable interactions of chlorine with tryptophan. Therefore even though the 
pocket might be small, it may be compensated by possible interactions between C5-chloro 
group and Trp161.[115,121]  
 For the larger dBrU-Me adduct, moderate repair by the various AGTs was observed. 
hAGT was found to be the least efficient of the AGT proteins at repairing dBrU-Me achieving 
45% repair. Ada-C and OGT were slightly more efficient with approximately 55% repair 
observed. The hOGT chimera’s repair efficiency towards the dBrU-Me adduct was only slightly 
better than hAGT (a similar trend was observed for dFU-Me whereas the opposite occurred for 
dClU-Me). Perhaps with a group the size of bromine at the C5-position, a point is reached 
where the influence is the same for all the AGT proteins evaluated. If this is the case, the repair 
observed will come mostly from favorable interactions of bromine with some proximal residues 
as well as its own electronic effects on the heterocycle. 
 From the repair outcomes observed between the two substrates, the most significant 
difference between the AGT variants was observed for hAGT, which performs full repair of 
dClU-Me and only 46% repair of dBrU-Me. For the AGTs investigated in this study, the human 
variant has been described to contain a slightly larger active site relative to the others, which 
better accomodates a C5-chlorine versus C5-bromine group.  
 Despite chlorine and bromine having a reduced inductive (electron withdrawing) and 
conjugation (electron donating) effect relative to fluorine, they have been shown to interact 
with different residues in proteins.[56] Halogens prefer to interact with hydrophobic amino acids 
(such as leucine and phenylalanine), carbonyl groups of the protein backbone and with other H-
bonding residues such as serine.[115,121] It is proposed that that the C5-chloro and C5-bromo 
groups of 2’-deoxyuridine could be interacting with the Ser159, which forms part of the active 
site wall of hAGT.[51,115] Studies in other protein systems (such as hydronitrile lyase) have shown 
the formation of hydrogen bonds between chlorine and the residues tryptophan and serine.[115] 
Hence, the significant repair efficiency observed by hAGT on dClU-Me could be attributed to 
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the formation of halogen bonds between the C5-chloro group and residues Tyr158 and Ser159. 
In the case of Ada-C, the C5-chloro group could be participating in similar bonds with Trp161. 
The average distance required for the formation of hydrogen-bonds increases as the halogen 












Figure 4.5: Interactions that might occur between C5-Chloro (gold atom) and the residues from 
hAGT active site.  (Modified from PDB 1T38 using UCSF-Chimera)  
 
 Other studies have shown that chlorine has an inclination to interact with leucine and 
bromine with arginine.[115] Arg160 is present in the active site of Ada-C and despite having a 
smaller pocket than hAGT, the presence of C5-bromo group does not impare the ability of Ada-
C to remove the O4-methyl adduct.[31] hAGT contains Arg135, which in previous studies has 
been suggested to sterically clash the aliphatic portion of its side chain with the C5-methyl 
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group of T. Perhaps the C5-bromo group might be interacting with Arg135, despite the size of 
the halogen.[34] Tyr158 also forms part of Ada-C’s active site pocket and thus it could possibly 
hydrogen bond with the C5-bromo group or even to form a halogen bond with the tyrosine’s π-












Figure 4.6: Interactions that might occur between C5-Bromo (darker red atom) and the residues 















Figure 4.7: Possible favourable interaction of C5-Bromo (darker red atom) with Tyr158. 
(Modified from PDB 1T38 using UCSF-Chimera) 
 Both OGT and hOGT have residues in their active site that have been reported to 
interact with chloride and bromide. Residues such as Ser134, conserved Arg141, Arg145, 
Thr148, Thr150 and Tyr152 (the numbering corresponds to the OGT protein) might potentially 
be interacting with the C5-chloro and C5-bromo groups via H-bonds if they are at an optimal 
distance or they may engage in hydrophobic interactions.[130] Unfortunately, to our knowledge, 
no crystal structures of these proteins are available at the moment to aid in this hypothesis.  
 Other examples of interactions related to the present study are those which occur 
between aryl halides and aromatic groups.[115,121] In addition, sulfur containing amino acids 
have also been found to act as halogen bonding partners.[121] Water molecules can also engage 
in halogen bonding between the oxygen atom and the halogen (with optimal distances 
between 2.6 Å to 3.6 Å).[115] The presence of halogen-water bridges with different residues has 
been observed.[116,126] A modification of interest to expand upon the present study is 5-iodo-O4-
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methyl-2’-deoxyuridine. 5-iodouracil is used clinically in order to enhance the efficacy of 
radiotherapy.[65] It would be interesting to investigate repair of 5-iodo-O4-methyl-2’-











Figure 4.8:  Comparison of the repair at 15 sec and 1 min of (A) dFU-Me, (B) dClU-Me and (C) 
dBrU-Me by hAGT, OGT, Ada-C and hOGT.  
 
4.4 Conclusion 
 The synthesis and incorporation of 5-chloro-O4-methyl-2’-deoxyuridine and 5-bromo-O4-
methyl-2’-deoxyuridine phosphoramidites into oligonucleotides by solid-phase synthesis was 
accomplished. The UV thermal denaturation and circular dichroism studies revealed a decrease 
of 11 oC upon the methylation at the O4-atom for both the 5-chloro and 5-bromo derivatives 
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 The repair studies of dClU-Me revealed that hAGT was efficient (in fact, slightly better 
relative to the fluorinated analogue) at removing the O4-methyl lesion. AGT proteins described 
as having a smaller active site (E. coli Ada-C and OGT and the chimera hOGT) were able to repair 
dClU-Me with 42-65% repair observed (Figure 4.8 B).  
 Despite the fact that chlorine is larger than fluorine and hydrogen, it demonstrates 
favourable influence on repair efficiency of an O4-methyl group by hAGT. The size of chlorine 
(smaller than methyl group) and its properties might be optimal to (1) engage in interactions 
with residues in the hAGT’s active site and assist in orienting the lesion towards the thiolate in 
Cys145 and (2) not introduce steric clashes with residues in the hAGT active site.   
 In the case of dBrU-Me, the larger size of bromide did influence repair, with hAGT 
activity the most affected in spite of its slightly larger active site relative to the other AGTs 
studied (Figure 4.8 C). For the O4-methyl adduct only 55% repair was observed by hAGT. 
Regardless of their larger size and potential steric effects, chloride and bromide have the ability 
to interact via halogen bonds with residues such as tyrosine, tryptophan, arginine and serine, 
which might facilitate removal of alkyl lesions at the O4-position. Furthermore, the inductive 
and conjugation effects of these halogens, despite being lower than in fluorine, can influence 
the O4-Cα bond making it more susceptible to removal by AGTs. Further investigation of C5-








  62 
Chapter 5. Conclusions and Future Directions 
 
5.1 Conclusions 
 Starting from 5-fluoro-2’-deoxyuridine, 5-chloro-2’-deoxyuridine and 5-bromo-2’-
deoxyuridine various phosphoramidite derivates of O4-alkyl adducts were successfully prepared 
by multistep synthesis.  These modified nucleosides were incorporated into oligonucleotides 
(14 nucleotides in length) by solid-phase synthesis, deprotected and purified. ESI-MS and 
nuclease digests confirmed the identity and composition of these sequences, ensuring that the 
deprotection conditions employed did not compromise the adducts at the O4-position. 
 UV thermal denaturation studies revealed a decrease of approximately 10oC with the 
introduction of alkylation at the O4-position for the lesions prepared. The unmodified analogues 
exhibited the following trend in duplex stability: T (C5-methyl) > dClU (C5-chloro) ≈ dBrU (C5-
bromo) > dU (C5-hydrogen) ≈ dFU (C5-fluoro) (displayed in Figure 5.1). This trend in 
stabilization most likely arises from differences in stacking interactions of the C5-group of the 
2’-deoxyuridines in the duplex. Circular dichroism spectra of all the O4-modified substrates 
revealed an overall B-form DNA structure with profiles similar to those of the unmodified 
(lacking an O4-alkyl group) duplexes. The small differences in the molar ellipticity likely result 
from minimal perturbations induced by larger lesions in addition to the influence of the 













Figure 5.1: Tm values (
oC) of unmodified duplexes containing T, dU, dFU, dClU, and dBrU. 
 The presence of the C5-fluorine enhances susceptibility towards repair by different 
AGTs. The presence of the C5-fluoro group resulted in a 20-fold increase in repair of an O4-
methyl adduct by hAGT relative to 2’-deoxyuridine (containing a C5-hydrogen) and 100-fold 
incease compared to thymidine (containing a C5-methyl group). The presence of the C5-fluoro 
group also had a positive influence on AGT repair of larger O4-adducts.  hAGT displayed more 
repair activity towards dFU-Et, relative to the 2’-deoxyuridine and thymidine analogs. 
Moreover, hAGT was able to repair the larger dFU-C4OH and dFU-C7OH adducts, which was not 
observed for the corresponding 2’-deoxyuridine and thymidine adducts. 
 Surprisingly, Ada-C was able to repair the larger dFU-Bn and dFU-C4OH adducts. For the 
bulky 4-hydroxybutyl and 7-hydroxyheptyl adducts at the O4-position, all AGTs displayed 
greater proficiency towards the latter except Ada-C (where no repair of 7-hydroxyheptyl 
occurred). The longer adduct is believed to be more capable of adopting an optimal orientation 
for the alkyl transfer as it is possible that its longer carbon chain could allow it to reach a closer 
position towards the reactive cysteine. Ada-C’s active site might be too small due to the 
presence of certain residues such as Trp161 preventing accommodation of the 7-hydroxyheptyl 
adduct. It is proposed that C5-fluorine atom does not encounter steric clashes in the active site 
and that the electronic properties of fluorine (inductive and resonance effects) might affect the 
O4-Cα bond allowing it to be more susceptible towards nucleophilic attack in the AGT active site. 
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In addition, favorable interactions of the C5-fluorine with active site residues may contribute to 
the nucleobase adopting an optimal orientation for transfer of the alkyl group. 
 The influence of size and electronic effects of the C5 group of 2’-deoxyuridine on 
susceptibility to undergo repair by AGTs was explored with substrates containing O4-methyl-5-
chloro-2’-deoxyuridine (dClU-Me) and 5-bromo-O4-methyl-2’-deoxyuridine (dBrU-Me). 
Unexpectedly (despite to the bigger size of both atoms where the van der Waals radius of 
chlorine is 1.75 Å and bromine is 1.85 Å compared to 1.47 Å for fluorine), both substrates were 
repaired by the 4 AGTs. The dClU-Me was efficiently repaired by hAGT. Moreover, dClU-Me 
repair by hAGT occurred faster relative to dFU-Me. This suggests that C5-chloro group might be 
interacting with the active site residues positioning the nucleobase to adopt an optimal 
orientation for the removal of the O4-methyl group. It is assumed that the bigger size of dBrU-
Me presented more of a challenge to the AGTs to repair the O4-methyl group.  All the AGT 
proteins displayed similar repair proficiency towards dBrU-Me with hAGT and Ada-C achieving 
45% and 55% repair, respectively. 
 Fluorine has inductive (σ-withdrawing electrons) and conjugation (π-donating electrons) 
effects that can alter the heterocycle contributing towards making the O4-Cα bond more 
susceptible for the removal of lesions by AGT. These effects are weaker for chlorine followed by 
bromine. In similar systems, such as in fluorotoluenes or fluorobenzenes, it has been observed 
that an ortho-fluoro group or β-fluorination with respect to amino, hydroxy or carboxyl groups 
increases their acidity mostly due to the inductive effect. The ortho-fluoro position with respect 
to these groups also tends to favor nucleophilic reactions (stabilized through the inductive 
effect).[56,62]  
 Studies have shown that fluorine, chlorine and bromine are able to engage in 
interactions with different residues. These halogens can be involved in hydrophobic 
interactions, which has been shown to occur with benzyl moieties.[35,59,63] Halogens can also 
decrease the pKa of neighbouring groups.[59,63] It may be that the fluorine enhances specific 
interactions in the AGT active site leading to a pKa shift by engaging interactions with certain  
active site residues such as Cys145 and His146. Short contacts between fluorine and the thiol 
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from Cys145 and the imidazole ring His146 could enhance the formation of the nucleophile 
required for alkyl transfer resulting in the enhanced efficiency in repair.[61,74,116] Other 
contributions may arise from fluorophilic moieties such as hydroxyl (present in Tyr114 and 












Figure 5.2: Possible interactions of C5-Fluoro (green atom) with residues in hAGT active site. 
(Modified from PDB 1T38 using UCSF-Chimera) 
 
 Halogens can participate in hydrogen bonds but it is not that common and optimal 
conditions and orientation are required for this to occur. Any interaction with fluorine or other 
halogens depends on the distance and position relative to the interacting atoms.[61,115] Chloride 
and bromide’s ability to interact via halogen bonds with residues such as tyrosine, tryptophan, 
arginine and serine might promote a more optimal accommodation and positioning of the 
lesion for removal.  
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 For example in human AGT, the C5-chloro group could be interacting with Tyr158 and 
Ser159 possible through halogen or hydrogen bonds.[115] Chlorine might also achieve similar 
interactions with Trp161 and Tyr159 (located on Ada-C’s active site).[115] Bromine has shown to 
have an inclination to interact with arginine.[115] Therefore it is possible that apart from 
interacting with the previous mentioned residues, this halogen could be interacting with Arg135 
(in hAGT), whose aliphatic region of its side chain is in proximity to the C5-methyl group in T, 
despite some steric issues.[34] Perhaps the underlying cause of why dBrU-Me is repaired by Ada-
C in spite of having a small active pocket could be a possible interaction with Arg160.[102,115]  
 A summary and comparison of the repair of all the different substrates with hAGT, OGT, 
Ada-C and hOGT are shown in Tables 5.1.1, 5.1.2 and 5.1.3. There still exist multiple questions 
for future studies. First, is there space available in the active site of the AGTs for these modified 
substrates? Second, how does the inductive and resonance effects of fluorine (or other 
halogens) make the α carbon of the lesion more prone to the nucleophilic attack by the AGT? 
Finally, once the substrate can fit in the active site, is fluorine able to interact with the active 
site residues and (1) generate certain favorable interactions that allow the nucleophilic attack 
to occur faster? and/or (2) generate interactions that might orient and accommodate the lesion 
better for removal? Many of these effects also depend on the environment. Crystal structures 
of these halogenated modified DNA-AGT complexes would contribute to understanding these 
interactions. It is evident that the C5-fluoro and (to a lesser extent) C5-chloro and C5-bromo 
groups of modified 2’-deoxyuridine have an influence on the repair of O4-alkylated adducts by 
the AGT variants.  
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Table 5.3 Relative repairs of different dFU, dClU and dBrU substrates by different AGTs 
 
+++++ (25% repair observed in < 15sec) 
++++ (25% repair observed between 15sec to1 min) 
+++ (25% repair observed between 1 min to 15 min) 
++ (25% repair observed between 15 min to 30 min) 
+ (25% repair observed in more than 30 min) 
-  (no repair observed) 
*Columns shaded in light orange correspond to the analyses I performed  
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5.2 Future Directions 
 An interesting extension of this study would be to prepare and evaluate repair of 5-
iodo-O4-alkyl-2’-deoxyuridine by the various AGTs. Iodine has a van der Waal radius of 1.95 Å 
and these results would contribute to our understanding of the steric and electronic effects of 
the C5-group on AGT repair of O4-alkyl groups. 5-Iodouracil is a compound that is used as a 
therapeutic agent that enhances radiosensitivity.[65]  
 Another interesting modification to investigate at the C5-position would be the 
trifluoromethyl (CF3) group. CF3 has been used to replace methyl groups in residues such as in 
lysine. Studies have shown that it might have the opposite conjugation effect relative to 
fluorine. For instance in a benzene ring system, CF3 is mainly an electron withdrawing 
substituent with a negative conjugation effect and a dominant inductive effect.[64] Moreover 






Figure 5.3: Structure of (A) 5-iodo-O4-methyl-2’-deoxyuridine and (B) 5-trifluoromethyl-O4-
methyl-2’-deoxyuridine.   
 
 The introduction of fluorine at the nucleobase of intra- and inter-strand crosslinks could 
be of interest to observe whether enhanced repair is observed for these bulky AGT substrates. 
Moreover, the enhaced reactivity observed with the C5-fluoro pyrimidine adducts could be 
exploited to direct the AGT reaction to produce well defined AGT-DNA cross-linked species. 
 Finally, it may be interesting to explore sugar-modified nucleic acids on AGT repair.  One 
example of an analog are the 2’-deoxy-2’-fluoroarabinoses (2’F-ANA) which have shown 
A B 
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promise as gene silencing agents and have a global structure similar to DNA. O4-Alkylated 
analogues of 2’F-ANA that contain modifications at the C5-position, such as 2’-fluoro-5-iodo-1-
β-D-arabinofuranosyluracil (FIAU) and 2’-fluoro-5-fluoro-1-β-D-arabinofuranosyluracil (FFAU), 
could be interesting to investigate as AGT substrates. Moreover, the use of these backbone 
modified and base alkylated oligonucleotides may be exploited as a combined hAGT inhibitor 






Figure 5.4: Structures of (A) FFAU and (B) FMAU  
A B 
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B3LYP/6-31+G(2d,2p) mode 
 
A1.1 Synthesis and characterization of nucleosides and oligonucleotides 
A1.1.1 General  
 5-fluoro-2’-deoxyuridine (compound 1) was purchased from Berry Associates (Dexter, 
Michigan). “Fast deprotecting” 5’-O-Dimethoxytrityl-2’-deoxyribonucleoside-3’-O-(β-
cyanoethyl-N,N-diisopropyl)phosphoramidites and protected 2’-deoxyribonucleoside–CPG 
supports were purchased from Glen Research (Sterling, Virginia). Compounds 2 and 4 were 
prepared according to previously published procedures.[54,97,98] All other chemicals and solvents 
were purchased from the Aldrich Chemical Company (Milwaukee, WI) or EMD Chemicals Inc. 
(Gibbstown, NJ). Flash column chromatography was performed using silica gel 60 (230–400 
mesh) purchased from Silicycle (Quebec City, QC). Thin layer chromatography (TLC) was carried 
out with precoated TLC plates (Merck, Kieselgel 60 F254, 0.25 mm) purchased from EMD 
Chemicals Inc. (Gibbstown, NJ). NMR spectra were recorded on a Varian 500 MHz NMR 
spectrometer at room temperature. 1H NMR spectra were recorded at a frequency of 500.0 
MHz and chemical shifts were reported in parts per million (ppm) downfield from 
tetramethylsilane. 13C NMR spectra (1H decoupled) were recorded at a frequency of 125.7 MHz 
and chemical shifts were reported in ppm with tetramethylsilane as a reference. 19F NMR 
spectra were recorded at a frequency of 470.4 MHz and chemical shifts were reported in ppm 
with trichlorofluoromethane as a reference. 31P NMR spectra (1H decoupled) were recorded at 
a frequency of 202.3 MHz and chemical shifts were reported in ppm with H3PO4 used as an 
external standard. High resolution mass spectrometry of modified nucleosides were obtained 
using an 7T-LTQ FT ICR instrument (Thermo Scientific), at the Concordia University Centre for 
Structural and Functional Genomics. The mass spectrometer was operated in full scan, positive 
ion detection mode. ESI mass spectra for oligonucleotides were obtained at the Concordia 
University Centre for Biological Applications of Mass Spectrometry (CBAMS) using a Micromass 
Qtof2 mass spectrometer (Waters) equipped with a nanospray ion source. The mass 
spectrometer was operated in full scan, negative ion detection mode. T4 polynucleotide kinase 
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(PNK) was obtained from New England BioLabs (NEB). [γ-32P]ATP was purchased from 
PerkinElmer (Woodbridge, ON). The Bcll restriction enzyme was purchased from New England 
Biolabs (Ipswich, MA).  
3’-O-(2-Cyanoethoxy(diisopropylamino)-phosphino)-5’-O-(4,4’-dimethoxytrityl)- 5-fluoro-2’-
deoxyuridine (3) DIPEA (0.19 mL, 1.12 mmol) was added to a solution of 5’-O-(4,4’-
dimethoxytrityl)-5-fluoro-2’-deoxyuridine (0.204 g, 0.372 mmol) in THF (3.7 mL), followed by 
the dropwise addition of N,N-diisopropylamino cyanoethyl phosphonamidic chloride (0.2 mL, 
0.893 mmol). After 30 min, the solvent was evaporated in vacuo, the crude product was taken 
up in ethyl acetate (40 mL), the solution was washed with 3% (w/v) solution of NaHCO3 (2 x 
50mL) and once with brine (50 mL). The organic layer was dried over anhydrous Na2SO4 (~ 4 g), 
and concentrated in vacuo. The crude product was purified by flash column chromatography 
using a hexanes/ethyl acetate (2:8) solvent system to afford 0.187 g (67%) of a colorless foam. 
Rf (SiO2 TLC): 0.87 (100% EtOAc). λmax(MeCN) = 268 nm. HRMS (ESI-MS) m/z calculated for 
C39H47FN4O8P
+: 749.3110; found 749.3104 [M + H]+. 1H NMR (500 MHz, d6-acetone, ppm): 7.93 
(d, J= 6.3 Hz, 0.5H; H6), 7.91 (d, J= 6.3 Hz, 0.5H; H6), 7.23–7.53 (m, 9H; Ar), 6.90-6.93 (m, 4H; 
Ar), 6.28-6.32 (m, 1H; H1’), 4.71-4.78 (m, 1H; H3’), 4.17-4.24 (m, 1H; H4’), 3.59-3.93 (m, 10H; 
NCH, ArOCH3, CH2OP), 3.39-3.50 (m, 2H; H5’, H5’’), 2.77-2.79 (t, J= 6 Hz, 1H; CH2CN), 2.65-2.67 
(t, J= 6 Hz, 1H; CH2CN), 2.47-2.52 (m, 1H; H2’), 2.06-2.07 (m, 1H; H2’’), 1.20-1.22 (m, 10H; CH3), 
1.13-1.14 (m, 2H; CH3). 
13C NMR (125.7 MHz, d6-acetone, ppm): 160.99, 158.82, 156.61, 148.65, 
144.96, 139.64, 137.15, 135.65, 135.55, 130.12, 130.09, 128.07, 128.03, 127.81, 126.80, 126.77, 
117.84, 113.11, 86.67, 86.61, 85.42, 85.39, 85.08, 85.01, 63.29, 63.15, 58.71, 58.56, 54.64, 
51.09, 43.11, 43.01, 39.33, 24.02, 23.96, 23.93, 19.85, 19.79. 19F NMR (470.4 MHz, d6-acetone, 
ppm): -167.84, -167.85, -167.90, -167.91. 31P NMR (202.3 MHz, d6-acetone, ppm): 148.31, 
148.34. IR (thin film); νmax (cm
−1) = 3195, 3066, 2967, 2932, 2836, 2362, 2336, 2252, 1717, 1607, 
1508, 1464, 1251, 1179, 1125, 829, 736. 
5’-O-(4,4’-Dimethoxytrityl)-5-fluoro-O4-methyl-2’-deoxyuridine (5): To a solution of triazole 
(0.28 g, 4.07 mmol) in anhydrous MeCN (6 mL) at 0oC under stirring, was added dropwise POCl3 
(0.084 ml, 0.91 mmol) followed by triethylamine (0.543 mL, 3.89 mmol). A solution of 3’-O-
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(tert-butyldimethylsilyl)-5’-O-(4,4’-dimethoxytrityl)-5-fluoro-2’-deoxyuridine (0.300 g, 0.45 
mmol) in anhydrous MeCN (6 mL) was added to the triazole solution. After 40 min, an 
additional solution of triazole (0.28 g, 4.07 mmol), POCl3 (0.084 mL, 0.91 mmol) and 
triethylamine (0.543 mL, 3.89 mmol) in anhydrous MeCN (3 mL) was added dropwise with 
stirring at 0oC to the solution containing the nucleoside. This extra addition was repeated for a 
second time after 40 min. After 1 h, the solvent was evaporated in vacuo, the crude was taken 
up in MeOH (7 mL) and a solution of NaOMe (0.086 g, 1.6 mmol) in MeOH (7 mL) was added. 
After 30 min, an additional solution of NaOMe (0.086 g, 1.6 mmol) in MeOH (3 mL) was added 
to the nucleoside. After 16 h, the solvent was evaporated in vacuo and the crude product was 
taken up in CH2Cl2 (40 mL), washed with a 3% (w/v) solution of NaHCO3 (2 x 50 ml), dried over 
anhydrous Na2SO4 (~ 4 g), and concentrated in vacuo. The crude product was taken up in THF 
(4.5 mL) and TBAF (1 M in THF) (0.543 mL, 0.54 mmol) was added drop-wise. After 30 min, the 
solvent was evaporated in vacuo and the crude product was taken up in CH2Cl2 (40 mL), washed 
with a 3% (w/v) solution of NaHCO3 (2 x 50 ml), dried over anhydrous Na2SO4 (~ 4 g), and 
concentrated in vacuo. The crude product was purified by flash column chromatography using a 
gradient of CH2Cl2/MeOH (49.5:0.5  49:1) as eluent to afford 0.189 g (74%) of a colorless 
foam. Rf (SiO2 TLC): 0.63 (100% EtOAc). λmax(MeCN) = 283 nm. HRMS (ESI-MS) m/z calculated for 
C31H31FN2NaO7
+: 585.2008; found 585.2006 [M + Na]+. 1H NMR (500 MHz, CDCl3, ppm): 8.06 (d, 
J= 5.6 Hz, 1H; H6), 7.21–7.41 (m, 9H; Ar), 6.83– 6.85 (m, 4H; Ar), 6.25-6.27 (m, 1H; H1’), 4.55-
4.57 (m, 1H; H3’), 4.15-4.17 (m, 1H; H4’), 4.04 (s, 3H; OCH3) 3.79 (s, 6H; ArOCH3), 3.42 (m, 2H; 
H5’, H5’’), 3.18 (s, 1H; OH), 2.72-2.76 (m, 1H; H2’), 2.23-2.28 (m, 1H; H2’’). 13C NMR (125.7 MHz, 
CDCl3, ppm): 162.68, 162.58, 158.63, 153.55, 144.31, 137.68, 135.72, 135.42, 135.25, 129.98, 
129.96, 127.98, 127.93, 127.68, 127.43, 127.02, 113.31, 113.29, 87.10, 87.02, 86.59, 63.11, 
55.22, 55.07, 42.03. 19F (470.4 MHz, CDCl3, ppm): -168.60, -168.62. IR (thin film); νmax (cm
−1) = 
3423, 2362, 2335, 1652, 1635, 1 506, 1497, 1403, 1251, 1176, 1035, 828. 
3’-O-(2-Cyanoethoxy(diisopropylamino)-phosphino)-5’-O-(4,4’-dimethoxytrityl)-5-fluoro-O4-
methyl-2’-deoxyuridine (6): DIPEA (0.14 mL, 0.80 mmol) was added to a solution of (5) (0.150 
g, 0.266 mmol) in THF (2.7 mL), followed by the dropwise addition of N,N-diisopropylamino 
cyanoethyl phosphonamidic chloride (0.14 mL, 0.64 mmol). After 30 min, the solvent was 
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evaporated in vacuo, the crude product was taken up in ethyl acetate (40 mL), then the solution 
was washed with a 3% (w/v) solution of NaHCO3 (2 x 50 ml) and once with brine (50 mL). The 
organic layer was dried over anhydrous Na2SO4 (~ 4 g) and concentrated in vacuo. The crude 
product was purified by flash column chromatography using a hexanes/ethyl acetate (2:8) 
solvent system to afford 0.173 g (86%) of a colorless foam. Rf (SiO2 TLC): 0.11, 0.26 (1:1 
Hexanes/EtOAc). λmax(MeCN) = 283 nm. HRMS (ESI-MS) m/z calculated for C40H49FN4O8P
+: 
763.3267; found 749.3104 [M + H]+. 1H NMR (500 MHz, CDCl3, ppm): 8.16 (d, J= 6.3 Hz, 0.5H; 
H6), 8.13 (d, J= 6.3 Hz, 0.5H; H6), 7.23–7.53 (m, 9H; Ar), 6.89– 6.93 (m, 4H; Ar), 6.18-6.23 (m, 
1H; H1’), 4.70-4.78 (m, 1H; H3’), 4.22-4.29 (m, 1H; H4’), 3.97-3.98 (s, 3H; OCH3), 3.63-3.88 (m, 
10H; NCH, ArOCH3, CH2OP), 3.43-3.52 (m, 2H; H5’, H5’’), 2.77-2.80 (t, J= 5.9 Hz, 1H; CH2CN), 
2.60-2.70 (t, J= 5.9 Hz, 1H; CH2CN), 2.39-2.47 (m, 1H; H2’’), 2.06-2.07 (m, 1H; H2’’) 1.20-1.23 (m, 
9H; CH3), 1.12-1.14 (m, 3H; CH3). 
13C NMR (125.7 MHz, CDCl3, ppm): 162.27, 162.17, 158.83, 
152.36, 144.93, 137.15, 137.12, 135.62, 135.60, 135.51, 135.47, 135.21, 135.18, 130.11, 130.08, 
128.06, 127.82, 127.81, 127.68, 127.65, 126.81, 126.79, 118.07, 117.94, 113.13, 113.11, 86.70, 
86.65, 86.58, 86.51, 85.73, 85.70, 85.46, 85.41, 73.18, 73.05, 72.71, 72.58, 63.00, 62.80, 58.73, 
58.67, 58.58, 58.52, 54.65, 54.63, 53.98, 43.13, 43.11, 43.03, 43.01, 40.36, 40.34, 40.17, 
40.13,19.90, 19.86, 19.84, 19.81. 19F (470.4 MHz, d6-acetone, ppm): -171.63, -171.64, -171.68, -
171.70. 31P NMR (202.3 MHz, d6-acetone, ppm): 148.35, 148.21. IR (thin film); νmax (cm
−1) 
=3071, 2966, 2869, 2836, 2362, 2335, 2252, 1683, 1652, 1607, 1541, 1506, 1457, 1401, 1336, 
1252, 1179, 1116, 1035, 977, 829, 734. 
 
A1.1.2 Preparation, purification and characterization of the dFU oligonucleotides 
The sequences containing the dFU adducts, which are shown in Figure 2.1, were assembled 
with an Applied Biosystems Model 3400 synthesizer on a 1.5 mol scale using β-
cyanoethylphosphoramidite chemistry supplied by the manufacturer with slight modifications 
to coupling times. The nucleoside phosphoramidites protected with "fast-deprotecting" groups 
were prepared in anhydrous MeCN at a concentration of 0.1 M for the 3’-O-
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deoxyphosphoramidites. Oligomer sequence assembly was carried out as previously 
described.[54,97] The capping step of the assembly was carried out using phenoxyacetic 
anhydride/pyridine/tetrahydrofuran 1:1:8 (v/v/v; solution A) and 1-methyl-imidazole/ 
tetrahydrofuran 16:84 (w/v; solution B). Coupling wait times for phosphoramidites 3 and 7 
were extended to 10 min (compared to 2 min for the commercially available 
phosphoramidites). Protecting group removal and cleavage from the solid support was carried 
out by treatment with 0.05M K2CO3 in MeOH for 4 h at room temperature with mild rocking in 
2 mL screw-cap microfuge tubes fitted with teflon lined caps. The base was neutralized with an 
equimolar amount of AcOH and crude oligomers were transferred and lyophilized in a Speedvac 
concentrator. Purification was achieved by strong anion exchange HPLC using a Dionex DNAPAC 
PA-100 column (0.4 cm x 25 cm) purchased from Dionex Corp, Sunnyvale, CA using a linear 
gradient of 0–52% buffer B over 24 min (buffer A: 100 mm Tris HCl, pH 7.5, 10% MeCN and 
buffer B: 100 mm Tris HCl, pH 7.5, 10% MeCN, 1 M NaCl) at 55 oC. The columns were monitored 
at 260 nm for analytical runs or 280 nm for preparative runs. The purified oligomers were 
desalted using C-18 SEP PAK cartridges (Waters Inc.) as previously described.[132] The molecular 
mass of the modified oligomers was identified by deconvolution of the ESI-MS and the 
measured values were in agreement with the expected masses (please see Figures A1.13 and 
A1.14 for MS spectra). dFU-Me (0.05 A260 units) was  also characterized by enzymatic digestion 
(snake venom phosphodiesterase: 0.28 units and calf intestinal phosphatase: 5 units, in 10 mM 
Tris, pH 8.1 and 2 mM MgCl2) for 48 h at 37 
oC. The resulting nucleoside mixture was analyzed 
by reversed phase HPLC carried out using a Symmetry® C-18 5 μm column (0.46 x 15 cm) via a 
linear gradient of 0-70% buffer B over 30 min (buffer A: 50 mM sodium phosphate, pH 5.8, 2% 
MeCN and buffer B: 50 mM sodium phosphate, pH 5.8, 50% MeCN). Results and nucleoside 
ratios from digestion are shown in Figure A1.15. 
A1.2 UV thermal denaturation 
 Molar extinction coefficients for the unmodified and dFU modified oligonucleotides 
were calculated from those of the mononucleotides and dinucleotides using the nearest-
neighbor approximations (M-1 cm-1). All duplexes were prepared by mixing equimolar amounts 
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of the interacting strands and lyophilizing the mixture to dryness. The resulting pellet was then 
dissolved in 90 mM sodium chloride, 10 mM sodium phosphate, 1 mM EDTA buffer (pH 7.0) to 
give a final duplex concentration of 3.6 μM. Prior to the thermal run, samples were degassed by 
placing them in a speed- vac concentrator for 2 min. Annealing curves were acquired at 260 nm 
starting at 95 oC and decreasing temperature at a rate of cooling of 0.5 oC min-1 until 15 oC, 
using a Varian CARY Model 3E spectrophotometer fitted with a 6-sample thermostated cell 
block and a temperature controller. The samples were then denatured by heating from 15 oC to 
95 oC at an increasing temperature rate of 0.5 oC min-1 to show reversibility. Processing of the 
UV thermal denaturation data was carried out as described by Puglisi and Tinoco[133] and 
transferred to Microsoft ExcelTM for viewing.  
A1.3 Circular dichroism (CD) spectroscopy 
 Circular dichroism spectra were obtained on a Jasco J-815 spectropolarimeter equipped 
with a Julaba F25 circulating bath. Samples were allowed to equilibrate for 5 min at 15 oC in 90 
mM NaCl, 10 mM sodium phosphate, 1 mM EDTA (pH 7.0), at a final duplex concentration of 
3.6 μM. Each spectrum was an average of 3 scans, collecting at a rate of 50 nm min-1, with a 
bandwidth of 1 nm and sampling wavelength of 0.2 nm using fused quartz cells (Starna 29-Q-
10). The CD spectra were recorded from 350 to 220 nm at 15 oC. The molar ellipticity (φ) was 
calculated from the equation φ = ε/Cl, where ε is the relative ellipticity (mdeg), C is the molar 
concentration of oligonucleotides (moles/L), and l is the path length of the cell (cm). The data 
were processed using software supplied by the manufacturer (JASCO, Inc.) and transferred into 
Microsoft ExcelTM for viewing. 
A1.4 AGT repair assay of the Modified DNA duplexes  
 DNA substrates were labeled at the 5’-end using γ-[ 32P]-ATP as previously described.5 
Briefly, a 20 μM solution of DNA was made in 1X PNK buffer along with 1 μL γ-[ 32P]-ATP (10 μCi 
μL−1 ) and 5 units of T4 PNK. The labeling reaction was performed for 1 h at 37 °C after which 
the reaction was terminated by boiling the sample for 5 min. 100 pmol of labeled DNA was 
added to 110 pmol of the complement strand in a total volume of 50 μL of water making a 2 
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μM dsDNA solution with 10% excess of the non-damaged/non-modified strand. The solution 
was boiled for 2 min, cooled slowly to room temperature and kept in a refrigerator at 4 °C 
overnight to ensure proper annealing of the duplex. The repair reaction mixtures were 
constituted of 2 pmol of the DNA duplex and 10 pmol of AGT in a total volume of 15 μL of 
Activity Buffer [10 mM Tris–HCl (pH 7.6), 100 mM NaCl and 1 mM DTT] and allowed to react at 
37 °C for 2.5 hours and overnight. The samples were boiled for 5 min and 1.66 μL of 0.1 M 
MgCl2 followed by 7.5 units of Bcll enzyme were added. Samples were incubated for at least 45 
min at 37 °C. The reaction was terminated by the addition of 24 μL of stop buffer [81 mM Tris–
HCl, 81 mM boric acid, 1.8 mM EDTA and 1% SDS (sodium dodecyl sulfate) (pH 8.0) in 80% 
formamide] followed by boiling for 2 min. Samples (10 μL) were loaded on a 14 cm × 16 cm, 
20% 7 M urea denaturing polyacrylamide gel (19:1) for separation. The gels were run using 1X 
TBE for 1 h at 450 V and the gels exposed to a storage phosphoroscreen. The image was 
captured on a Typhoon 9400 (GE Healthcare, Piscataway, NJ) and the autoradiography counts 
obtained by Image-Quant™ (Amersham Biosciences). For the repair time course assays, master 
mixes of 75 μL composed of 100 pmol (5-fold) of AGT and 20 pmol of DNA substrate were 
prepared. Each sample was placed at 37 oC and at each time point, 7.5 μL was removed from 
the master mix and placed in a tube with 0.8 μL 0.1 M MgCl2. 7.5 units of Bcll enzyme were then 
added to each tube and they were incubated for at least 45 min at 37 °C. 12 µL of stop reaction 
buffer were then added and analysis was performed as described above. All reactions were 
analyzed by polyacrylamide gel electrophoresis (using 1X TBE for 1 h at 450 V) and visualized as 
described above. 
A1.5 Molecular modelling  
 Molecular modeling was performed by using the Hyperchem 7.5 software package from 
Hypercube utilizing the AMBER force field. Hybridized oligomers containing a T·dA, dFU·dA, and 
dFU-Me·dA base pair were constructed from the nucleic acid template option using a B-form 
duplex. Sequence contexts were the following 5’-GGC TXG ATC ACC AG and 3’-CCG AYC TAG 
TGG TC for proper solvation. Duplexes were solvated with water using a periodic box. Standard 
Amber99 parameters were used with the dielectric set to constant “one to four scale factors” 
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and non-bonded interactions were set to 0.5 (both electrostatic and van der Waals). Cutoffs 
were applied to “switched” to an outer and inner radius of 14.5 and 10.5 Å. All structures were 
geometry optimized using Polak-Ribiere conjugate gradient until the RMS gradient was less 
than 0.1 kcal/(Å mol) using the periodic boundary condition option. 
 
A1.6 Geometry optimization 
 GaussView was the visualization software employed and Gaussian 09 was the software 
used for the calculation of the geometrical optimized structures under the B3LYP/6-
31+G(2d,2p) mode. 136-139 
 
Figure A1.1: Structures of (A) O6-benzylguanine (hAGT inhibitor).[90–92] (B) 5-fluorouracil.[96,134] 
(C) 2’-deoxy-2’-fluoro-arabinonucleic acid (F-ANA)[72] 
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Figure A1.4 - 470.4 MHz 19F NMR spectrum of compound (3) (in d6-acetone)  
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Figure A1.5 - 202.3 MHz 31P NMR spectrum of compound (3) (in d6-acetone)  
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Figure A1.6 - 500 MHz 1H NMR spectrum of compound (5) (in CDCl3) 
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 Figure A1.7 - 125.7 MHz 13C NMR spectrum of compound (5) (in CDCl3) 
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Figure A1.8 - 470.4 MHz 19F NMR spectrum of compound (5) (in CDCl3) 
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 Figure A1.9 - 500 MHz 1H NMR spectrum of compound (6) (in d6-acetone) 
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 Figure A1.10 - 125.7 MHz 13C NMR spectrum of compound (6) (in d6-acetone) 
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Figure A1.11 - 470.4 MHz 19F NMR spectrum of compound (6) (in d6-acetone) 
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Figure A1.12 - 202.3 MHz 31P NMR spectrum of compound (6) (in d6-acetone) 
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 Figure A1.15- C-18 reversed phase HPLC profile of nuclease-digested dFU-Me. The column was 
eluted with a linear gradient of 0-70% buffer B over 30 min (buffer A: 50 mM sodium 









dC 4 4.0 
dG 4 4.1 
dA (dI) 3 2.4 
dT 2 2.0 
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 Figure A1.16- SAX-HPLC profile of dFU-Me crude (A) and pure (B). The column (Dionex DNAPAC 
PA- 100) was eluted using a linear gradient of 0-70% buffer B over 30 min (buffer A: 100 mM 
Tris HCl, pH 7.5, 10% MeCN and buffer B: 100mM Tris HCl, pH 7.5, 10% MeCN, 1 M NaCl) 
Figure A1.17 - Hyperchromicity change (A260) versus temperature (
oC) profiles of duplexes 













  104 
Figure A1.18 - Circular dichroism spectra of duplexes containing dFU (—), dFU-Me (———) and 
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Figure A1.19 - Time course repair gel of duplexes containing dFU-Me by (A) hAGT, (B) OGT, (C) 
Ada-C and (D) hOGT. (A) Denaturing gel of the repair of 2 pmol of dFU-Me by 10 pmol hAGT as 
a function of time: lane 1, 2 pmol Control; lanes 2-10, 2 pmol  + 10 pmol hAGT incubated for 
0.25, 0.5, 0.75, 1, 1.5, 2, 5, 15, 45 min, respectively. (B) Denaturing gel of the repair of 2 pmol of 
dFU-Me by 10 pmol OGT as a function of time: lane 1, 2 pmol Control; lanes 2-10, 2 pmol  + 10 
pmol OGT incubated for 0.25, 0.5, 0.75, 1, 1.5, 2, 5, 15, 45 min, respectively. (C) Denaturing gel 
of the repair of 2 pmol of dFU-Me by 10 pmol Ada-C as a function of time: lane 1, 2 pmol 
Control; lanes 2-10, 2 pmol  + 10 pmol Ada-C incubated for 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 5, 15, 45, 
150 min, respectively. (D) Denaturing gel of the repair of 2 pmol of dFU-Me by 10 pmol hOGT as 
a function of time: lane 1, 2 pmol Control; lanes 2-10, 2 pmol  + 10 pmol hOGT incubated for 
0.25, 0.5, 0.75, 1, 1.5, 2, 3, 5, 15, 45, 150 min, respectively. All the time courses were performed 
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Figure A1.20 – Molecular models of unmodified control duplex (T) and duplexes containing dFU 
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Figure A1.21– Geometry optimization of the dFU-Me, dU-Me and T-Me nucleobases with a 
methyl group at the N1 atom using Gaussian 09 and B3LYP/6-31+G(2d,2p) mode (Red sphere: 
oxygen; White sphere: hydrogen; Grey sphere: carbon; Blue sphere: nitrogen; Light blue 
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A2.1 Synthesis and characterization of nucleosides and oligonucleotides 
A2.1.1 General  
 5-fluoro-2’-deoxyuridine was purchased from Berry Associates (Dexter, Michigan). “Fast 
deprotecting” 5’-O-dimethoxytrityl-2’-deoxyribonucleoside-3’-O-(β-cyanoethyl-N,N-
diisopropyl)phosphoramidites and protected 2’-deoxyribonucleoside–CPG supports were 
purchased from Glen Research (Sterling, Virginia). Compound 1 was prepared according to 
previously published procedures. [54,97,98] All other chemicals and solvents were purchased from 
the Aldrich Chemical Company (Milwaukee, WI) or EMD Chemicals Inc. (Gibbstown, NJ). Flash 
column chromatography was performed using silica gel 60 (230–400 mesh) purchased from 
Silicycle (Quebec City, QC). Thin layer chromatography (TLC) was carried out with precoated TLC 
plates (Merck, Kieselgel 60 F254, 0.25 mm) purchased from EMD Chemicals Inc. (Gibbstown, NJ). 
NMR spectra were recorded on a Varian 500 MHz NMR spectrometer at room temperature. 1H 
NMR spectra were recorded at a frequency of 500.0 MHz and chemical shifts were reported in 
parts per million (ppm) downfield from tetramethylsilane. 13C NMR spectra (1H decoupled) 
were recorded at a frequency of 125.7 MHz and chemical shifts were reported in ppm with 
tetramethylsilane as a reference. 19F NMR spectra were recorded at a frequency of 470.4 MHz 
and chemical shifts were reported in ppm with trichlorofluoromethane as a reference.31P NMR 
spectra (1H decoupled) were recorded at a frequency of 202.3 MHz and chemical shifts were 
reported in ppm with H3PO4 used as an external standard. High resolution mass spectrometry of 
modified nucleosides were obtained using an 7T-LTQ FT ICR instrument (Thermo Scientific), at 
the Concordia University Centre for Structural and Functional Genomics. The mass 
spectrometer was operated in full scan, positive ion detection mode. ESI mass spectra for 
oligonucleotides were obtained at the Concordia University Centre for Biological Applications of 
Mass Spectrometry (CBAMS) using a Micromass Qtof2 mass spectrometer (Waters) equipped 
with a nanospray ion source. The mass spectrometer was operated in full scan, negative ion 
detection mode. T4 polynucleotide kinase (PNK) was obtained from New England BioLabs 
(NEB). [γ-32P]ATP was purchased from PerkinElmer (Woodbridge, ON). Bcll restriction enzyme 
was obtained from New England Biolabs (Ipswich, MA).  
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5’-O-(4,4’-Dimethoxytrityl)-5-fluoro-O4-ethyl-2’-deoxyuridine (2a): To a solution of triazole 
(0.28 g, 4.07 mmol) in anhydrous MeCN (5.6 mL) at 0oC under stirring, was added dropwise 
POCl3 (0.084 ml, 0.91 mmol) followed by triethylamine (0.543 mL, 3.89 mmol). A solution of 3’-
O-(tert-butyldimethylsilyl)-5’-O-(4,4’-dimethoxytrityl) -5-fluoro-2’-deoxyuridine (0.300g, 
0.45mmol) in anhydrous MeCN (5.6mL) was added to the triazole solution. After 40 min, an 
additional solution of triazole (0.28 g, 4.07 mmol), POCl3 (0.084 mL, 0.91 mmol) and 
triethylamine (0.543 mL, 3.89 mmol) in anhydrous MeCN (3 mL) was added dropwise with 
stirring at 0oC to the solution containing the nucleoside. This extra addition was repeated for a 
second time after 40 min.  After 1 h, the solvent was evaporated in vacuo, the crude was taken 
up in EtOH (6 mL) and a solution of NaOEt (0.108 g, 1.1 mmol) in EtOH (6 mL) was added. After 
30 min, an additional solution of NaOEt (0.108 g, 1.1 mmol) in EtOH (3 mL) was added to the 
nucleoside. After 16 h, the solvent was evaporated in vacuo and the crude product was taken 
up in CH2Cl2 (40 mL), washed with a 3% (w/v) solution of NaHCO3 (2 x 50 ml), dried over 
anhydrous Na2SO4 (~ 4 g), and concentrated in vacuo. The crude product was taken up in THF 
(4.5 mL) and TBAF (1 M in THF) (0.543 mL, 0.54 mmol) was added drop-wise. After 30min, the 
solvent was evaporated in vacuo and the crude product was taken up in CH2Cl2 (40 mL), washed 
with a 3% (w/v) solution of NaHCO3 (2 x 50 ml), dried over anhydrous Na2SO4 (~ 4 g), and 
concentrated in vacuo. The crude product was purified by flash column chromatography using a 
EtOAc/hexanes (6:4 7:3) gradient as eluent to afford 0.154 mg (59%) of a colorless foam. Rf 
(SiO2 TLC): 0.60  (100% EtOAc). λmax(MeCN) = 283 nm. HRMS (ESI-MS) m/z calculated for 
C32H33FN2NaO7
+: 599.2164; found 599.2165 [M + Na]+. 1H NMR (500 MHz, CDCl3, ppm): 8.00-
8.01 (d, J= 8.0 Hz, 1H; H6), 7.24–7.42 (m, 9H; Ar), 6.84– 6.86 (m, 4H; Ar), 6.22-6.25 (dd, J= 6.24 
Hz, 1H; H1’), 4.49-4.55 (m, 3H; H3’, CH2), 4.08-4.15 (m, 1H; H4’), 3.80 (s, 6H; ArOCH3), 3.41-3.48 
(m, 2H; H5’, H5’’), 2.64-2.69 (m, 1H; H2’), 2.24-2.29 (m, 1H; H2’’), 1.41-1.44 (t, J= 7.4 Hz, 3H; 
CH3). 
13C NMR (125.7 MHz, CDCl3, ppm): 158.65, 135.37, 135.25, 129.98, 128.01, 127.94, 
127.05, 113.31, 87.07, 86.72, 86.20, 77.25, 76.99, 76.74, 71.53, 64.22, 62.91, 58.23, 41.83, 
14.11. 19F (470.4 MHz, CDCl3, ppm): -168.43, -168.44. IR (thin film); νmax (cm
−1) = 3420, 3054, 
2966, 2837, 2362, 2331, 1675, 1652, 1549, 1495, 1457, 1385, 1332, 1250, 1177, 1093, 1034, 
828, 736. 
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5’-O-(4,4’-Dimethoxytrityl)-5-fluoro-O4-benzyl-2’-deoxyuridine (2b): To a solution of triazole 
(0.188 g, 2.72 mmol) in anhydrous MeCN (3 mL) at 0oC under stirring, was added dropwise 
POCl3 (0.056 mL, 0.60 mmol) followed by triethylamine (0.362 mL, 2.6 mmol). A solution of 3’-
O-(tert-butyldimethylsilyl)-5’-O-(4,4’-dimethoxytrityl)-5-fluoro-2’-deoxyuridine (0.200 g, 0.30 
mmol) in anhydrous MeCN (3 mL) was added to the triazole solution. After 40 min, an 
additional solution of triazole (0.188 g, 2.72 mmol), POCl3 (0.056 mL, 0.60 mmol) and 
triethylamine (0.362 mL, 2.6 mmol) in anhydrous MeCN (2 mL) was added dropwise with 
stirring at 0oC to the solution containing the nucleoside.  This extra addition was repeated for a 
second time after 40 min.  After 1 h, the solvent was evaporated in vacuo and the crude was 
taken up in MeCN (4 mL). BnOH (0.320 mL, 3.1 mmol) was added dropwise followed by the 
addition of DBU (0.104 mL, 1.02 mmol).  After 16 h, the solvent was evaporated in vacuo and 
the crude product was taken up in CH2Cl2 (40 mL), washed with a 3% (w/v) solution of NaHCO3 
(2 x 50 mL), dried over anhydrous Na2SO4 (~ 4 g), and concentrated in vacuo. The crude product 
was taken up in THF (4 mL) and TBAF (1 M in THF) (0.36 mL, 0.36 mmol) was added drop-wise. 
After 30min, the solvent was evaporated in vacuo and the crude product was taken up in CH2Cl2 
(40 mL), washed with a 3% (w/v) solution of NaHCO3 (2 x 50 ml), dried over anhydrous Na2SO4 
(~ 4g), and concentrated in vacuo. The crude product was purified by flash column 
chromatography using CH2Cl2/MeOH (49:1) as eluent to afford 0.111 mg (58%) of a colorless 
foam. Rf (SiO2 TLC): 0.66 (CH2Cl2/MeOH (47.5:2.5)). λmax(MeCN) = 283 nm. HRMS (ESI-MS) m/z 
calculated for C37H35FN2NaO7
+: 661.2321; found 661.2322 [M + Na]+. 1H NMR (500 MHz, CDCl3, 
ppm): 8.06-8.07 (d, J= 8.06 Hz, 1H; H6), 7.18–7.47 (m, 15H; Ar, Bn), 6.83– 6.86 (m, 4H; Ar), 6.26-
6.28 (dd, J= 6.27 Hz, 1H; H1’), 5.49 (s, 2H; OCH2 Bn) 4.53-4.55 (m, 1H; H3’), 4.13-4.15 (m, 1H; 
H4’), 3.79 (s, 6H; ArOCH3), 3.41-3.47 ( m, 2H; H5’, H5’’), 2.70-2.76 (m, 1H; H2’), 2.25-2.31 (m, 
1H; H2’’). 13C NMR (125.7 MHz, CDCl3, ppm): 162.12, 162.01, 158.66, 153.36, 144.29, 137.56, 
135.59, 135.37, 135.23, 134.80, 129.98, 129.96, 129.12, 128.62, 128.57, 127.92, 127.58, 127.04, 
113.33, 113.30, 113.17, 87.08, 86.45, 85.98, 77.26, 77.01, 76.75, 71.63, 69.50, 63.00, 55.23, 
41.96, 0.01. 19F (470.4 MHz, CDCl3, ppm): -168.09, -168.10. IR (thin film); νmax (cm
−1) = 3384, 
2929, 2836, 2361, 2337, 1683, 1645, 1540, 1507, 1487, 1456, 1360, 1251, 1177, 1094, 1034, 
828, 735, 699. 
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3’-O-(2-Cyanoethoxy(diisopropylamino)-phosphino)-5’-O-(4,4’-dimethoxytrityl)- 5-fluoro-O4-
ethyl- 2’-deoxyuridine (3a) : DIPEA (0.14 mL, 0.80 mmol) was added to a solution of (2a) (0.154 
g, 0.266 mmol) in THF (2.7 mL), followed by the dropwise addition of N,N-diisopropylamino 
cyanoethyl phosphonamidic chloride (0.14 mL, 0.64 mmol). After 30 min, the solvent was 
evaporated in vacuo, the crude product was taken up in ethyl acetate (40 mL), the solution 
washed with 3% (w/v) solution of NaHCO3 (2 x 50 mL) followed by brine (50 mL). The organic 
layer was dried over anhydrous Na2SO4 (~ 4 g), and concentrated in vacuo. The crude product 
was purified by flash column chromatography using a hexanes/ethyl acetate (2:8) solvent 
system to afford 0.163 g (79%) of a colorless foam. Rf (SiO2 TLC): 0.18, 0.36 (1:1 
Hexanes/EtOAc).  λmax(MeCN) = 283 nm. HRMS (ESI-MS) m/z calculated for C41H50FN4NaO8P
+: 
799.3243; found 799.3238 [M + Na]+. 1H NMR (500 MHz, CDCl3, ppm): 8.11-8.15 (m, 1H; H6), 
7.24–7.54 (m, 9H; Ar), 6.90– 6.93 (m, 4H; Ar), 6.19-6.24 (m, 1H; H1’), 4.70-4.78 (m, 1H; H3’), 
4.42-4.47 (m, 2H; CH2CH3), 4.22-4.29 (m, 1H; H4’), 3.61-3.94 (m, 10H; 2 x NCH, 2 x ArOCH3, 
CH2OP), 3.43-3.52 (m, 2H; H5’, H5’’), 2.76-2.81 (t, J= 6.0 Hz, 2H; CH2CN), 2.61-2.70 (m, 4H; 
H2’,CH2CH3), 2.39-2.46 (m, 1H; H2’’), 1.20-1.23 (m, 9H; CH3 ), 1.12-1.14 (m, 3H; CH3). 
13C NMR 
(125.7 MHz, CDCl3, ppm):  161.91, 161.81, 158.83, 152.42, 144.93, 137.11, 135.62, 135.47, 
135.20, 130.11, 128.06, 127.88, 127.81, 127.63, 127.59, 126.84, 126.75, 118.06, 117.96, 113.11, 
86.69, 86.65, 86.55, 86.47, 85.68, 85.47, 85.44, 85.39, 73.23, 73.09, 72.76, 72.63, 63.37, 63.03, 
62.83, 58.72, 58.68, 58.57, 58.52, 54.64, 54.62, 43.12, 43.11, 43.02, 43.01, 40.36, 40.33, 40.17, 
40.14, 24.04, 24.01, 23.98, 23.95, 23.93, 19.89, 19.86, 19.83, 19.80, 13.44. 19F (470.4 MHz, d6-
acetone, ppm): -171.28, -171.29, -171.34, -171.35. 31P NMR (202.3 MHz, d6-acetone, ppm): 
148.34, 148.21. IR (thin film); νmax (cm
−1) = 3421, 2966, 2930, 2361, 2336, 1684, 1652, 1558, 
1540, 1506, 1495, 1457, 1251, 1178, 1034, 977, 828. 
3’-O-(2-Cyanoethoxy(diisopropylamino)-phosphino)-5’-O-(4,4’-dimethoxytrityl)-5-fluoro-O4-
benzyl-2’-deoxyuridine (3b): DIPEA (0.091 mL, 0.52 mmol) was added to a solution of (2b) 
(0.111 g, 0.174 mmol) in THF (2 mL), followed by the dropwise addition of N,N-
diisopropylamino cyanoethyl phosphonamidic chloride (0.092 mL, 0.42 mmol). After 30 min, 
the solvent was evaporated in vacuo, the crude product was taken up in ethyl acetate (40 mL), 
the solution was washed with a 3% (w/v) solution of NaHCO3 (2 x 50 mL) and once with brine 
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(50 mL). The organic layer was dried over anhydrous Na2SO4 (~ 4 g), and concentrated in vacuo. 
The crude product was purified by flash column chromatography using hexanes/ethyl acetate 
(2:8) as eluent to afford 0.102 g (70%) of a colorless foam. Rf (SiO2 TLC): 0.36, 0.51 (1:1 
Hexanes/EtOAc). λmax(MeCN) = 283 nm. HRMS (ESI-MS) m/z calculated for C46H52FN4NaO8P
+: 
861.3399; found: 861.3395 [M + Na]+. 1H NMR (500 MHz, d6-acetone, ppm): 8.15-8.20 (m, 1H; 
H6), 7.21–7.54 (m, 14H; Ar, Bn), 6.89– 6.93 (m, 4H; Ar), 6.19-6.25 (m, 1H; H1’), 5.46 (s, 2H; 
CH2Bn), 4.71-4.79 (m, 1H; H3’), 4.23-4.30 (m, 1H; H4’), 3.62-3.94 (m, 10H; 2 x NCH, 2 x ArOCH3, 
CH2OP), 3.43-3.53 (m, 2H; H5’, H5’’), 2.78-2.80 (t, J= 6.0 Hz, 1H; CH2CN), 2.62-2.72 (m, 2H; H2’, 
CH2CN), 2.41-2.49 (m, 1H; H2’’), 1.20-1.23 (m, 9H; 3 x CH3), 1.13-1.14 (m, 3H; CH3). 
13C NMR 
(125.7 MHz, CDCl3, ppm):  161.72, 161.57, 158.87, 152.26, 144.94, 144.93, 137.05, 137.03, 
135.61, 135.60, 135.58, 135.49, 135.45, 135.11, 135.09, 130.11, 130.09, 130.08, 128.57, 128.49, 
128.38, 128.29, 128.27, 128.04, 128.01, 127.82, 126.81, 126.78, 113.13, 113.11, 86.71, 86.66, 
86.58, 85.77, 85.74, 85.49, 85.45, 73.21, 73.08, 72.75, 72.62, 68.86, 63.01, 62.81, 58.73, 58.68, 
58.58, 58.53, 54.64, 54.62, 43.13, 43.11, 43.03, 43.02, 40.39, 40.36, 40.20, 40.16, 24.04, 23.99, 
23.93, 19.90, 19.84, 19.81. 19F (470.4 MHz, d6-acetone, ppm): -171.22, -171.23, -171.28, -
171.29. 31P NMR (202.3 MHz, d6-acetone, ppm): 148.36, 148.23. IR (thin film); νmax (cm
−1) = 
3423, 2361, 2336, 1652, 1506, 1456, 1251, 1178, 1035, 735. 
5’-O-(4,4’-Dimethoxytrityl)-5-fluoro-O4-(phenoxyacetyloxybutyl)-2’-deoxyuridine (4a): A 
convertible nucleoside was prepared by slowly adding triethylamine (1.45 mL, 10.4 mmol) 
followed by dropwise addition of POCl3 (0.105 mL, 1.13 mmol) to a solution containing triazole 
(0.703 g, 10.8 mmol) and compound 1 in anhydrous MeCN (4.5 mL) at 0oC under stirring. After 2 
hours the reaction was over and the solvent was evaporated in vacuo. To a solution of 
convertible nucleoside (0.32 g, 0.45 mmol) and 1,4-butanediol (0.29 g, 3.2 mmol) in MeCN (3 
mL) was added dropwise DBU (0.15 mL, 1.0 mmol). After 16 h, the solvent was evaporated in 
vacuo and the crude product was taken up in CH2Cl2 (40 mL), washed with a 3% (w/v) solution 
of NaHCO3 (2 x 50 mL), dried over anhydrous Na2SO4 (~ 4 g), and concentrated in vacuo. To a 
solution of this intermediate and triethylamine (0.11 mL, 0.81 mmol) in THF (5 mL) was added 
dropwise Pac-Cl (0.094 mL, 0.68 mmol) while stirring at 0oC. After 30 min, the solvent was 
evaporated in vacuo and the crude product was taken up in CH2Cl2 (40 mL), washed with a 3% 
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(w/v) solution of NaHCO3 (2 x 50 mL), dried over anhydrous Na2SO4 (~ 4 g), and concentrated in 
vacuo. The resulting residue was taken up in THF (5 mL) and TBAF (1 M in THF) (0.68 mL, 0.68 
mmol) was added dropwise. After 30 min, the solvent was evaporated in vacuo and the crude 
product was taken up in CH2Cl2 (40 mL), washed with a 3% (w/v) solution of NaHCO3 (2 x 50 
mL), dried over anhydrous Na2SO4 (~ 4 g), and concentrated in vacuo. The crude product was 
purified by flash column chromatography using EtOAc / Hex (4 : 1) as eluent to afford 0.16 g (47 
% over 3 steps) of a colorless foam. Rf (SiO2 TLC): 0.32 (100% EtOAc). λmax(MeCN) = 276 nm. HRMS 
(ESI-MS) m/z calculated for C42H43FN2NaO10
+: 777.2794; found 777.2807 [M + Na]+. 1H NMR 
(500 MHz, CDCl3, ppm): 8.03 (d, 1H; H6, J = 5.5 Hz), 7.41–7.38 (m, 2H; Ar), 7.32-7.20 (m, 9H; Ar), 
6.98 (m, 1H; Ar), 6.92– 6.89 (m, 2H; Ar), 6.85-6.82 (m, 4H; Ar), 6.24 (m, 1H; H1’), 4.64 (s, 2H; 
COCH2OPh), 4.53 (m, 1H; H3’), 4.44-4.42 (m, 2H; ArOCH2), 4.26-4.24 (m, 2H; COOCH2), 4.12 (m, 
1H; H4’), 3.78 (2 s, 6H; 2 x OCH3), 3.41-3.42 (m, 2H; H5’, H5’’), 2.72-2.67 (m, 2H; H2’, OH), 2.24 
(m, 1H; H2’’), 1.81-1.77 (m, 4H; CH2CH2). 
13C NMR (125.7 MHz, CDCl3, ppm): 171.14, 168.99, 
162.27, 162.17, 158.64, 157.75, 153.43, 144.30, 137.56, 135.59, 135.38, 135.23, 129.97, 129.95, 
129.55, 127.99, 127.92, 127.67, 127.42, 127.02, 121.74, 114.60, 113.31, 113.29, 87.04, 86.95, 
86.45, 71.61, 67.45, 65.29, 64.64, 63.03, 60.38, 55.22, 41.95, 25.08, 24.95, 21.03, 14.18. 19F 
(470.4 MHz, CDCl3, ppm): -168.40, -168.41. IR (thin film); νmax (cm
−1) = 3391, 3066, 2956, 2931, 
2837, 2362, 2336, 1760, 1679, 1542, 1510, 1492, 1458, 1379, 1251, 1176, 1090, 1034, 829, 755. 
5’-O-(4,4’-Dimethoxytrityl)-5-fluoro-O4-(phenoxyacetyloxyheptyl)-2’-deoxyuridine (4b): A 
convertible nucleoside was prepared by slowly adding triethylamine (1.45 mL, 10.4 mmol) 
followed by dropwise addition of POCl3 (0.105 mL, 1.13 mmol) to a solution containing triazole 
(0.703 g, 10.8 mmol) and compound 1 in anhydrous MeCN (4.5 mL) at 0oC under stirring. After 2 
h the reaction was over and the solvent was evaporated in vacuo. To a solution of convertible 
nucleoside (0.32 g, 0.45 mmol) and 1,7-heptanediol (0.072 g, 0.54 mmol) in MeCN (6 mL) was 
added dropwise DBU (0.088 mL, 0.59 mmol). After 16 h, the solvent was evaporated in vacuo 
and the crude product was taken up in CH2Cl2 (40 mL), washed with a 3% (w/v) solution of 
NaHCO3 (2 x 50 ml), dried over anhydrous Na2SO4 (~ 4 g), and concentrated in vacuo. To a 
solution of the intermediate and triethylamine (0.11 mL, 0.81 mmol) in THF (5 mL) was added 
dropwise Pac-Cl (0.094 mL, 0.68 mmol) while stirring at 0oC. After 30 min, the solvent was 
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evaporated in vacuo and the crude product was taken up in CH2Cl2 (40 mL), washed with a 3% 
(w/v) solution of NaHCO3 (2 x 50 ml), dried over anhydrous Na2SO4 (~ 4 g), and concentrated in 
vacuo. The resulting residue was taken up in THF (5 mL) and TBAF (1 M in THF) (0.68 mL, 0.68 
mmol) was added dropwise. After 30 min, the solvent was evaporated in vacuo and the crude 
product was taken up in CH2Cl2 (40 mL), washed with a 3% (w/v) solution of NaHCO3 (2 x 50 ml), 
dried over anhydrous Na2SO4 (~ 4 g), and concentrated in vacuo. The crude product was 
purified by flash column chromatography using EtOAc / Hex (7 : 3) as eluent to afford 0.084 g 
(23 % over 3 steps) of a colorless foam. Rf (SiO2 TLC): 0.54 (100% EtOAc). λmax(MeCN) = 276 nm. 
HRMS (ESI-MS) m/z calculated for C45H49FN2NaO10
+ 819.3263; found 819.3266 [M + Na]+. 1H 
NMR (500 MHz, CDCl3, ppm): 8.01 (d, 1H; H6, J =  6 Hz), 7.41–7.38 (m, 2H; Ar), 7.30-7.20 (m, 9H; 
Ar), 6.98 (m, 1H; Ar), 6.92– 6.89 (m, 2H; Ar), 6.85-6.82 (m, 4H; Ar), 6.24 (m, 1H; H1’), 4.63 (s, 2H; 
COCH2OPh), 4.51 (m, 1H; H3’), 4.43-4.41 (m, 2H; ArOCH2), 4.20 (t, 2H; COOCH2, J = 7 Hz), 4.11 
(m, 1H; H4’), 3.78 (2 s, 6H; 2 x OCH3), 3.41-3.42 (m, 2H; H5’, H5’’), 2.68 (m, 1H; H2’), 2.41 (bs, 
1H; OH), 2.24 (m, 1H; H2’’), 1.76 (m, 2H; CH2), 1.64 (m, 2H; CH2), 1.39-1.32 (m, 6H; CH2CH2CH2). 
13C NMR (125.7 MHz, CDCl3, ppm): 169.07, 162.45, 162.35, 158.64, 157.80, 153.48, 144.30, 
137.65, 135.68, 135.38, 135.24, 129.97, 129.95, 129.52, 127.99, 127.92, 127.41, 127.16, 127.02, 
121.69, 114.60, 113.31, 113.29, 87.04, 86.84, 86.33, 71.60, 68.21, 65.35, 65.29, 62.99, 55.22, 
41.91, 28.76, 28.43, 28.26, 25.64, 25.60. 19F (470.4 MHz, CDCl3, ppm): -168.19, -168.20. IR (thin 
film); νmax (cm
−1) = 3394, 3065, 2935, 2836, 2362, 2336, 1760, 1679, 1607, 1542, 1510, 1492, 
1458, 1377, 1251, 1176, 1090, 1034, 829, 755. 
3’-O-(2-Cyanoethoxy(diisopropylamino)-phosphino)-5’-O-(4,4’-dimethoxytrityl)-5-fluoro-O4-
(phenoxyacetyloxybutyl)-2’-deoxyuridine (5a): DIPEA (52 µL, 0.30 mmol) was added to a 
solution of (4a) (0.075 g, 0.098 mmol) in THF (1.5 mL), followed by the dropwise addition of 
N,N-diisopropylamino cyanoethyl phosphonamidic chloride (53 µL, 0.24 mmol). After 30 min, 
the solvent was evaporated in vacuo, the crude product was taken up in ethyl acetate (40 mL), 
the solution was washed with 3% (w/v) solution of NaHCO3 (2 x 50 ml) and once with brine (50 
mL). The organic layer was dried over anhydrous Na2SO4 (~ 4 g), and reconcentrated in vacuo. 
The crude product was purified by flash column chromatography using an ethyl acetate solvent 
system to afford 0.80 g (82%) of a colorless foam. Rf (SiO2 TLC): 0.73, 0.85 (EtOAc). λmax(MeCN) = 
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276 nm. HRMS (ESI-MS) m/z calculated for C51H60FN4NaO11P
+ 977.3872; found 977.3868 [M + 
Na]+. 1H NMR (500 MHz, d6-acetone, ppm): 8.16-8.11 (m, 1H, H6), 7.52–7.49 (m,2H; Ar), 7.38-
7.24 (m, 9H; Ar), 6.95-6.88 (m, 7H; Ar), 6.23-6.18 (m, 1H; H1’), 4.77-4.70 (m, 3H; H3’, 
COCH2OPh), 4.43-4.31 (m, 2H; ArOCH2), 4.28-4.21 (m, 3H; H4', COOCH2), 3.93-3.60 (m, 10H; 
POCH2, 2 x NCH, 2 x OCH3),  3.51-3.42 (m, 2H; H5’, H5’’), 2.78-2.75 (m, 1H; CHCN), 2.70-2.59 (m, 
2H; CHCN, H2’), 2.46-2.38 (m, 1H; H2’’), 1.87-1.77 (m, 4H; CH2CH2), 1.31-1.29 (m, 3H; CH3), 1.20-
1.19 (m, 6H; 2 x CH3), 1.13-1.11 (m, 3H; CH3). Residual EtOAc solvent peaks are observed. 
13C 
NMR (125.7 MHz, CDCl3, ppm): 169.98, 168.59, 161.93, 161.83, 158.82, 158.20, 152.36, 144.93, 
144.92, 137.12, 137.09, 135.61, 135.58, 135.49, 135.46, 135.17, 135.15, 130.11, 130.09, 129.39, 
128.05, 128.01, 127.97, 127.94, 127.82, 127.72, 127.69, 126.82, 126.79, 121.19, 118.07, 117.95, 
114.51, 113.13, 113.12, 86.70, 86.65, 86.58, 86.50, 85.73, 85.69, 85.44, 85.39, 73.18, 73.05, 
72.74, 72.61, 66.91, 64.78, 64.14, 63.00, 62.81, 61.90, 61.86, 59.64, 58.71, 58.66, 58.56, 58.51, 
54.66, 54.64, 47.31, 47.27, 43.12, 43.11, 43.02, 43.01, 40.37, 40.35, 40.18, 40.14, 24.95, 24.84, 
24.05, 24.02, 24.00, 23.96, 23.94, 21.92, 21.90, 20.43, 20.41, 19.95, 19.90, 19.86, 19.84, 19.81, 
18.95, 18.88, 13.63.19F (470.4 MHz, d6-acetone, ppm): -171.19, -171.21, -171.25, -171.26. 
31P 
NMR (202.3 MHz, d6-acetone, ppm): 148.32, 148.19. IR (thin film); νmax (cm
−1) = 3069, 2968, 
2831, 2872, 2252, 1760, 1683, 1648, 1542, 1510, 1492, 1459, 1409, 1364, 1252, 1180, 1087, 
1035, 977, 830, 755. 
3’-O-(2-Cyanoethoxy(diisopropylamino)-phosphino)-5’-O-(4,4’-dimethoxytrityl)-5-fluoro-O4-
(phenoxyacetyloxyheptyl)-2’-deoxyuridine (5b): DIPEA (49 µL, 0.28 mmol) was added to a 
solution of (4b) (0.075 g, 0.094 mmol) in THF (1.5 mL), followed by the dropwise addition of 
N,N-diisopropylamino cyanoethyl phosphonamidic chloride (50 µL, 0.23 mmol). After 30 min, 
the solvent was evaporated in vacuo, the crude product was taken up in ethyl acetate (40 mL), 
the solution was washed with 3% (w/v) solution of NaHCO3 (2 x 50 ml) and once with brine (50 
mL). The organic layer was dried over anhydrous Na2SO4 (~ 4 g), and concentrated in vacuo. The 
crude product was purified by flash column chromatography using ethyl acetate as eluent to 
afford 0.74 g (78%) of a colorless foam. Rf (SiO2 TLC): 0.83, 0.90 (EtOAc). λmax(MeCN) = 277 nm. 
HRMS (ESI-MS) m/z calculated for C54H66FN4NaO11P
+ 1019.4342; found 1019.4332 [M + Na]+. 1H 
NMR (500 MHz, d6-acetone, ppm): 8.15-8.10 (m, 1H, H6), 7.52–7.48 (m, 2H; Ar), 7.41-7.22 (m, 
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9H; Ar), 6.97-6.88 (m, 7H; Ar), 6.23-6.18 (m, 1H; H1’), 4.77-4.70 (m, 3H; H3’, COCH2OPh), 4.39-
4.32 (m, 2H; ArOCH2), 4.28-4.21 (m, 1H; H4'), 4.18-4.16 (m, 2H; COOCH2), 3.93-3.60 (m, 10H; 
POCH2, 2 x NCH, 2 x OCH3),  3.51-3.42 (m, 2H; H5’, H5’’), 2.78-2.75 (m, 1H; CHCN), 2.70-2.59 (m, 
2H; CHCN, H2’), 2.46-2.38 (m, 1H; H2’’), 1.80-1.74 (m, 2H; CH2), 1.68-1.62 (m, 2H; CH2), 1.46-
1.35 (m, 6H; CH2CH2CH2), 1.32-1.29 (m, 3H; CH3), 1.21-1.19 (m, 6H; 2 x CH3), 1.13-1.11 (m, 3H; 
CH3). Signals for residual EtOAc solvent peaks are also observed. 
13C NMR (125.7 MHz, CDCl3, 
ppm): 169.97, 168.62, 162.03, 161.92, 158.81, 158.21, 152.39, 144.93, 144.92, 137.15, 137.12, 
135.61, 135.58, 135.50, 135.46, 135.21, 135.18, 130.11, 130.08, 129.39, 128.05, 128.01, 127.89, 
127.86, 127.82, 127.64, 127.61, 126.81, 126.78, 121.19, 118.06, 117.94, 114.48, 113.13, 113.11, 
86.69, 86.64, 86.56, 86.48, 85.72, 85.68, 85.43, 85.38, 73.20, 73.07, 72.75, 72.62, 67.40, 64.80, 
64.53, 63.01, 62.82, 61.90, 61.86, 59.64, 58.71, 58.66, 58.56, 58.51, 54.65, 54.63, 47.31, 47.27, 
43.12, 43.10, 43.02, 43.01, 40.36, 40.34, 40.17, 40.14, 25.50, 25.49, 24.05, 24.02, 23.99, 23.96, 
23.94, 21.92, 21.90, 20.42, 20.41, 19.95, 19.89, 19.86, 19.84, 19.80, 18.95, 18.88, 13.63. 19F 
(470.4 MHz, d6-acetone, ppm): -171.20, -171.22, -171.26, -171.28. 
31P NMR (202.3 MHz, d6-
acetone, ppm): 148.32, 148.19. IR (thin film); νmax (cm
−1) = 3068, 2966, 2834, 2864, 2252, 1759, 
1683, 1647, 1607, 1541, 1510, 1492, 1458, 1409, 1365, 1252, 1179, 1086, 1035, 978, 829, 755. 
 
A2.1.2 Preparation, purification and characterization of the dFU oligonucleotides 
 The sequences containing the different dFU adducts, which are shown in Figure 3.1, 
were assembled with an Applied Biosystems Model 3400 synthesizer on a 1.5 mol scale using 
β-cyanoethylphosphoramidite chemistry supplied by the manufacturer with slight modifications 
to coupling times. The nucleoside phosphoramidites protected with "fast-deprotecting" groups 
were dissolved in anhydrous MeCN at a concentration of 0.1 M for the 3’-O-
deoxyphosphoramidites, and 0.15 M for the modified phosphoramidites (3a, 3b, 5a and 5b). 
Oligomer sequence assembly was carried out as previously described.[104] The capping step of 
the assembly was carried out using phenoxyacetic anhydride/pyridine/tetrahydrofuran 1:1:8 
(v/v/v; solution A) and 1-methyl-imidazole/ tetrahydrofuran 16:84 (w/v; solution B). Coupling 
wait times for phosphoramidites 3a, 3b, 5a and 5b were extended to 10 min (compared to 2 
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min for the commercially available phosphoramidites). Protecting group removal and cleavage 
from the solid support was carried out by treatment with 10% DBU in their corresponding 
alcohol (ethanol for the ethyl adduct, benzyl alcohol for the benzyl adduct, etc.) overnight at 50 
oC in 2 mL screw-cap microfuge tubes fitted with Teflon lined caps.[54] The base was neutralized 
with an equimolar amount of AcOH and crude oligomers were transferred and lyophilized in a 
Speedvac concentrator. Purification was achieved by strong anion exchange HPLC using a 
Dionex DNAPAC PA-100 column (0.4 cm x 25 cm) purchased from Dionex Corp, Sunnyvale, CA 
using a linear gradient of 0–52% buffer B over 24 min (buffer A: 100 mm Tris HCl, pH 7.5, 10% 
MeCN and buffer B: 100 mm Tris HCl, pH 7.5, 10% MeCN, 1M NaCl) at 55 oC. The columns were 
monitored at 260 nm for analytical runs or 280 nm for preparative runs. The purified oligomers 
were desalted using C-18 SEP PAK cartridges (Waters Inc.) as previously described.[132] The 
molecular mass of the modified oligomers was identified by deconvolution of the ESI-MS and 
the measured values were in agreement with the expected masses (Figures A2.30, A2.31, 
A2.32 and A2.33 for MS spectra). Oligonucleotides dFU-Et, dFU-Bn, dFU-C4OH and dFU-C7OH  
(0.05 A260 units each) were also characterized by enzymatic digestion (snake venom 
phosphodiesterase: 0.28 units and calf intestinal phosphatase: 5 units, in 10 mM Tris, pH 8.1 
and 2 mM MgCl2) for 48 h at 37 
oC. The resulting nucleoside mixture was analyzed by reversed 
phase HPLC carried out using a Symmetry® C-18 5 μm column (0.46 x 15 cm) via a linear 
gradient of 0-70% buffer B over 30 min (buffer A: 50 mM sodium phosphate, pH 5.8, 2% MeCN 
and buffer B: 50 mM sodium phosphate, pH 5.8, 50% MeCN). Results and nucleoside ratios 
from digestion are shown in Figures A2.34, A2.35, A2.36 and A2.37. The molecular mass of the 
modified oligomers was identified by deconvolution of the ESI-MS and the measured values 
were in agreement with the expected masses 
A2.2 UV thermal denaturation 
 Please refer to section A1.2 for the experimental details. The results obtained are shown 
in Figure A2.42. 
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A2.3 Circular dichroism (CD) spectroscopy 
 Please refer to section A1.3 for the experimental details. The results obtained are shown 
in Figure A2.43. 
A2.4 AGT repair assay of DNA duplexes  
 Please refer to section A1.4 for the experimental details. 
 
Figure A2.1: (A) 2’-deoxy-2’-fluoro-arabinonucleic acid (F-ANA),[71–73]  (B) 5-fluorouracil,[67,135] 
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 Figure A2.2 - 500 MHz 1H NMR spectrum of compound (2a) (in CDCl3) 
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 Figure A2.3 - 125.7 MHz 13C NMR spectrum of compound (2a) (in CDCl3)  
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Figure A2.4 - 470.4 MHz 19F NMR spectrum of compound (2a) (in CDCl3) 
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Figure A2.5 - 500 MHz 1H NMR spectrum of compound (3a) (in d6-acetone) 
 
  125 
Figure A2.6 - 125.7 MHz 13C NMR spectrum of compound (3a) (in d6-acetone)   
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Figure A2.7 - 470.4 MHz 19F NMR spectrum of compound (3a) (in d6-acetone) 
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Figure A2.8 - 202.3 MHz 31P NMR spectrum of compound (3a) (in d6-acetone)  
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 Figure A2.9 - 500 MHz 1H NMR spectrum of compound (2b) (in CDCl3) 
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 Figure A2.10 - 125.7 MHz 13C NMR spectrum of compound (2b) (in CDCl3)  
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Figure A2.11 - 470.4 MHz 19F NMR spectrum of compound (2b) (in CDCl3)  (in d6-acetone) 
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Figure A2.12 - 500 MHz 1H NMR spectrum of compound (3b) (in d6-acetone) 
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 Figure A2.13 - 125.7 MHz 13C NMR spectrum of compound (3b) (in d6-acetone) 
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Figure A2.14 - 470.4 MHz 19F NMR spectrum of compound (3b) (in d6-acetone) 
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 Figure A2.15 - 202.3 MHz 31P NMR spectrum of compound (3b) (in d6-acetone)  
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 Figure A2.16 - 500 MHz 1H NMR spectrum of compound (4a) (in CDCl3)  
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 Figure A2.17 – 125.7 MHz 1H NMR spectrum of compound (4a) (in CDCl3)  
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Figure A2.19 - 500 MHz 1H NMR spectrum of compound (5a) (in d6-acetone) 
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Figure A2.20 – 125.7 MHz 1H NMR spectrum of compound (5a) (in d6-acetone) 
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Figure A2.21 – 470.4 MHz 19F NMR spectrum of compound (5a) (in d6-acetone)  
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Figure A2.22 - 202.3 MHz 31P NMR spectrum of compound (5a) (in d6-acetone) 
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Figure A2.24 – 125.7 MHz 1H NMR spectrum of compound (4b) (in CDCl3)  
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Figure A2.27 – 125.7 MHz 1H NMR spectrum of compound (5b) (in d6-acetone) 
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Figure A2.30 - ESI MS spectrum of oligonucleotide dFU-Et (expected mass of 4295.1) 
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Figure A2.33 - ESI MS spectrum of oligonucleotide dFU-C7OH (expected mass of 4382.9) 
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Figure A2.34- C-18 reversed phase HPLC profile of nuclease-digested dFU-Et. The column was 
eluted with a linear gradient of 0-70% buffer B over 30 min (buffer A: 50 mM sodium phosphate, 
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Figure A2.35- C-18 reversed phase HPLC profile of nuclease-digested dFU-Bn. The column was 
eluted with a linear gradient of 0-70% buffer B over 30 min (buffer A: 50 mM sodium phosphate, 
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Figure A2.36- C-18 reversed phase HPLC profile of nuclease-digested dFU-C4OH. The column 
was eluted with a linear gradient of 0-70% buffer B over 30 min (buffer A: 50 mM sodium 
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 Figure A2.37- C-18 reversed phase HPLC profile of nuclease-digested dFU-C7OH. The column 
was eluted with a linear gradient of 0-70% buffer B over 30 min (buffer A: 50 mM sodium 
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Figure A2.38- SAX-HPLC profile of dFU-Et crude (A) and pure (B). The column (Dionex DNAPAC 
PA- 100) was eluted using a linear gradient of 0-70% buffer B over 30 min (buffer A: 100 mM Tris 
HCl, pH 7.5, 10% MeCN and buffer B: 100 mM Tris HCl, pH 7.5, 10% MeCN, 1 M NaCl) 
 
  
Figure A2.39- SAX-HPLC profile of dFU-Bn crude (A) and pure (B). The column (Dionex DNAPAC 
PA- 100) was eluted using a linear gradient of 0-70% buffer B over 30 min (buffer A: 100 mM Tris 
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Figure A2.40- SAX-HPLC profile of dFU-C4OH crude (A) and pure (B). The column (Dionex 
DNAPAC PA- 100) was eluted using a linear gradient of 0-70% buffer B over 30 min (buffer A: 
100 mM Tris HCl, pH 7.5, 10% MeCN and buffer B: 100 mM Tris HCl, pH 7.5, 10% MeCN, 1 M 
NaCl) 
 
 Figure A2.41- SAX-HPLC profile of dFU-C7OH crude (A) and pure (B). The column (Dionex 
DNAPAC PA- 100 ) was eluted using a linear gradient of 0-70% buffer B over 30 min (buffer A: 
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 Figure A2.42 - Hyperchromicity change (A260) versus temperature (
oC) profiles of duplexes 










Figure AII.43 - Circular dichroism spectra of duplexes containing dFU control (—), dFU-Et (•••),  
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Figure A2.44 - Repair of (A) dFU-Et, (B) dFU-Bn, (C) dFU-C4OH and (D) dFU-C7OH by hAGT, OGT, 
Ada-C, and hOGT for 2.5 h at 37oC. Denaturing PAGE of repair reactions as described in the 
experimental section with 5-fold protein concentration. Panel A; Lane 1, 2 pmol dFU-Et DNA; 
lane 2, 2 pmol dFU-Et + Bcll; lane 3, 2 pmol dFU- Et + 10 pmol hAGT; lane 4, 2 pmol dFU-Et + 10 
pmol hAGT + Bcll; lane 5, 2 pmol dFU-Et + 10 pmol OGT; lane 6, 2 pmol dFU-Et + 10 pmol OGT+ 
Bcll; lane 7, 2 pmol dFU-Et + 10 pmol Ada-C; lane 8, 2 pmol dFU-Et + 10 pmol Ada-C + Bcll; lane 
9, 2 pmol dFU-Et + 10 pmol hOGT; lane 10, 2 pmol dFU-Et + 10 pmol hOGT + BclI. Panel B; 
Identical to panel A except with dFU-Bn instead of dFU-Et. Panel C; Identical to panel A except 
with dFU-C4OH instead of dFU-Et. Panel D; Identical to panel A except with dFU-C7OH instead 
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Figure A2.45 - Time course repair gel of duplexes containing dFU-Et by (A) hAGT, (B) OGT, (C) 
Ada-C and (D) hOGT. (A) Denaturing gel of the repair of 2 pmol of dFU-Et by 10 pmol hAGT as a 
function of time: lane 1, 2 pmol Control; lanes 2-10, 2 pmol  + 10 pmol hAGT incubated for 0.25, 
0.5, 0.75, 1, 1.5, 3, 5, 15, 45 min, respectively. (B) Denaturing gel of the repair of 2 pmol of dFU-
Et by 10 pmol OGT as a function of time: lane 1, 2 pmol Control; lanes 2-10, 2 pmol  + 10 pmol 
OGT incubated for 0.25, 0.5, 0.75, 1, 1.5, 2, 5, 15, 45 min, respectively. (C) Denaturing gel of the 
repair of 2 pmol of dFU-Et by 10 pmol Ada-C as a function of time: lane 1, 2 pmol Control; lanes 
2-10, 2 pmol  + 10 pmol Ada-C incubated for 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 5, 15, 45 min, 
respectively. (D) Denaturing gel of the repair of 2 pmol of dFU-Et by 10 pmol hOGT as a function 
of time: lane 1, 2 pmol Control; lanes 2-10, 2 pmol  + 10 pmol hOGT incubated for 0.25, 0.5, 
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Figure A2.46 - Time course repair gel of duplexes containing dFU-Bn by (A) hAGT, (B) OGT, (C) 
Ada-C and (D) hOGT. (A) Denaturing gel of the repair of 2 pmol of dFU-Bn by 10 pmol hAGT as a 
function of time: lane 1, 2 pmol Control; lanes 2-10, 2 pmol  + 10 pmol hAGT incubated for 0.25, 
0.5, 0.75, 1, 1.5, 2, 5, 15, 45 min, respectively. (B) Denaturing gel of the repair of 2 pmol of dFU-
Bn by 10 pmol OGT as a function of time: lane 1, 2 pmol Control; lanes 2-10, 2 pmol  + 10 pmol 
OGT incubated for 0.25, 0.5, 0.75, 1, 1.5, 3, 5, 15, 45 min, respectively. (C) Denaturing gel of the 
repair of 2 pmol of dFU-Bn by 10 pmol Ada-C as a function of time: lane 1, 2 pmol Control; lanes 
2-10, 2 pmol  + 10 pmol Ada-C incubated for 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 5, 15, 45 min, 
respectively. (D) Denaturing gel of the repair of 2 pmol of dFU-Bn by 10 pmol hOGT as a 
function of time: lane 1, 2 pmol Control; lanes 2-10, 2 pmol  + 10 pmol hOGT incubated for 0.25, 
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Figure A2.47 - Time course repair gel of duplexes containing dFU-C4OH by (A) hAGT, (B) OGT, 
(C) Ada-C and (D) hOGT. (A) Denaturing gel of the repair of 2 pmol of dFU-C4OH by 10 pmol 
hAGT as a function of time: lane 1, 2 pmol Control; lanes 2-10, 2 pmol  + 10 pmol hAGT 
incubated for 0.25, 0.5, 0.75, 1, 1.5, 3, 5, 15, 45 min, respectively. (B) Denaturing gel of the 
repair of 2 pmol of dFU-C4OH by 10 pmol OGT as a function of time: lane 1, 2 pmol Control; 
lanes 2-10, 2 pmol  + 10 pmol OGT incubated for 0.25, 0.5, 0.75, 1, 1.5, 2, 5, 15, 45 min, 
respectively. (C) Denaturing gel of the repair of 2 pmol of dFU-C4OH by 10 pmol Ada-C as a 
function of time: lane 1, 2 pmol Control; lanes 2-10, 2 pmol  + 10 pmol Ada-C incubated for 0.25, 
0.5, 0.75, 1, 1.5, 2, 3, 5, 15, 45 min, respectively. (D) Denaturing gel of the repair of 2 pmol of 
dFU-C4OH by 10 pmol hOGT as a function of time: lane 1, 2 pmol Control; lanes 2-10, 2 pmol  + 
10 pmol hOGT incubated for 0.25, 0.5, 0.75, 1, 1.5, 3, 5, 15, 45, 150 min, respectively. All the 
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Figure A2.48 -  Time course repair gel of duplexes containing dFU-C7OH by (A) hAGT, (B) OGT, 
(C) Ada-C and (D) hOGT. (A) Denaturing gel of the repair of 2 pmol of dFU-C7OH by 10 pmol 
hAGT as a function of time: lane 1, 2 pmol Control; lanes 2-10, 2 pmol  + 10 pmol hAGT 
incubated for 0, 0.25, 0.5, 0.75, 1, 1.5, 3, 5, 15, 45, 150 min, respectively. (B) Denaturing gel of 
the repair of 2 pmol of dFU-C7OH by 10 pmol OGT as a function of time: lane 1, 2 pmol Control; 
lanes 2-10, 2 pmol  + 10 pmol OGT incubated for 0, 0.25, 0.5, 0.75, 1, 1.5, 3, 5, 15, 45, 150 min, 
respectively. (C) Denaturing gel of the repair of 2 pmol of dFU-C7OH by 10 pmol Ada-C as a 
function of time: lane 1, 2 pmol Control; lanes 2-10, 2 pmol  + 10 pmol Ada-C incubated for 0, 
0.25, 0.5, 0.75, 1, 1.5, 3, 5, 15, 45, 150 min, respectively. (D) Denaturing gel of the repair of 2 
pmol of dFU-C7OH by 10 pmol hOGT as a function of time: lane 1, 2 pmol Control; lanes 2-10, 2 
pmol  + 10 pmol hOGT incubated for 0, 0.25, 0.5, 0.75, 1, 1.5, 3, 5, 15, 45, 150 min, respectively. 
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Figure A2.49 – Time course of repair (2.5 h) graphs of dFU-Et (•••), dFU-Bn (———), dFU-C4OH 
(—•—) and dFU-C7OH (—••—) at room temperature: A) by hAGT, B) by OGT, C) by Ada-C and 
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 Figure A2.50 – Repair of dFU-Et (white bars), dFU-Bn (granite bars), dFU-C4OH (black bars) and 
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A3.1 Synthesis and characterization of nucleosides and oligonucleotides 
A3.1.1 General  
 5-chloro-2’-deoxyuridine and 5-bromo-2’-deoxyuridine were purchased from the 
Cayman Chemical Company (Ann Arbor, Michigan) and Carbosynth Limited (Berkshire, UK) 
respectively. “Fast deprotecting” 5’-O-dimethoxytrityl-2’-deoxyribonucleoside-3’-O-(β-
cyanoethyl-N,N-diisopropyl)phosphoramidites and protected 2’-deoxyribonucleoside–CPG 
supports were purchased from Glen Research (Sterling, Virginia). Compounds 2a and 2b were 
prepared according to previously published procedures.[54,97,98] All other chemicals and solvents 
were purchased from the Aldrich Chemical Company (Milwaukee, WI) or EMD Chemicals Inc. 
(Gibbstown, NJ). Flash column chromatography was performed using silica gel 60 (230–400 
mesh) purchased from Silicycle (Quebec City, QC). Thin layer chromatography (TLC) was carried 
out with precoated TLC plates (Merck, Kieselgel 60 F254, 0.25 mm) purchased from EMD 
Chemicals Inc. (Gibbstown, NJ). NMR spectra were recorded on a Varian 500 MHz NMR 
spectrometer at room temperature. 1H NMR spectra were recorded at a frequency of 500.0 
MHz and chemical shifts were reported in parts per million (ppm) downfield from 
tetramethylsilane. 13C NMR spectra (1H decoupled) were recorded at a frequency of 125.7 MHz 
and chemical shifts were reported in ppm with tetramethylsilane as a reference. 31P NMR 
spectra (1H decoupled) were recorded at a frequency of 202.3 MHz and chemical shifts were 
reported in ppm with H3PO4 used as an external standard. High resolution mass spectrometry of 
modified nucleosides were obtained using an 7T-LTQ FT ICR instrument (Thermo Scientific), at 
the Concordia University Centre for Structural and Functional Genomics. The mass spectrometer 
was operated in full scan, positive ion detection mode. ESI mass spectra for oligonucleotides 
were obtained at the Concordia University Centre for Biological Applications of Mass 
Spectrometry (CBAMS) using a Micromass Qtof2 mass spectrometer (Waters) equipped with a 
nanospray ion source. The mass spectrometer was operated in full scan, negative ion detection 
mode. T4 polynucleotide kinase (PNK) was obtained from New England BioLabs (NEB). [γ-
32P]ATP was purchased from PerkinElmer (Woodbridge, ON). The Bcll restriction enzyme was 
obtained from New England Biolabs (Ipswich, MA).  
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3’-O-(2-Cyanoethoxy(diisopropylamino)-phosphino)-5’-O-(4,4’-dimethoxytrityl)-5-chloro-2’-
deoxyuridine (3a) DIPEA (0.12 mL, 0.69 mmol) was added to a solution of 5’-O-(4,4’-
dimethoxytrityl)-5-chloro-2’-deoxyuridine (0.130 g, 0.23 mmol) in THF (2.0 mL), followed by the 
dropwise addition of N,N-diisopropylamino cyanoethyl phosphonamidic chloride (0.123 mL, 
0.55 mmol). After 30 min, the solvent was evaporated in vacuo, the crude product was taken up 
in ethyl acetate (40 mL) and washed with a 3% (w/v) solution of NaHCO3 (2 x 50 ml) followed by 
brine (50 mL). The organic layer was dried over anhydrous Na2SO4 (~ 4 g), and concentrated in 
vacuo. The crude product was purified by flash column chromatography using hexanes/ethyl 
acetate (2:8) as eluent to afford 0.103 g (81%) of a colorless foam. Rf (SiO2 TLC): 0.88 (100% 
EtOAc). λmax(MeCN) = 275 nm. HRMS (ESI-MS) m/z calculated for C39H46ClN4NaO8P
+: 787.2634; 
found 787.2644 [M + Na]+. 1H NMR (500 MHz, d6-acetone, ppm): 8.01-8.03 (2 s, 1H; H6), 7.50-
7.53 (m, 2H; Ar), 7.23-7.41 (m, 7H; Ar), 6.89-6.92 (m, 4H; Ar), 6.26-6.30 (m, 1H; H1’), 4.70-4.77 
(m, 1H; H3’), 4.17-4.24 (m, 1H; H4’), 3.88-3.92 (m, 2H; CH2OP), 3.79 (2 s, 6H; ArOMe), 3.74-3.77 
(m, 1H; NCH), 3.62-3.69 (m, 1H; NCH), 3.38-3.48 (m, 2H; H5’, H5’’), 2.76-2.78 (t, J= 6.1 Hz, 1H; 
CH2CN), 2.63-2.66 (t, J= 6.1 Hz, 1H; CH2CN), 2.50-2.58 (m, 2H; H2’, H2’’), 1.18-1.21 (m, 9H; CH3), 
1.10-1.12 (m, 3H; CH3).  
13C NMR (125.7 MHz, d6-acetone, ppm): 160.97, 158.83, 156.60, 149.27, 
148.65, 144.89, 139.64, 137.15, 137.12, 136.89, 135.52, 135.44, 130.12, 130.09, 128.07, 127.83, 
126.76, 117.82, 113.12, 109.98, 108.14, 86.77, 85.58, 85.22, 73.53, 73.14, 64.54, 63.38, 63.18, 
58.81, 58.52, 54.63, 51.09, 43.10, 43.00, 39.33, 23.94, 19.76.  IR (thin film); νmax (cm
−1): 3716, 
3208, 2966, 2361, 2340, 1709, 1607, 1548, 1509, 1461, 1445, 1364, 1250, 1178, 1154, 1079, 
1033, 977, 827, 790. 
3’-O-(tert-butyldimethylsilyl)-5’-O-(4,4’-dimethoxytrityl)-5-chloro-2’-deoxyuridine (4a) 
Imidazole (0.174 g, 2.55 mmol) and DMAP (approximately 1 mg) were added to a solution of 5’-
O-(4,4’-dimethoxytrityl)-5-chloro-2’-deoxyuridine (0.400 g, 0.708 mmol) in DCM (15 mL), 
followed by tert-butyldimethylsilyl chloride (0.192 mg, 1.27 mmol). After 4 h, the solvent was 
evaporated in vacuo and the crude product was taken up in DCM (20 mL). The solution was 
washed with a 3% (w/v) solution of NaHCO3 (3 x 50 ml). The organic layer was dried over 
anhydrous Na2SO4 (~ 4 g), and concentrated in vacuo. The crude product was purified by flash 
column chromatography using hexanes/ethyl acetate (6:4) as eluent to afford 0.430 g (90%) of a 
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colorless foam. Rf (SiO2 TLC): 0.62 (1:1 hexanes/EtOAc). λmax(MeCN) = 275 nm. HRMS (ESI-MS) m/z 
calculated for C36H43ClN2NaO7Si
+: 701.2420; found 701.2419 [M + Na]+. 1H NMR (500 MHz, CDCl3, 
ppm): 8.60 (s, 1H; NH), 8.03 (s, 1H; H6), 7.22-7.42 (m, 9H; Ar), 6.82-6.85 (m, 4H; Ar), 6.26-6.29 
(m, 1H; H1’), 4.47-4.50 (m, 1H; H3’), 3.99-4.01 (m, 1H; H4’), 3.79 (s, 6H; ArOMe), 3.30-3.40 (m, 
2H; H5’, H5’’), 2.37-2.41 (m, 1H; H2’), 2.17-2.22 (m, 1H; H2’’), 0.85 (s, 9H; t-Bu), 0.04 (s, 3H; CH3), 
0.01 (s, 3H; CH3). 
13C NMR (125.7 MHz, CDCl3, ppm): 158.68, 149.02, 144.22, 136.79, 135.25, 
129.95, 128.01, 127.95, 127.06, 113.31, 109.22, 87.31, 87.08, 85.83, 76.99, 76.74, 72.28, 62.95, 
60.37, 55.23, 41.93, 25.69, 21.02, 17.93, 14.18. IR (thin film); νmax (cm
−1) = 3648, 3420, 3060, 
2953, 2930, 2856, 2361, 1700, 1608, 1508, 1457, 1252, 1177, 1104, 1034, 832, 778, 736, 701. 
5’-O-(4,4’-dimethoxytrityl)-5-chloro-O4-methyl-2’-deoxyuridine (5a): To a solution of 
compound (4a) in anhydrous MeCN (4.5 mL) was added triazole (0.713 g, 10.34 mmol) and 
triethylamine (1.48 ml, 10.56 mmol) while stirring at 0oC. Then, POCl3 (0.107 mL, 1.15 mmol) 
was added dropwise. After 16 h, the solvent was evaporated in vacuo and the crude product 
was taken up in CH2Cl2 (40 mL), washed with a 3% (w/v) solution of NaHCO3 (2 x 50 ml), dried 
over anhydrous Na2SO4 (~ 4 g), and concentrated in vacuo. The crude was taken up in MeOH (7 
mL) and a solution of NaOMe (0.087 g, 1.61 mmol) in MeOH (7 mL) was added. After 2 h, the 
solvent was evaporated in vacuo and the crude product was taken up in CH2Cl2 (30 mL), washed 
with a 3% (w/v) solution of NaHCO3 (3 x 50 ml), dried over anhydrous Na2SO4 (~ 4 g), and 
concentrated in vacuo. The crude product was taken up in THF (2.5 mL) and TBAF (1 M in THF) 
(0.144 mL, 0.551 mmol) was added drop-wise. After 30min, the solvent was evaporated in 
vacuo and the crude product was taken up in CH2Cl2 (40 mL), washed with a 3% (w/v) solution of 
NaHCO3 (2 x 50 ml), dried over anhydrous Na2SO4 (~ 4 g), and concentrated in vacuo. The crude 
product was purified by flash column chromatography using a gradient of hexanes/EtOAc (3:7 
 100% EtOAc) as eluent to afford 0.087 g (34%) of colorless foam. Rf (SiO2 TLC): 0.64 (100% 
EtOAc). λmax(MeCN) = 282 nm. HRMS (ESI-MS) m/z calculated for C31H31ClN2NaO7
+: 601.1712; 
found 601.1732 [M + Na]+. 1H NMR (500 MHz, CDCl3, ppm): 8.19 (s, 1H; H6), 7.20-7.40 (m, 9H; 
Ar), 6.80-6.83 (m, 4H; Ar), 6.27-6.29 (m, 1H; H1’), 4.55-4.57 (m, 1H; H3’), 4.17-4.19 (m, 1H; H4’), 
4.01 (s, 3H; OCH3), 3.77 (s, 6H; ArOMe), 3.38-3.39 (m, 2H; H5’, H5’’), 2.73-2.77 (m, 1H; H2’), 
2.21-2.28 (m, 1H; H2’’).  13C NMR (125.7 MHz, CDCl3, ppm): 166.79, 158.61, 154.47, 144.38, 
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140.35, 135.36, 129.99, 127.98, 127.93, 126.97, 113.31, 113.29, 102.54, 87.41, 86.97, 86.78, 
77.05, 76.79, 71.95, 63.36, 60.41, 55.50, 55.22, 53.42, 42.25, 21.03, 20.68, 14.17, 14.00. IR (thin 
film); νmax (cm
−1) = 3439, 2753, 2364, 2348, 2335, 2283, 1645, 1562, 1543, 1510, 1250, 1176, 
663. 
3’-O-(2-Cyanoethoxy(diisopropylamino)-phosphino)-5’-O-(4,4’-dimethoxytrityl)-5-chloro-O4-
methyl-2’-deoxyuridine (6a): DIPEA (0.078 mL, 0.50 mmol) was added to a solution of (5a) 
(0.087 g, 0.15 mmol) in THF (1.5 mL), followed by the dropwise addition of N,N-
diisopropylamino cyanoethyl phosphonamidic chloride (0.080 mL, 0.36 mmol). After 30 min, the 
solvent was evaporated in vacuo and the crude product was taken up in ethyl acetate (40 mL). 
The solution was washed with a 3% (w/v) solution of NaHCO3 (2 x 50 ml) and then brine (50 mL). 
The organic layer was dried over anhydrous Na2SO4 (~ 4 g), and concentrated in vacuo. The 
crude product was purified by flash column chromatography using hexanes/ethyl acetate (2:8) 
as eluent to afford 0.094 g (76%) of a colorless foam. Rf (SiO2 TLC): 0.71, 0.79 (100% EtOAc). 
λmax(MeCN) = 283 nm. HRMS (ESI-MS) m/z calculated for C40H49ClN4O8P
+: 779.2971; found 
779.2994 [M + H]+.  1H NMR (500 MHz, d6-acetone, ppm): 8.23-8.20 (2 s, 1H; H6), 7.22-7.52 (m, 
9H; Ar), 6.88-6.92 (m, 4H; Ar), 6.18-6.22 (m, 1H; H1’), 4.68-4.76 (m, 1H; H3’), 4.22-4.29 (m, 1H; 
H4’), 3.96 (s, 3H; OCH3), 3.81-3.92 (m, 2H; CH2OP), 3.78-3.79 (s, 6H; ArOCH3), 3.61-3.69 (m, 2H; 
NCH,), 3.40-3.49 (m, 2H; H5’, H5’’), 2.70-2.72 (m, 2H; CH2CN), 2.20-2.27 (m, 2H; H2’, H2’’), 1.18-
1.21 (m, 9H; CH3), 1.11-1.12 (m, 3H; CH3). 
13C NMR (125.7 MHz, d6-acetone, ppm): 166.78, 
158.62, 154.42, 144.36, 140.30, 135.35, 129.99, 127.99, 127.93, 126.98, 113.31, 113.30, 102.48, 
87.35, 86.99, 86.71, 77.02, 76.76, 71.96, 65.82, 63.31, 55.50, 55.22, 52.01, 42.21, 20.43, 15.24, 
13.80. 31P NMR (202.3 MHz, d6-acetone, ppm): 148.34, 148.13. IR (thin film); νmax (cm
−1) =3683, 
2966, 2361, 2251, 1710, 1607, 1509, 1461, 1445, 1365, 1250, 1178, 1079, 1033, 827, 726, 702. 
3’-O-(2-Cyanoethoxy(diisopropylamino)-phosphino)-5’-O-(4,4’-dimethoxytrityl)-5-bromo-2’-
deoxyuridine (3b): DIPEA (0.297 mL,  1.686 mmol) was added to a solution of 5’-O-(4,4’-
dimethoxytrityl)-5-bromo-2’-deoxyuridine (0.3433 g, 0.562 mmol) in THF (4 mL), followed by the 
dropwise addition of N,N-diisopropylamino cyanoethyl phosphonamidic chloride (0.298 mL,  
1.348 mmol). After 30 min, the solvent was evaporated in vacuo and the crude product was 
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taken up in ethyl acetate containing few drops of triethylamine (40 mL). The solution was 
washed with a 3% (w/v) solution of NaHCO3 (3 x 50 mL) followed by brine (50 mL). The organic 
layer was dried over anhydrous Na2SO4 (~ 4 g), and reconcentrated in vacuo. The crude product 
was purified by flash column chromatography with hexanes/ethyl acetate (2:8) as eluent to 
afford 0.3425 g (80%) of a colorless foam. Rf (SiO2 TLC): 0.833 (8:2 EtOAc/Hexane). λmax(MeCN) = 
276 nm. HRMS (ESI-MS) m/z calculated for C39H46BrKN4O8P
+: 847.1868; found 847.2090 [M + 
K]+. 1H NMR (500 MHz, d6-acetone, ppm): 8.12 (s, 0.51H; H6), 8.10 (s, 0.43H; H6), 7.39-7.42 (m, 
9H; Ar), 6.90-6.92 (m, 4H; Ar), 6.27-6.31 (m, 1H; H1’), 4.71-4.74 (m, 1H; H3’), 4.19-4.25 (m, 1H; 
H4’), 3.61-3.89 (m, 10H; NCH, ArOCH3, CH2OP), 3.41-3.45 (m, 2H; H5’, H5’’), 2.75-2.77 (t, J= 6.0 
Hz, 1H; CH2CN), 2.63-2.65 (t, J= 6.0 Hz, 1H; CH2CN), 2.52-2.54 (m, 1H; H2’), 2.04-2.06 (m, 1H; 
H2’’), 1.18-1.21 (m, 10H; CH3), 1.10-1.12 (m, 2H; CH3). 
13C NMR (125.7 MHz, d6-acetone, ppm): 
170.01, 158.83, 158.81, 158.64, 158.62, 149.61, 144.95, 139.47, 139.41, 135.70, 135.67, 135.60, 
135.55, 130.15, 130.14, 130.12, 130.11, 128.10, 128.05, 127.87, 127.86, 126.80, 126.78, 118.05, 
117.91, 113.16, 96.32, 96.27, 86.72, 86.67, 85.67, 85.62, 85.45, 85.39, 85.37, 7370, 73.57, 73.38, 
73.24, 63.38, 63.22, 59.66, 58.74, 58.70, 58.59, 58.55, 54.69, 54.67, 54.66, 43.12, 43.02, 39.74, 
39.71, 39.68, 39.65, 29.45, 29.29, 29.14, 28.98 28.83, 28.68, 28.52, 24.05, 24.02, 24.01, 23.99, 
23.96, 23.95, 19.97, 19.90, 19.85, 19.79, 13.64. 31P NMR (202.3 MHz, d6-acetone, ppm): 148.18, 
148.33. IR (thin film); νmax (cm
−1) = 3436, 2965, 2364, 2348, 2362, 1648, 1580, 1547, 1444, 1250, 
1178, 1032, 662. 
3’-O-(tert-Butyldimethylsilyl)-5’-O-(4,4’-dimethoxytrityl)-5-bromo-2’-deoxyuridine (4b) 
Imidazole (0.141 g, 2.05 mmol) and DMAP were added to a solution of 5’-O-(4,4’-
dimethoxytrityl)-5-bromo-2’-deoxyuridine (0.370 g, 0.572 mmol) in DCM (8 mL), followed by the 
addition of tert-butyldimethylsilyl chloride (0.155 mg, 1.03 mmol). After 4 h, the solvent was 
evaporated in vacuo and the crude product was taken up in DCM (20 mL). The solution was 
washed with a 3% (w/v) solution of NaHCO3 (3 x 50 ml). The organic layer was dried over 
anhydrous Na2SO4 (~ 4 g), and concentrated in vacuo. The crude product was purified by flash 
column chromatography using hexanes/ethyl acetate (7:3) as eluent to afford 0.387 g (85%) of a 
colorless foam. Rf (SiO2 TLC): 0.68 (1:1 hexanes/EtOAc). λmax(MeCN) = 275 nm. HRMS (ESI-MS) m/z 
calculated for C36H43BrN2NaO7Si
+: 745.1915; found 745.1914 [M + Na]+. 1H NMR (500 MHz, 
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CDCl3, ppm): 8.89 (s, 1H; NH), 8.13 (s, 1H; H6), 7.21-7.43 (m, 9H; Ar), 6.84-6.85 (m, 4H; Ar), 6.27-
6.30 (m, 1H; H1’), 4.47-4.49 (m, 1H; H3’), 3.99-4.01 (m, 1H; H4’), 3.79 (s, 6H; ArOMe), 3.39-3.41 
(m, 1H; H5’), 3.29-3.32 (m, 1H; H5’’), 2.37-2.41 (m, 1H; H2’), 2.17-2.23 (m, 1H; H2’’), 0.85 (s, 9H; 
t-Bu), 0.03 (s, 3H; CH3), 0.01 (s, 3H; CH3). 
13C NMR (125.7 MHz, CDCl3, ppm): 158.89, 158.67, 
149.40, 144.26, 139.33, 135.31, 130.03, 128.03, 127.98, 127.05, 113.33, 113.32, 96.97, 87.34, 
87.05, 85.86, 77.01, 76.75, 72.37, 62.98, 55.24, 41.98, 29.67, 29.64, 29.34, 25.70, 25.63, 22.67, 
17.94, 14.10.  IR (thin film); νmax (cm
−1) = 3056, 2955, 2928, 2849, 2361, 2336, 1716, 1695, 1653, 
1608, 1576, 1456, 1265, 1252, 1177, 1099, 1033, 832, 737, 703.  
5’-O-(4,4’-Dimethoxytrityl)-5-bromo-O4-methyl-2’-deoxyuridine (5b): Compound 4b (2.2733 g, 
3.136 mmol) was dissolved in anhydrous MeCN (30 mL). Triazole (4.871 g, 70.57 mmol) was 
added to the solution at 0oC under stirring followed by triethylamine (10 mL, 72.128 mmol). 
Then, POCl3 (0.730 mL, 7.840 mmol) was added dropwise. After 4 h, the solvent was evaporated 
and the reaction was co-evaporated twice with methanol. The crude was taken up in MeOH (7 
mL) and a solution of NaOMe (0.592 g, 10.98 mmol) in MeOH (7 mL) was added. After 16 h, the 
solvent was evaporated in vacuo and the crude product was taken up in CH2Cl2 (40 mL), washed 
with a 3% (w/v) solution of NaHCO3 (3 x 50 ml), dried over anhydrous Na2SO4 (~ 4 g), and 
concentrated in vacuo. The crude product was taken up in THF (20 mL) and TBAF (1 M in THF) 
(3.76 mL, 3.76 mmol) was added drop-wise. After 30 min, the solvent was evaporated in vacuo 
and the crude product was taken up in CH2Cl2 (40 mL), washed with a 3% (w/v) solution of 
NaHCO3 (2 x 50 ml), dried over anhydrous Na2SO4 (~ 4 g), and concentrated in vacuo. The crude 
product was purified by flash column chromatography using EtOAc/Hexane (7:3) as eluent to 
afford 1.11 g (71.12%) of a colorless foam. Rf (SiO2 TLC): 0.261 (7:3 EtOAc/Hexane). λmax(MeCN) = 
283 nm. HRMS (ESI-MS) m/z calculated for C31H31BrN2NaO7
+: 646.4803; found: 646.4833 [M + 
Na]+. 1H NMR (500 MHz, CDCl3, ppm): 8.27 (s, 1H; H6), 7.26–7.41 (m, 9H; Ar), 6.81– 6.84 (m, 4H; 
Ar), 6.28-6.30 (m, 1H; H1’), 4.55-4.56 (m, 1H; H3’), 4.17-4.18 (m, 1H; H4’), 4.00 (s, 3H; OCH3) 
3.77 (s, 6H; ArOCH3), 3.37-3.38 (m, 2H; H5’, H5’’), 2.73-2.77 (m, 1H; H2’), 2.25-2.28 (m, 1H; H2’’). 
13C NMR (125.7 MHz, CDCl3, ppm): 167.24, 158.59, 154.76, 144.43, 142.92, 135.58, 135.42, 
130.02, 129.99, 127.99, 127.96, 126.95, 113.31, 88.72, 87.49, 86.93, 86.87, 77.36, 77.11, 76.85, 
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72.01, 63.45, 55.66, 55.23, 53.46, 42.32, 20.55, 13.91. IR (thin film); νmax (cm
−1) = 3396, 2955, 
2361, 2336, 1652, 1616, 1507, 1473, 1386, 1301, 1250, 1176, 1096, 1035, 827, 701. 
3’-O-(2-Cyanoethoxy(diisopropylamino)-phosphino)-5’-O-(4,4’-dimethoxytrityl)-5-bromo-O4-
methyl-2’-deoxyuridine (6b): DIPEA (0.181 mL, 0. 1044 mmol) was added to a solution of (5b) 
(0.2231 g, 0.3483 mmol) in THF (4 mL), followed by the dropwise addition of N,N-
diisopropylamino cyanoethyl phosphonamidic chloride (0.154 mL, 0.697  mmol). After 30 min, 
the solvent was evaporated in vacuo and the crude product was taken up in ethyl acetate (40 
mL). The solution was washed with a 3% (w/v) solution of NaHCO3 (3 x 50 ml) followed by brine 
(50 mL). The organic layer was dried over anhydrous Na2SO4 (~ 4 g), and concentrated in vacuo. 
The crude product was purified by flash column chromatography using hexanes/ethyl acetate 
(2:8) solvent as eluent to afford 0.2431 g (83%) of a colorless foam. Rf (SiO2 TLC): 0.908, 0.857 
(2:8 Hexanes/EtOAc). λmax(MeCN) = 283 nm. HRMS (ESI-MS) m/z calculated for C40H48BrN4NaO8P
+: 
846.6981; found 846.7110[M + Na]+. 1H NMR (500 MHz, CDCl3, ppm): 8.31 (s, 0.43H; H6), 8.26 
(s, 0.5H; H6), 7.33–7.51 (m, 9H; Ar), 6.89– 6.92 (m, 4H; Ar), 6.19-6.24 (m, 1H; H1’), 4.68-4.75 (m, 
1H; H3’), 4.24-4.33 (m, 1H; H4’), 3.92-3.97 (s, 3H; OCH3), 3.61-3.91 (m, 10H; NCH, ArOCH3, 
CH2OP), 3.44-3.47 (m, 2H; H5’, H5’’), 2.75-2.77 (t, J= 6.0 Hz, 1H; CH2CN), 2.63-2.66 (t, J= 6.0 Hz, 
1H; CH2CN), 2.41-2.49 (m, 1H; H2’’), 2.04-2.06 (m, 1H; H2’’) 1.19-1.22 (m, 9H; CH3), 1.11-1.12 (m, 
3H; CH3). 
13C NMR (125.7 MHz, CDCl3, ppm): 169.99, 168.68, 158.82, 153.30, 144.96, 144.94, 
143.25, 143.20, 135.68, 135.65, 135.59, 135.54, 130.15, 130.14, 130.12, 130.10, 128.08, 138.04, 
127.92, 127.88, 126.81, 126.79, 118.05, 117.93, 113.18, 87.03, 86.96, 86.89, 86.84, 86.74, 86.70, 
85.99, 85.95, 85.72, 85.67, 73.59, 73.45, 73.16, 73.03, 63.20, 62.98, 59.66, 58.73, 58.58, 54.78, 
54.70, 54.69, 54.67, 54.64, 43.13, 43.03, 40.65, 40.62, 40.50, 40.47, 29.47, 29.32, 29.26, 29.16, 
29.01, 28.85, 28.75, 28.70, 28.55, 28.70, 28.55, 24.08, 24.05, 24.02, 23.99, 23.97, 21.96, 21.94, 
20.48, 20.45, 20.00, 19.92, 19.87, 19.81, 13.66. 31P NMR (202.3 MHz, d6-acetone, ppm): 148.34, 
148.08. IR (thin film); νmax (cm
−1) =3421, 2966, 2361, 1733, 1717, 1674, 1616, 1559, 1536, 1472, 
1457, 1386, 1301, 1251, 1222, 11179, 1118, 1082, 1037, 977, 828, 735. 
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A3.1.2 Preparation, purification and characterization of the dClU and dBrU oligonucleotides 
 The sequences containing the modified dClU and dBru nucleosides, which are shown in 
Figure 4.1, were assembled with an Applied Biosystems Model 3400 synthesizer on a 1.5 mol 
scale using β-cyanoethylphosphoramidite chemistry supplied by the manufacturer with slight 
modifications to coupling times. The nucleoside phosphoramidites protected with "fast-
deprotecting" groups were dissolved in anhydrous MeCN at a concentration of 0.1 M for the 3’-
O-deoxyphosphoramidites. Oligomer sequence assembly was carried out as previously 
described.[54,97] The capping step of the assembly was carried out using phenoxyacetic 
anhydride/pyridine/tetrahydrofuran 1:1:8 (v/v/v; solution A) and 1-methyl-imidazole/ 
tetrahydrofuran 16:84 (w/v; solution B). Coupling wait times for phosphoramidites 3a, 3b, 6a 
and 6b were extended to 10 min (compared to 2 min for the commercially available 
phosphoramidites). Protecting group removal and cleavage from the solid support was carried 
out by treatment with 0.05M K2CO4 in MeOH for 4 h at room temperature with mild rocking in 2 
mL screw-cap microfuge tubes fitted with Teflon lined caps. The base was neutralized with an 
equimolar amount of AcOH and crude oligomers were transferred and solvent removed in a 
Speedvac concentrator. Purification was achieved by strong anion exchange HPLC using a 
Dionex DNAPAC PA-100 column (0.4 cm x 25 cm) purchased from Dionex Corp, Sunnyvale, CA 
using a linear gradient of 0–52% buffer B over 24 min (buffer A: 100 mm Tris HCl, pH 7.5, 10% 
MeCN and buffer B: 100 mm Tris HCl, pH 7.5, 10% MeCN, 1M NaCl) at 55 oC. The columns were 
monitored at 260 nm for analytical runs or 280 nm for preparative runs. The purified oligomers 
were desalted using C-18 SEP PAK cartridges (Waters Inc.) as previously described.[132] The 
molecular mass of the modified oligomers was identified by deconvolution of the ESI-MS and 
the measured values were in agreement with the expected masses (Figures A3.21, A3.22, A3.23 
and A3.24 for MS spectra). dClU-Me and dBrU-Me (0.05 A260 units each) were  also 
characterized by enzymatic digestion (snake venom phosphodiesterase: 0.28 units and calf 
intestinal phosphatase: 5 units, in 10 mM Tris, pH 8.1 and 2 mM MgCl2) for 48 h at 37 
oC. The 
resulting nucleoside mixture was analyzed by reversed phase HPLC carried out using a 
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Symmetry® C-18 5 μm column (0.46 x 15 cm) via a linear gradient of 0-70% buffer B over 30 min 
(buffer A: 50 mM sodium phosphate, pH 5.8, 2% MeCN and buffer B: 50 mM sodium phosphate, 
pH 5.8, 50% MeCN). Results and nucleoside ratios from the digestion are shown in Figures 
A3.25 and A3.26. 
 
A3.2 UV thermal denaturation 
 Please refer to section A1.2 for the experimental details.  
A3.3 Circular dichroism (CD) spectroscopy 
 Please refer to section A1.3 for the experimental details.  
A3.4 AGT repair assay  
 Please refer to section A1.4 for the experimental details.
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 Figure A3.3 - 202.3 MHz 31P NMR spectrum of compound (3a) (in d6-acetone) 
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 Figure A3.5 - 125.7 MHz 13C NMR spectrum of compound (4a) (in CDCl3) 
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 Figure A3.6 - 500 MHz 1H NMR spectrum of compound (5a) (in CDCl3)  
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 Figure A3.23 - ESI MS spectrum of oligonucleotide dBrU (expected mass of 4328)  
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Figure A3.24 - ESI MS spectrum of oligonucleotide dBrU-Me (expected mass of 4342.5)














1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00 16.00
Figure A3.25- C-18 reversed phase HPLC profile of nuclease-digested dClU-Me. The column was 
eluted with a linear gradient of 0-70% buffer B over 30 min (buffer A: 50 mM sodium phosphate, 










dC 4 4.2 
dG 4 4.0 
dA (dI) 3 2.8 
dT 2 2.1 




























1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00 16.00
Figure A3.26- C-18 reversed phase HPLC profile of nuclease-digested dBrU-Me. The column was 
eluted with a linear gradient of 0-70% buffer B over 30 min (buffer A: 50 mM sodium phosphate, 
pH 5.8, 2% MeCN and buffer B: 50 mM sodium phosphate, pH 5.8, 50% MeCN). 
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Figure A3.27- SAX-HPLC profile of dClU crude (A) and pure (B). The column (Dionex DNAPAC PA- 
100) was eluted using a linear gradient of 0-70% buffer B over 30 min (buffer A: 100 mM Tris 







Figure A3.28- SAX-HPLC profile of dClU-Me crude (A) and pure (B). The column (Dionex DNAPAC 
PA- 100) was eluted using a linear gradient of 0-70% buffer B over 30 min (buffer A: 100 mM Tris 
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Figure A3.29- SAX-HPLC profile of dClU crude (A) and pure (B). The column (Dionex DNAPAC PA- 
100) was eluted using a linear gradient of 0-70% buffer B over 30 min (buffer A: 100 mM Tris 
HCl, pH 7.5, 10% MeCN and buffer B: 100 mM Tris HCl, pH 7.5, 10% MeCN, 1 M NaCl) 
 
Figure A3.30- SAX-HPLC profile of dBrU-Me crude (A) and pure (B). The column (Dionex 
DNAPAC PA- 100) was eluted using a linear gradient of 0-70% buffer B over 30 min (buffer A: 
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Figure A3.31 - Hyperchromicity change (A260) versus temperature (
oC) profiles of duplexes 









 Figure A3.32 - Circular dichroism spectra of duplexes containing dClU (—), dClU-Me (•••), dBrU  
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Figure A3.33: Repair of (A) dClU (2 pmol) and (B) dClU-Me (2 pmol) by hAGT (10 pmol), OGT (10 
pmol), Ada-C (10 pmol), and hOGT (10 pmol), for 2.5 h at 37oC. Panel A; Lane 1, dFU DNA; lane 
2, dClU + Bcll; lane 3, dClU + hAGT; lane 4, dClU + hAGT + Bcll; lane 5, dClU + OGT; lane 6, dClU + 
OGT+ Bcll; lane 7, dClU + Ada-C; lane 8, dClU + Ada-C + Bcll; lane 9, dClU + hOGT; lane 10, dClU + 
hOGT + BclI. Panel B; Lane 1, dClU-Me DNA; lane 2, dClU-Me + Bcll; Lane 3, dClU-Me; lane 4, 
dClU-Me + hAGT; lane 5, dClU-Me + hAGT; lane 6, dClU-Me + hAGT + Bcll; lane 7, dClU-Me + 
OGT; lane 8, dClU-Me + OGT+ Bcll; lane 9, dClU-Me + Ada-C; lane 10, dClU-Me + Ada-C + Bcll; 
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Figure A3.34: Repair of (A) dBrU (2 pmol) and (B) dBrU-Me (2 pmol) by hAGT (10 pmol), OGT 
(10 pmol), Ada-C (10 pmol), and hOGT (10 pmol), for 2.5 h at 37oC. Panel A; Lane 1, dBrU + 
hAGT; lane 2, dBrU + hAGT + Bcll; lane 3, dBrU + OGT; lane 4, dBrU + OGT+ Bcll; lane 5, dBrU + 
Ada-C; lane 6, dBrU + Ada-C + Bcll; lane 7, dBrU + hOGT; lane 8, dBrU + hOGT + BclI. Panel B; 
Lane 1, dBrU-Me DNA; lane 2, dBrU-Me + Bcll; Lane 3, dBrU-Me; lane 4, dBrU-Me + hAGT; lane 
5, dBrU-Me + hAGT; lane 6, dBrU-Me + hAGT + Bcll; lane 7, dBrU-Me + OGT; lane 8, dBrU-Me + 
OGT+ Bcll; lane 9, dBrU-Me + Ada-C; lane 10, dBrU-Me + Ada-C + Bcll; lane 11, dBrU-Me + 10 
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Figure A3.35 - Time course repair gel of duplexes containing dClU-Me by (A) hAGT, (B) OGT, (C) 
Ada-C and (D) hOGT. (A) Denaturing gel of the repair of 2 pmol of dClU-Me by 10 pmol hAGT as 
a function of time: lane 1, 2 pmol Control; lanes 2-10, 2 pmol  + 10 pmol hAGT incubated for 
0.25, 0.5, 0.75, 1, 1.5, 3, 5, 15, 45 min, respectively. (B) Denaturing gel of the repair of 2 pmol of 
dClU-Me by 10 pmol OGT as a function of time: lane 1, 2 pmol Control; lanes 2-10, 2 pmol  + 10 
pmol OGT incubated for 0.25, 0.5, 0.75, 1, 1.5, 3, 5, 15, 45, 90 min, respectively. (C) Denaturing 
gel of the repair of 2 pmol of dClU-Me by 10 pmol Ada-C as a function of time: lane 1, 2 pmol 
Control; lanes 2-10, 2 pmol  + 10 pmol Ada-C incubated for 0.25, 0.5, 0.75, 1, 1.5, 3, 5, 15, 45, 
90, 150 min, respectively. (D) Denaturing gel of the repair of 2 pmol of dClU-Me by 10 pmol 
hOGT as a function of time: lane 1, 2 pmol Control; lanes 2-10, 2 pmol  + 10 pmol hOGT 
incubated for 0.25, 0.5, 0.75, 1, 1.5, 3, 5, 15, 45, 90, 150 min, respectively. All the time courses 
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Figure A3.36 - Time course repair gel of duplexes containing dBrU-Me by (A) hAGT, (B) OGT, (C) 
Ada-C and (D) hOGT. (A) Denaturing gel of the repair of 2 pmol of dBrU-Me by 10 pmol hAGT as 
a function of time: lane 1, 2 pmol Control; lanes 2-10, 2 pmol  + 10 pmol hAGT incubated for 
0.25, 0.5, 0.75, 1, 1.5, 3, 5, 15, 45, 90 min, respectively. (B) Denaturing gel of the repair of 2 
pmol of dBrU-Me by 10 pmol OGT as a function of time: lane 1, 2 pmol Control; lanes 2-10, 2 
pmol  + 10 pmol OGT incubated for 0.25, 0.5, 0.75, 1, 1.5, 3, 5, 15, 45, 90 min, respectively. (C) 
Denaturing gel of the repair of 2 pmol of dBrU-Me by 10 pmol Ada-C as a function of time: lane 
1, 2 pmol Control; lanes 2-10, 2 pmol  + 10 pmol Ada-C incubated for 0.25, 0.5, 0.75, 1, 1.5, 3, 5, 
15, 45, 90, 150 min, respectively. (D) Denaturing gel of the repair of 2 pmol of dBrU-Me by 10 
pmol hOGT as a function of time: lane 1, 2 pmol Control; lanes 2-10, 2 pmol  + 10 pmol hOGT 
incubated for 0.25, 0.5, 0.75, 1, 1.5, 3, 5, 15, 45, 90, 150 min, respectively. . All the time courses 
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Figure A3.37 –Time course repair assay graphs of (A) dClU-Me and (B) dBrU-Me by hAGT (•••), 
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 The use of crosslinks has been explored in order to help generate small circular single 
stranded DNA. Different sequences have been explored in order to achieve circularization. In 
this specific case, the advantage of being able to remove the  crosslink once the oligonucleotide 
is circularized plays an attractive role in therapeutic and diagnostic applications using small 
circular oligonucleotides as molecular recognition agents. Recent studies have also shown the 
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A4.2 Main text 
 Another type of DNA damage that can occur is the formation of crosslinks. In this section 
we are using a crosslink as a splint in order to generate a single-stranded circular DNA. The 
crosslink used corresponds to divinylsulfone, which can be removed under basic conditions 
(0.05M K2CO3 in methanol for more than 48 h).  Different sequences with different length and 
base composition were studied. For instance, the sequences have a tendency to form tetraloops 
(GATA) or a triloop (GAA) in the case of the smallest sequence. They also form a CG loop-closing 
base pair.[137–139] 20, 28, 32 and 40 nucleotide long sequences were studied. In the preliminary 
ligation studies, it was observed that the smaller sequences had difficulty to undergo ligation. It 
was thought that the circularization in the smaller sequences was more challenging due to their 
reduced flexibity and the greater influence of the cross-link, which may induce structural 















Figure A4.1: Oligonucleotide sequences in the presence of the divinylsulfone crosslink; (A) 
20mer, (B) 28mer, (C) 32mer and (D) 40mer.  
 
(A) (B) (C) (D) 
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 Out the sequences studied, the 40mer showed the most promise to undergo ligation 
with the formation of some multimeric species. Therefore, the conditions for the ligation were 
optimized in order to reduce the production of multimeric species and favour the 
intramolecular ligation.  It is important to mention that the 40mer sequence also has the ability 









Figure A4.2: 40mer sequence representing the possible formation of a Holiday Junction 
 
 
A4.2.1 Bisamidite of the nucleoside dimer  
The following procedure and characterization of the bisamidite (Figure A4.3) was obtained from 
Roger Tresánchez, PhD Thesis, University of Barcelona, 2013. 
 
 To a solution of the nucleoside dimer (1.96 g, 1.62 mmol, 1 eq) in anhydrous DCM (25 
mL) (in a dry 10 mL-round bottomed flask) DIPEA (1.15 mL, 6.59 mmol, 4 eq) was added under 
an Ar atmosphere. After 5 min stirring, Cl-P(OCNE)NiPr2 (1.00 g, 4.22 mmol, 2.6 eq) was added, 
and the mixture was reacted for 2.5 h (Ar). The reaction mixture was diluted with DCM (100 mL) 
and washed with 10% aq. NaHCO3 (3  100 mL). The organic fraction was dried over anhydrous 
MgSO4 and taken to dryness. Purification: silica gel column chromatography eluting with 
hexanes/AcOEt/TEA mixtures (from 48:50:2 to 28:70:2). 2.00 g of product were obtained (77 % 
yield). 












Figure A4.3: Bisamidite with divinylsulfone linker 
 
White solid; Rf: 0.74 (AcOEt/Hexanes 7:3); 
1H NMR (400 MHz, CDCl3) δ (ppm): 7.67, 7.63, (2 s, 1H, H6), 
7.41–7.23 (m, 9H, Ar-DMT), 6.85–6.6.82 (m, 4H, Ar-DMT), 6.39 (q, J=8 Hz, 1H, H1’), 4.67-4.61  
(m,1H,H3’),4.17-4.13 (2q, J=4 Hz, 1H, H4’), 4.46–4.41 (m, 2H, CH2α), 3.79 (s, 6H, OMe), 3.82–3.69 (m, 2H, 
CH2α’), 3.63–3.47 (m, 4H, CH2β, CH 
iPr), 3.33-3.28 (m, 2H, H5’ i H5’’), 2.62 (t, J=6 Hz) & 2.41 (t, J=6 Hz) 
(2H, CH2β’), 2.57-2.46 (m) & 2.37–2.30 (m) (2H, H2’, H2’’), 1.43 (s, 3H, CH3), 1.17, 1.16, 1.05 (3d, J=4 Hz, 
12H, CH3 
iPr); 13C NMR (101 MHz, CDCl3) δ (ppm): 163.33 (C4), 158.88 (Ar-DMT), 150.74 (C2), 144.39, 
133.52 , 133.46 (Ar-DMT), 134.36 (C6), 130.34, 128.41, 128.13, 127.28 , 113.40 (Ar-DMT), 110.46 (C5), 
87.04 (C1’), 85.84, 84.65 (C4’, Ar-DMT), 73.23 (C3’), 63.28 (C5’), 58.56 (CH2α’), 55.43 (OMe), 49.06 
(CH2β), 43,43 (CH 
iPr), 40.40 (C2’), 35.22 (CH2α), 24.75 (CH3 
iPr), 20.53 (CH2β’), 12.55 (CH3); 
31P NMR (121 






A4.2.2 Synthesis of cross-linked oligonucleotides. 
 All oligonucleotides were automatically synthesized with an Applied Biosystems Model 
3400 synthesizer in a 1.5 μmol scale. Protecting group removal and cleavage from the solid 
support was carried out by treatment with 0.05M K2CO3 in MeOH for 4 h at room temperature 
with mild rocking in 2 mL screw-cap microfuge tubes fitted with teflon lined caps. The base was 
neutralized with an equimolar amount of AcOH and crude oligomers were transferred and 
lyophilized in a Speedvac concentrator. Purification was achieved by 20% polyacrylamide (19:1) 
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A4.2.3 Phosphorylation of cross-linked oligonucleotides. 
 The required amount of cross-linked oligonucleotide was introduced into a 
microcentrifuge tube, and a solution (the volume necessary to yield a 10 μM solution of cross-
linked oligonucleotide) containing 70 mM Tris·HCl pH=7.6, 10 mM MgCl2, 5 mM DTT, 0.5 mM 
ATP and T4 PNK (NE BioLabs, 1 U/μL) was added. The mixture was incubated at 37 oC for 1 h. 
The reaction was quenched by heating at 70 oC for about 10 min, and this reaction mixture was 
used in the cyclization experiments. 
 Chemical phosphorylation was also attempted by solid-phase synthesis with the Applied 
Biosystems Model 3400 DNA synthesizer by using a commercially available chemical 
phosphorylating agent II ([3-(4,4'-Dimethoxytrityloxy)-2,2-dicarboxyethyl]propyl-(2-cyanoethyl)-
(N,N-diisopropyl)-phosphoramidite from Glen Research). 
 
A4.2.4 Cyclization of cross-linked oligonucleotides. 
 The mixture resulting from the phosphorylation reaction was heated at 95 oC for 10 min, 
and allowed to cool down slowly. A solution (the volume necessary to yield a 6 μM solution of 
cross-linked oligonucleotide) containing 50 mM Tris·HCl, 10 mM MgCl2, 5 mM DTT, and T4 DNA 
ligase (NE BioLabs, 1 U/μL) was added, and the mixture reacted at 30 oC. After 20 minutes, the 
reaction was then quenched by heating at 70 oC for 15 min. Cyclization crudes were analyzed by 









Figure A4.4: First attempts of the (A) Phosphorylation reaction of the 40mer and (B) Cyclization 
reaction of the 40mer (10% PAGE) 
A B 




Figure A4.5: Scheme of the phosphorylation and cyclization of the oligonucleotides and the site 









Figure A4.6: Results after the cyclization reaction of the 40mer sequence (20% PAGE) for cyclic 
product recovery. 
 From the results obtained in figure A4.4 and A4.6 it can be summarized that the 
phosphorylated product and the ligated product migrated at different levels and that the 
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A4.2.5 Removal of cross-link 
 About 0.5 OD of the cyclic oligonucleotide was dissolved with a solution of 0.05 M K2CO3 
in methanol and left at 65oC for 72 hours with some gently shaking in between. After the 72 
hours, an equivalent amount of AcOH was added to neutralize the reaction. As it can be 
observed in figure A4.7, it seems that 72 hours were not enough to completely remove the 
crosslink. This suggests that the sequence might be adopting a structure that could be 
minimizing the exposure of the crosslink. The results obtained also showed that after the 
removal of the crosslink, the cyclic oligonucleotide seemed to adopt a more flexible structure 
(like a supercoiled) allowing it to travel a bit further in the gel. It is important to mention that 
only two products were observed, which implies that the cyclic product was successfully ligated 
as no smaller products (20mer), which would have been generated as a result of the removal of 
the crosslink in the non-ligated sequences, appeared in the gel.  
 Further work has to be performed; for example: trying a more concentrated sample 
(minimum 1 OD), higher temperatures such as 80 oC, going over 72 hours and adding extra 
solution of 0.05 M K2CO3 in methanol in order to compensate for the possible MeOH 







Figure A4.7: Removal of the divinylsulfone crosslink 
 Due to the high molecular weight of the 40mer sequence, the circular product was not 
able to be analyzed by mass spectrometry. Another way to confirm the circularity was to 
perform S1 endonuclease digestion.   
0h    12h   24h         48h  72h 
DNA Marker (28nt) 
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A4.2.6 S1 Endonuclease Digestion 
 About 0.05 OD of the cyclic oligonucleotide was dried and 3 μL of 5X S1 buffer containing 
200 mM sodium acetate (pH 4.5 at 25°C), 1.5 M NaCl and 10 mM ZnSO4, 0.5 μL of S1 nuclease 
(Thermo Scientific 100U/μL) and 10.5 μL of deionized water were added. The reaction mixture 
was incubated at 37 oC for 10 min and it was later stopped by heating to 70 oC for another 10 
min. The challenge of this digestion is to stop the reaction right on the first cleavage without 
letting further cleavage of the sample. The results obtained are shown in figure A4.8 where it 
can be observed that the first product of the digestion of the cyclic 40mer traveled similarly to 








Figure A4.8: Digestion of the phosphorylated and cyclic 40mer sequence, both in the absence 
(X) and presence (S1) of S1 endonuclease.  
 After performing the S1 nuclease digestion and removing the crosslink of the 40mer 
sequence, the results suggested the possibility of successful ligation. Future work will required 
to collect more cyclic 40mer and repeat the steps of crosslink removal and S1 endonuclease 
digestion to confirm ligation.
Cyclic 40mer  
S1 X 
Phosphorylated 40mer  
S1 X 
First product of digestion Phosphorylated 40mer 
